valsartan has been researched along with Cardiac Failure in 1133 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (1.15) | 18.2507 |
| 2000's | 148 (13.06) | 29.6817 |
| 2010's | 418 (36.89) | 24.3611 |
| 2020's | 554 (48.90) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, LE; Pogge, EK | 2 |
| Shen, X; Zeng, Y; Zhao, J | 1 |
| Hori, M; Imamura, T; Kinugawa, K | 1 |
| Bai, X; Chen, F; Li, J; Tian, G; Yuan, Z | 1 |
| Abdelnabi, M; Almaghraby, A; Gerges, F; Girgis, H; Saleh, Y | 1 |
| Acosta, J; Berruezo, A; Bosch, X; Jáuregui, B | 1 |
| Allen, LA; Blumer, V; Carnicelli, AP; Fonarow, GC; Greene, SJ; Greiner, MA; Hardy, NC; Li, Z; Lippmann, SJ; Mentz, RJ; O'Brien, EC; Peterson, PN; Shen, X; Yancy, CW | 1 |
| Bhatt, AS | 1 |
| Brunetti, ND; Correale, M; Fortunato, M; Leopizzi, A; Magnesa, M; Mallardi, A; Mazzeo, P; Mennella, R; Tricarico, L; Tucci, S | 1 |
| Yancy, CW | 1 |
| Aggarwal, R; Bhatt, AS; Claggett, BL; Fonarow, GC; Greene, SJ; McMurray, JJV; Solomon, SD; Vaduganathan, M | 1 |
| Krittayaphong, R; Permsuwan, U | 2 |
| Crea, F | 1 |
| Bonni, E; Coppola, G; Corrado, E; Dattilo, G; de Gregorio, C; Morabito, C; Novo, G; Zappia, L | 1 |
| Axelsson, A; Bach, RG; Becker, JR; Benson, L; Braunwald, E; Bundgaard, H; Burns, KM; Canter, C; Cirino, AL; Colan, SD; Day, SM; Ho, CY; Lakdawala, NK; Lever, HM; MacRae, CA; Margossian, R; McMurray, JJV; Mestroni, L; Murphy, AM; Orav, EJ; Owens, AT; Patel, AR; Pereira, AC; Rossano, JW; Russell, MW; Seidman, CE; Solomon, SD; Soslow, JH; Taylor, MRG; Thrush, P; Vargas, JD; Wheeler, MT; Wilmot, I; Zahka, K | 1 |
| Karabulut, D; Karabulut, U; Keskin, K; Yiğit, E; Yiğit, Z | 1 |
| Aspromonte, N; Caldarola, P; Cipriani, M; Colivicchi, F; Di Lenarda, A; Di Tano, G; Gabrielli, D; Gulizia, MM; Iacoviello, M; Murrone, A; Oliva, F; Urbinati, S | 1 |
| Gallo, G; Volpe, M; Zieroth, S | 1 |
| Calò, L; Cicogna, F; De Ruvo, E; Gaudio, C; Mennuni, S; Monzo, L; Petronilli, V; Tota, C | 1 |
| Alba, PR; Bress, AP; Choi, ME; Cook, J; Dodson, JA; Fang, JC; He, T; Herrick, JS; King, JB; Levitan, EB; Mohanty, AF; Obi, EN; Patterson, OV; Russo, PA; Vardeny, O | 1 |
| Bedhomme, S; Bouchant, S; Boussageon, R; Bœuf-Gibot, S; Charuel, E; Menini, T; Pereira, B; Piñol-Domenech, N; Vaillant-Roussel, H | 1 |
| Bhatti, P; Bromage, DI; Cannata, A; DeCourcey, J; Holm, N; Huang, M; McDonagh, TA | 1 |
| Belarte-Tornero, LC; Farré, N; Mojón, D | 1 |
| Chen, Z; Deng, Q; Diao, K; He, S; He, Y; Huang, B; Li, C; Ma, M; Sun, J; Tang, L; Wang, D; Wang, H; Wang, M; Wu, T; Wu, X; Yan, T; Zhang, L; Zhu, Y | 1 |
| Bian, W; Cheng, H; Yang, L; Ye, N | 1 |
| Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A | 2 |
| Clark, J; Gandotra, C; Liu, Q; Rose, M; Senatore, FF; Stockbridge, NL; Zhang, J | 1 |
| Jang, HN; Kang, MG; Kim, MJ; Lee, JS; Song, HN | 1 |
| Fu, G; Lu, J; Shen, C; Xiong, C; Yang, Y | 1 |
| Abdelnabi, M; Almaghraby, A; Babazade, N; Cihan, D; Dağdeviren, B; Fiore, C; Haseeb Raza Naqvi, S; Omar, B; Öz, TK | 1 |
| Anstrom, KJ; Braunwald, E; Desvigne-Nickens, P; DeVore, AD; Givertz, MM; Gupta, D; Hernandez, AF; Kiernan, MS; Lala, A; Lewis, GD; Mahr, C; Mann, DL; Margulies, KB; McNulty, SE; Redfield, MM; Shah, P; Starling, RC; Vader, JM | 1 |
| Gallo, G; Rubattu, S; Volpe, M | 1 |
| Apaer, R; Che, H; Chen, J; Dou, X; Feng, Z; Fu, L; Fu, X; He, C; Huang, R; Ke, G; Kong, Y; Li, S; Li, X; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Mei, L; Shi, W; Su, X; Tang, B; Tao, Y; Wang, X; Wang, Y; Wen, F; Xia, Y; Xiao, J; Xiong, Y; Xu, L; Xue, Z; Ye, Z; Zhang, H; Zhang, L | 1 |
| Heidenreich, PA; Kohsaka, S; Lewis, EF; Sandhu, AT; Turakhia, MP | 1 |
| Berwanger, O; Braunwald, E; Cikes, M; Claggett, B; De Pasquale, CG; East, C; Fernandez, A; Gong, J; Granger, CB; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Mehran, R; Merkely, B; Petrie, MC; Petrov, I; Pfeffer, MA; Rouleau, JL; Schou, M; Senni, M; Sim, D; Solomon, SD; Steg, PG; Vaghaiwalla Mody, F; van der Meer, P; Zhou, Y | 1 |
| Baldridge, A; Cowie, MR; Ibram, G; Pieske, B; Shah, SJ; Shi, V; Szeczoedy, P; Wachter, R; Zhao, Z | 1 |
| Boulmpou, A; Doumas, M; Papadopoulos, C; Patoulias, D; Toumpourleka, M; Tranidou, A | 1 |
| Chai, P; Cheong, AJY; Lee, CH; Lim, YC; Lin, W; Sia, CH; Syn, NL; Teo, YH; Teo, YN; Wee, CF; Wong, RCC; Yeo, TC; Yoong, CSY | 1 |
| Berwanger, O; Braunwald, E; Cikes, M; Claggett, B; De Pasquale, CG; Fernandez, A; Filippatos, G; Granger, CB; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Menon, V; Merkely, B; Petrie, MC; Petrov, I; Pfeffer, MA; Rouleau, JL; Schou, M; Senni, M; Sim, D; Solomon, SD; Steg, PG; van der Meer, P; Wang, Y; Zhou, Y | 1 |
| Benson, L; Daubert, JC; Donal, E; Hage, C; Linde, C; Lund, LH; Lundberg, A; Oger, E; Savarese, G; Venkateshvaran, A | 1 |
| Austin, AM; Gilstrap, L; King, A; Tomlin, S | 1 |
| Arnaud, H; Bouali, Y; Donal, E; Galli, E; Laurin, C; Oger, E; Paven, E | 1 |
| Ammendola, E; Boriani, G; Bottino, R; D'Andrea, A; Gasperetti, A; Golino, P; Lip, GYH; Masarone, D; Nigro, G; Pacileo, G; Proietti, R; Russo, V; Schiavone, M | 1 |
| Ryo, Y; Sunaga, T | 1 |
| Lin, J; Liu, J; Xie, G; Zhou, J | 1 |
| Castagno, D; Curtain, JP; Desai, AS; Docherty, KF; Jackson, AM; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Petrie, MC; Rohde, LE; Rouleau, JL; Shen, L; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Chen, Z; Li, T; Wang, L; Xi, Q | 1 |
| Ambrosio, G; Bitto, R; Brunetti, ND; Carluccio, E; Ciccarelli, M; Correale, M; D'Agostino, A; Dattilo, G; Dini, FL; Ferretti, M; Grelli, A; Guida, S; Jacoangeli, F; Lupi, L; Luschi, L; Masarone, D; Mercurio, V; Nodari, S; Pacileo, G; Palazzuoli, A; Piepoli, M; Pugliese, NR; Rispoli, A; Scelsi, L; Tocchetti, CG | 2 |
| Abukhalaf, SA; Alzughayyar, TZ; Amerson-Brown, MH; Aqel, R; Brown, CA; Dunn, JJ; Misk, RA; Rahman, A; Singh, IR; Webb, CR; Zalloum, JS | 1 |
| Duan, X; Feng, Y; Wang, J; Yuan, J; Zhou, J | 1 |
| Bhattacharya, J; Goldhaber-Fiebert, JD; Heidenreich, PA; Lin, J; Parizo, J; Sandhu, AT | 1 |
| De Ponti, F; Diemberger, I; Poluzzi, E; Potena, L; Raschi, E; Sabatino, M | 1 |
| Ammirati, E; Cantone, R; Cipriani, M; D'Angelo, L; Foti, G; Frigerio, M; Garascia, A; Gentile, P; Masciocco, G; Perna, E; Varrenti, M; Verde, A | 1 |
| Claggett, BL; Cunningham, JW; Lefkowitz, M; McMurray, JJV; Pabón, MA; Packer, M; Pfeffer, MA; Rizkala, A; Shi, V; Solomon, SD; Vaduganathan, M; Zile, M | 1 |
| Liu, H; Liu, X; Wang, L; Xu, Q; Zhang, L | 1 |
| Fröb, EJ; Reinecke, H; Sindermann, JR; Tuleta, I | 1 |
| Claggett, B; Desai, AS; Fang, JC; Januzzi, JL; Mitchell, GF; Murphy, SP; Myhre, PL; Prescott, MF; Solomon, SD; Ward, JH | 1 |
| Akin, I; El-Battrawy, I | 1 |
| Chen, H; Chen, X; Guan, F; Han, S; Huang, S; Huang, Z; Li, H; Lin, W; Wang, Y; Ye, F | 1 |
| Grimm, D; Norre, T; Simonsen, U | 1 |
| Edwards, DG; Farquhar, WB; Hosmane, V; McGinty, S; Nathaniel, S; Wenner, MM; Witman, MA | 1 |
| Chen, H; Chen, M; Han, J; Jiang, J; Shu, Z; Sun, Z; Wang, Q; Wu, B; Xia, Q; Zhang, B; Zhao, J; Zheng, L; Zhou, D; Zhuo, C | 1 |
| Kim, BS; Kim, HJ; Lee, AH; Lim, YH; Park, IH; Shin, JH | 1 |
| Biondi-Zoccai, G; Bocchi, EA; Chan, JS; de Souza Lima Bitar, Y; Duraes, AR; Liu, T; Mesquita, ET; Neto, MG; Roever, L; Tse, G | 1 |
| Kozak, PM; Stacey, RB; Upadhya, B; Vasan, RS | 1 |
| Andersen, UØ; Goetze, JP; Gustafsson, F; Hansen, LH; Mark, PD; Plomgaard, P; Prickett, TCR; Terzic, D; Thonsgaard, S; Wewer Albrechtsen, NJ | 1 |
| Du, H; Jiang, N; Li, X; Zhao, W | 1 |
| Yoshikawa, T | 1 |
| Hellenkamp, K; Nolte, K; von Haehling, S | 1 |
| Ohishi, M | 1 |
| Ambrosio, G; Celant, S; Colatrella, A; Colivicchi, F; Di Lenarda, A; Gensini, GF; Olimpieri, PP; Onder, G; Reboldi, G; Rosano, GMC; Russo, P | 1 |
| Agostoni, P; Barillà, F; Basso, C; Correale, M; Curcio, A; Filardi, PP; Indolfi, C; Mancone, M; Merlo, M; Metra, M; Muscoli, S; Nodari, S; Palazzuoli, A; Paolillo, S; Pedrinelli, R; Pontremoli, R; Senni, M; Sinagra, G; Volpe, M | 1 |
| Abumayyaleh, M; Akin, I; Aweimer, A; Behnes, M; Demmer, J; El-Battrawy, I; Krack, C; Lang, S; Mügge, A; Pilsinger, C | 1 |
| Chen, J; Chen, T; Shou, Y; Yan, K; Zhang, L; Zhao, H | 1 |
| Colvin, BM; Guglin, M; Kido, K; Szymanski, TW | 1 |
| Tsutsui, H | 1 |
| Heerspink, HJL; Ter Maaten, JM; Voordes, GHD | 1 |
| Woods, RH | 1 |
| Pathak, P | 1 |
| Pudil, R | 1 |
| Agostoni, P; Barillà, F; Basile, C; Basso, C; Correale, M; Curcio, A; Indolfi, C; Mancone, M; Merlo, M; Metra, M; Muscoli, S; Nodari, S; Palazzuoli, A; Paolillo, S; Pedrinelli, R; Perrone-Filardi, P; Pontremoli, R; Senni, M; Sinagra, G; Volpe, M | 1 |
| Chen, X; Feng, Y; Li, W; Liu, H | 1 |
| Arps, K; Piccini, JP | 1 |
| Anand, I; Chiang, LM; Cikes, M; Claggett, B; Cunningham, J; Desai, AS; Gori, M; Lam, CSP; Linssen, G; McMurray, JJV; Milicic, D; Packer, M; Pfeffer, M; Planinc, I; Redfield, M; Senni, M; Shah, SJ; Solomon, SD; Sweitzer, N; Zile, MR | 1 |
| Cartailler, J; Cohen-Solal, A; Launay, JM; Lefèvre, G; Logeart, D; Michel, T; Nougué, H; Picard, F; Sadoune, M; Vodovar, N | 1 |
| Kario, K; Williams, B | 1 |
| Cheang, I; Dai, C; Li, X; Liao, S; Lu, Q; Lu, X; Shi, S; Su, X; Wang, J; Xu, D; Yuan, F; Yuan, J; Zhang, M; Zhao, Y; Zhou, J; Zhu, X | 1 |
| Meier, ML; Pierce, KN | 1 |
| Barnes, JA; Gaziano, TA; Gilstrap, L; King, A; O'Malley, AJ; Tosteson, ANA; Zipkin, RJ | 1 |
| Addison, D; Breathett, K; Brewer, LC; Essien, UR; Johnson, AE; Magnani, JW; Mazimba, S; Mohammed, SF; Swabe, GM | 1 |
| Claggett, BL; Desai, AS; Fang, JC; Mitchell, GF; Myhre, PL; Prescott, MF; Shah, AM; Solomon, SD; Ward, JH | 1 |
| Cheng, YY; Hsu, WT; Lee, CM; Wang, SR; Weng, SE; Yang, TY | 1 |
| Abdul-Jawad Altisent, O; Barceló, E; Bayes-Genis, A; Casquete, D; Cediel, G; Codina, P; de la Espriella, R; Domingo, M; Gastelurrutia, P; Lupón, J; Nuñez, J; Pascual-Figal, DA; Ruiz-Cueto, M; Santesmases, J; Santiago-Vacas, E; Spitaleri, G; Vila, J; Zamora, E | 1 |
| Bao, Q; Li, G; Li, Y; Liu, T; Shao, S; Suo, Y; Wang, Y; Yang, Q; Yuan, M; Zhang, Y | 1 |
| Abadir, PM; Dickinson, LE; Gilkes, DM; Godet, I; Marin, S; Nidadavolu, LS; Tian, J; Walston, JD | 1 |
| Atıcı, A; Bal, E; Barman, HA; Dogan, O; Özyıldırım, S; Tanyolaç, S; Yiğit, Z | 1 |
| Ding, Y; Li, J; Wei, Z; Zhu, L | 1 |
| Chen, C; Fan, L; Li, J; Li, X; Lv, Q; Tian, D; Zuo, C | 2 |
| Acker, N; Bailey, KR; Burnett, JC; Desai, V; Gonzalez Bonilla, HM; Iyer, S; Liu, D; Murthy, V; Nguyen, TTL; Pereira, NL; Redfield, M; Shrivastava, S; Wang, M; Weinshilboum, RM | 1 |
| Bojsen-Møller, KN; Deacon, CF; Gluud, LL; Goetze, JP; Gustafsson, F; Hansen, LH; Holst, JJ; Kjeldsen, S; Madsbad, S; Martinussen, C; Møller, A; Plomgaard, P; Rashu, EB; Richter, MM; Wewer Albrechtsen, NJ | 1 |
| Dai, W; Huang, X; Luo, J | 1 |
| Bhatt, AS; Desai, RJ; Lauffenburger, JC; Schneeweiss, S; Solomon, SD; Vaduganathan, M | 1 |
| Lozhkina, NG; Spiridonov, AN | 1 |
| Campanile, A; Carrizzo, A; Ciccarelli, M; Citro, R; Correale, M; Cuomo, A; Dattilo, G; Di Pietro, P; Galasso, G; Giallauria, F; Masarone, D; Mazzeo, P; Mercurio, V; Pacileo, G; Radano, I; Ravera, A; Silverio, A; Tocchetti, CG; Vecchione, C; Visco, V | 1 |
| Gupta, R; Maitz, TN; Persin, K; Sundlof, DW | 1 |
| Slawson, DC | 1 |
| Jia, R; Jiang, L; Li, S; Raj, A; Sun, C; Sun, D; Wu, X; Xu, Y; Zhang, X; Zheng, Z | 1 |
| Claggett, B; Cunningham, JW; Jackson, A; Lefkowitz, M; McMurray, JJV; Packer, M; Pfeffer, MA; Rouleau, J; Rørth, R; Shah, SJ; Solomon, SD; Swedberg, K; Vaduganathan, M; Wijkman, MO; Zile, M | 1 |
| Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE | 1 |
| Samsky, MD; Sen, S | 1 |
| Jatić, Z; Kulić, M; Naser, N | 1 |
| Yan, C; Zhang, X; Zheng, M | 1 |
| Antonio, EL; Arruda-Junior, DF; Girardi, AC; Gowdak, LHW; Martins, FL; Salles, TA; Tavares, CAM; Tucci, PJF | 1 |
| Adams, J; Mosler, C | 1 |
| Agrawal, R; Cristino, J; Gautam, R; Proudfoot, C; Thakur, L; Tolley, K | 1 |
| Alemayehu, WG; Armstrong, PW; Butler, J; Edelmann, F; Ezekowitz, J; Hernandez, AF; Lam, CSP; McMullan, C; O'Connor, CM; Pieske, B; Ponikowski, P; Roessig, L; Senni, M; Sim, D; Voors, AA; Westerhout, CM | 1 |
| Gao, M; Gong, L; Wang, X; Wang, Z; Wei, Z; Zhang, M; Zhang, Q; Zhang, Z | 1 |
| Fu, Y; Peng, ML; Ren, H; Wu, CW; Zhang, Y; Zhou, SS | 1 |
| Gok, M; Ozturk, C; Yalta, K; Yalta, T | 1 |
| Alper, CJ; Bacon, R; Clements, KM; Coelho, A; Gabot, A; Greenwood, BC; Lavitas, P; Lenz, K; Pomfret, TC; Taylor, M | 1 |
| Álvarez-García, J | 1 |
| Beldhuis, IE; Chatur, S; Claggett, BL; Kober, L; Lefkowitz, M; McCausland, FR; McMurray, JJV; Peikert, A; Pfeffer, MA; Seferovic, P; Skali, H; Solomon, SD; Vaduganathan, M | 1 |
| Fan, H; Ning, T; Tian, Q; Xiong, Z; Zheng, Z | 1 |
| Butt, JH; McMurray, JJV | 1 |
| Abdin, A; Bauersachs, J; Böhm, M; Hadëri, B; Kindermann, I; Laufs, U; Riemer, U; Schulz, M; Vukadinović, D; Wachter, R | 1 |
| Chen, S; Kang, L; Liu, Y; Si, J; Xu, B; Zhong, C | 1 |
| Barron, A; Mahtani, K; Patel, B; Wang, B | 1 |
| Chen, D; Lai, P; Liao, YL; Ling, JY; Tian, KJ; Xie, MJ; Xue, JH; Ye, JH; Zhong, WT; Zhong, YM | 1 |
| Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Huang, HT; Huang, JL; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY | 1 |
| Lewicka, E; Sławiński, G | 1 |
| Ageev, FT; Ovchinnikov, AG | 1 |
| Crespo-Leiro, MG; Escobar, C; Esteban-Fernández, A; Farré, N; Garcia, A; Luis-Bonilla, J; Nuñez, J | 1 |
| Alonso-Titos, J; Gaitán-Román, D; Hernández, D; Martín-Reyes, G; Martínez-Esteban, MD; Moreno-Ortiz, A; Pozo-Álvarez, R; Ruiz-Esteban, P; Vázquez-Sánchez, T | 1 |
| Basu, T; Birati, E; Brady, P; Chopra, V; Hummel, SL; Kamdar, N; Nallamothu, BK; Shore, S | 1 |
| Abdullah, DM; Alsemeh, AE; Khamis, T | 1 |
| Bojsen-Møller, KN; Wewer Albrechtsen, NJ | 1 |
| Ikari, Y; Ikeda, T; Ishii, S; Kida, K; Konishi, M; Matsumoto, S; Nakamura, N; Shibata, A | 1 |
| Anker, SD; Bhatt, DL; Butler, J; Harrington, J; Hernandez, AF; Jones, WS; Petrie, MC; Udell, JA | 1 |
| Anand, IS; Atar, D; Butt, JH; Desai, AS; Dewan, P; Echeverria, LE; Ge, J; Gong, J; Jhund, PS; Køber, L; Lam, CSP; Lefkowitz, MP; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Sim, D; Solomon, SD; Van Veldhuisen, DJ; Vrtovec, B; Zannad, F; Zile, MR | 1 |
| Berwanger, O; Braunwald, E; Claggett, B; De Pasquale, C; Filippatos, G; Granger, CB; Jering, KS; Lewis, EF; Maggioni, AP; McMurray, JJV; Mehran, R; Merkely, B; Pfeffer, M; Solomon, SD; Steg, PG; van der Meer, P; Zhou, Y | 1 |
| Huang, J; Liu, J; Lou, Y; Yu, Y | 1 |
| Abushanab, D; Al-Badriyeh, D; Alyafei, SA; Arabi, AR; Kaddoura, R | 1 |
| Bernard, ML; Dominic, P; Elise Hiltbold, A; Huang, E; Khatib, S; Morin, DP; Polin, GM; Rogers, PA | 1 |
| Aimo, A; Anker, SD; Arfsten, H; Barison, A; Bayes-Genis, A; Butler, J; Castiglione, V; Coats, AJS; de Boer, RA; Emdin, M; Fabiani, I; Filippatos, G; González, A; Januzzi, JL; Jhund, P; Lupón, J; Metra, M; Mueller, C; Núñez, J; Ponikowski, P; Richards, M; Rosano, G; Rossignol, P; Seferovic, P; Teerlink, J; Vergaro, G; Zannad, F | 1 |
| Cho, GY; Hwang, IC; Kim, HK; Kim, SH; Kim, YJ; Lee, HJ; Lee, SP; Moon, MG; Park, JB; Yoon, YE | 1 |
| Abdo, VB; Ashour, RH; Elshenawy, DSA; Ramadan, NM | 1 |
| Angoran, I; Anzouan-Kacou, JB; Bamba-Kamagaté, D; Coulibaly, I; Koffi, F; N'cho-Mottoh, MB; Traoré, F | 1 |
| Imamura, T; Kinugawa, K | 1 |
| Barrios, V; Clark, AL; Damy, T; Drozdz, J; Ferber, PC; Fonseca, C; Hussain, RI; Kalus, S; Koch, C; Lund, LH; Maggioni, AP; Zeymer, U | 2 |
| Wang, S; Zhang, F; Zhu, M | 1 |
| Polovina, M; Rosano, G; Seferović, J; Seferović, PM | 1 |
| Ji, Y; Jia, R; Sun, D | 1 |
| Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F | 1 |
| Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH | 3 |
| Belohlavek, J; Butylin, D; Chiang, Y; Fonseca, C; Lonn, E; Noè, A; Pascual-Figal, D; Schwende, H; Senni, M; Straburzynska-Migaj, E; Wachter, R; Witte, KK | 1 |
| Hellenkamp, K; Valentova, M; von Haehling, S | 1 |
| Xu, Z; Yang, S; Zhang, X | 1 |
| Beckendorf, J; Estler, B; Frankenstein, L; Frey, N; Fröhlich, H; Mäck, M; Schlegel, P; Täger, T | 1 |
| Montepara, CA; Proco, D; Rodgers, JE; Sharma-Huynh, P; Skersick, PT | 1 |
| Abuyousef, S; Ahmed, E; Alyafei, S; Hamou, F; Kasem, M; Mahfouz, A; Orabi, B; Rahhal, A; Shoukry, AE | 1 |
| Ge, T; Yang, Y; Zhao, Y | 1 |
| Chatur, S; Claggett, BL; Desai, AS; Jering, K; Lefkowitz, M; McMurray, JJV; Pfeffer, MA; Solomon, SD; Vaduganathan, M; Vardeny, O | 1 |
| Butler, J; Contreras, J; Felker, GM; Januzzi, JL; Liu, Y; Murphy, S; Omar, AMS; Piña, IL; Solomon, S; Ward, J | 1 |
| Cao, QY; Fan, ZB; Qi, GX; Shen, JF; Wu, CW; Xu, F | 1 |
| Chen, W; Dai, C; Lin, G; Wu, M; Xu, K | 1 |
| Adamsson Eryd, S; Bodegård, J; Bozkurt, B; Kishi, T; Lund, LH; Savarese, G; Thuresson, M; Vardeny, O | 1 |
| Allam, EA; Elsharkawy, AM; Hammadi, SH; Hassan, MA; Shams, SS | 1 |
| Barrios, V; Clark, AL; Damy, T; Drożdż, J; Ferber, PC; Fonseca, C; Kalus, S; Koch, C; Lund, LH; Maggioni, AP; Zeymer, U | 1 |
| Walsh, MN | 1 |
| Babes, EE; Behl, T; Bungau, SG; Horvath, T; Iovanovici, DC; Moisi, M; Rus, M; Tit, DM; Vesa, CM | 1 |
| Chen, L; Chen, Y; He, Q; Huang, J; Li, RX; Lu, JL; Mo, DC | 1 |
| Slomski, A | 1 |
| Gąsior, M; Grabowski, M; Lelonek, M | 1 |
| Brugaletta, S; Cristóbal, H; Dantas, AP; García de Frutos, P; García-Álvarez, A; Mendieta, G; Ortega, E; Ortega-Paz, L; Ortiz-Perez, JT; Rodriguez, JJ; Sabaté, M; Sandoval, E | 1 |
| Allen, LA; Fonarow, GC; Greene, SJ; Greiner, MA; Hardy, NC; Li, Z; Lippmann, SJ; Mentz, RJ; O'Brien, EC; Peterson, PN; Pierce, JB; Shen, X; Stampehl, M | 1 |
| Berwanger, O; Braunwald, E; Claggett, B; De Pasquale, CG; Ducrocq, G; Granger, C; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Leng, DSK; Lewis, EF; Maggioni, A; Mann, DL; McMurray, JJV; Mehran, R; Petrie, M; Pfeffer, MA; Rouleau, JL; Solomon, SD; Steg, PG; van der Meer, P; Zhou, Y | 1 |
| Butt, JH; Claggett, BL; de Boer, RA; Desai, AS; Docherty, KF; Hernandez, AF; Inzucchi, SE; Jering, KS; Jhund, PS; Kondo, T; Kosiborod, MN; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M; Wilderäng, U; Yang, M | 1 |
| Duan, X; He, Y; Wu, Q; Yan, F; Zhu, H | 1 |
| Chandra, A; Claggett, BL; Desai, AS; Lefkowitz, MP; Lewis, EF; Liu, J; McMurray, JJV; Packer, M; Pfeffer, MA; Polanczyk, CA; Rouleau, JL; Schwende, H; Shi, VC; Solomon, SD; Vaduganathan, M; Zile, MR | 1 |
| Patel, RB; Sinha, A | 1 |
| Benfari, G; Brunetti, ND; Cameli, M; Canepa, M; Carluccio, E; Ciccarelli, M; Cicoira, M; Citro, R; Corrado, E; Correale, M; De Carli, G; Degiovanni, A; Dini, FL; Emdin, M; Giannoni, A; Guaricci, AI; Loria, V; Malagoli, A; Mandoli, GE; Mazzeo, P; Mengoni, A; Moderato, L; Novo, G; Pasquini, A; Pastore, MC; Patti, G; Piscitelli, L; Pugliese, NR; Rosa, G; Santoro, C; Taddei, C | 1 |
| Adhikari, S; Blecker, S; Chunara, R; Dodson, JA; Kozloff, S; Kronish, IM; Li, X; Mukhopadhyay, A; Ramatowski, M; Shah, B | 1 |
| Butler, J; Felker, GM; Januzzi, JL; Maisel, AS; Meng, X; Murphy, SP; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH | 1 |
| Fusco, F; Grimaldi, N; Iannuzzi, A; Merola, A; Palma, M; Sarubbi, B; Scognamiglio, G | 1 |
| Shaikh, AS; Xu, XD; Yang, HR; Zhou, BT | 1 |
| Andreozzi, F; Armentaro, G; Arturi, F; Cassano, V; Condoleo, V; Maio, R; Miceli, S; Pelaia, C; Pelle, MC; Perticone, M; Salzano, A; Sciacqua, A; Sesti, G; Succurro, E | 1 |
| Abumayyaleh, M; Akin, I; Aweimer, A; Crack, C; Demmer, J; El-Battrawy, I; Mügge, A; Pilsinger, C; Zhou, X | 1 |
| Wang, L; Wang, R; Wang, Y; Wei, J; Ye, H; Zhang, X; Zhao, Y | 1 |
| Hawkins, NM; Yao, RJR | 1 |
| Benini, A; Bingel, A; Edelmann, F; Messroghli, D; Neumann, K; Pieske, B; Schönrath, F | 1 |
| Martínez-Del Río, J; Morón-Alguacil, A; Negreira-Caamaño, M; Pérez-Díaz, P; Piqueras-Flores, J | 1 |
| Asile, G; Basile, C; Buonocore, D; Chirico, A; Colella, A; Gargiulo, P; Marzano, F; Nardi, E; Paolillo, S; Parlati, ALM; Perrone-Filardi, P | 1 |
| Bonnet, D; Burch, M; Garito, T; Kantor, PF; Kocun, M; Shaddy, R; Solar-Yohay, S; Zhang, S | 1 |
| Gao, M; Gu, L; Hou, Y; Ma, K; Wang, X; Zhang, F; Zhang, Y; Zheng, S | 1 |
| Dudek, M; Kałużna-Oleksy, M; Kolasa, J; Lelonek, M; Nessler, J; Ptaszyńska-Kopczyńska, K; Rostoff, P; Straburzyńska-Migaj, E | 1 |
| Chen, WW; Dang, HQ; Gao, J; Jiang, J; Li, YM; Liu, YL; Zhang, XZ | 1 |
| Asai, K; Asano, M; Kanai, H; Matsushita, M; Noma, S; Nomura, A; Sawatani, T; Shirakabe, A; Takayasu, T | 1 |
| Page, RL | 1 |
| Chen, X; Cheng, J; Du, W; Hu, Y; Li, J; Li, X; Li, Z; Su, J; Yang, J; Yu, Q; Zhang, Z; Zheng, N | 1 |
| Fukushima, H; Horio, T; Ishimitsu, T; Iwashima, Y; Rai, T | 1 |
| Franceschi, F; Gabrielli, M; Romani, GR | 1 |
| Cohen-Solal, A; Laribi, S; Lassus, J; Launay, JM; Logeart, D; Michel, T; Nougué, H; Picard, F; Sadoune, M; Vodovar, N | 1 |
| Chen, M; Fu, P; Gan, Y; He, X; He, Y; Jin, Y; Li, K; Liao, R; Liu, R; Qin, M; Wang, Z; Xue, H; Zhang, M; Zheng, L; Zhong, H; Zhou, X; Zou, H | 1 |
| Braunwald, E; Hernandez, AF; Lepage, S; Mentz, RJ; Morrow, DA; Sarwat, S; Sharma, K; Solomon, SD; Starling, RC; Velazquez, EJ; Ward, JH; Williamson, K; Zieroth, S | 1 |
| Angelini, F; Coppini, L; Ferraro, I; Giordana, F; Musumeci, G; Rossini, R; Ruffino, E; Tizzani, E; Valente, E; Varbella, F | 1 |
| Goetze, JP; Hansen, LH; Nersting, J; Terzic, D | 1 |
| Chatur, S; Claggett, BL; Lefkowitz, M; McCausland, FR; McMurray, JJV; Packer, M; Pfeffer, MA; Rouleau, J; Solomon, SD; Vaduganathan, M; Zile, MR | 1 |
| Aoki, J; Asami, M; Horiuchi, Y; Ishizawa, T; Kawakami, T; Komiyama, K; Nakajima, M; Nakase, M; Nonaka, H; Sekiguchi, M; Setoguchi, N; Tanabe, K; Tanaka, J; Watanabe, Y; Yahagi, K; Yuzawa, H | 1 |
| Ahmad, J; Dominic, P; Mohammad, Z; Morin, D; Penagaluri, A; Sultan, A | 1 |
| Dodd, JD; Fox, R; Gallagher, J; Ledwidge, M; McDonald, K; McVeigh, N; Murphy, DJ; Ryan, F; Shorten, E; Sweeney, C; Watson, C; Zhou, S | 1 |
| Flynn, H; Hayes, W; Henter, J | 1 |
| Januzzi, JL; Murphy, SP | 1 |
| Ye, G | 1 |
| Agostoni, P; Cimino, R; Ferrari, C; Mantegazza, V; Mapelli, M; Maragna, R; Pepi, M; Pontone, G | 1 |
| Ashraf, T; Balouch, IJ; Bashir, S; Bhatti, UH; Karim, M; Khan, MN; Moazzam, A; Naseeb, K; Rauf, R; Soomro, NA | 1 |
| Bonilla Palomas, JL; Escobar Cervantes, C; Esteban Fernández, A; González Costello, J; González Franco, A; Mirabet, S; Núñez Villota, J; Recio Mayoral, A; Rubio Gracia, J | 1 |
| Abdelaziz, RR; Abo-Khookh, AM; Ghoneim, HA; Nader, MA; Shawky, NM | 1 |
| Akrobetu, DJ; Barks, MC; Campagna, A; Davis, JK; Dickert, NW; Farley, S; Gutterman, S; Mitchell, AR; Nguyen, TV; Rao, BR; Santanam, T; Sharma, A; Speight, CD; Ubel, PA | 1 |
| Chen, R; Cheng, Y; Deng, P; Gao, LC; Li, CX; Li, FJ; Li, HL; Li, L; Long, HZ; Luo, HY; Peng, XY; Xu, SG; Zhou, ZW | 1 |
| Li, X; Lou, Y; Sun, M; Wang, Q; Wang, Y; Wang, Z | 1 |
| Gu, J; Wang, CQ; Wang, Y; Zhang, JF | 1 |
| Fu, K; Hu, Y; Ji, X; Lin, Z; Lu, H; Miao, D; Sun, Y; Wang, C; Wang, F; Xiao, J; Zhang, H; Zhang, X | 1 |
| Appelbaum, JS; Huetteman, AT; Reyes, EA; Zhang, H | 1 |
| Bin, J; Cao, S; Chen, L; He, M; Huang, X; Li, M; Liao, W; Liao, Y; Lin, H; Liu, C; Shen, M; Zheng, C | 1 |
| Biering-Sørensen, T; Claggett, B; Lassen, MCH; Lefkowitz, M; McMurray, JJV; Packer, M; Pieske, B; Pieske-Kraigher, E; Shah, A; Shi, V; Solomon, SD; Voors, A; Zile, M | 1 |
| Ayesta, A; Datino, T; Díez-Villanueva, P; Esteban-Fernández, A; Jimenez-Mendez, C; Martínez-Sellés, M; Pérez, Á | 1 |
| Chen, L; He, J; Li, Q; Qiu, Z; Tang, M; Wu, Q; Xie, L; Zheng, J | 1 |
| Amir, O; Braunwald, E; Butt, JH; Cadena, A; Carrillo-Calvillo, J; Cho, MC; Claggett, BL; Granger, CB; Jering, KS; Kerkar, P; Køber, L; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Merkely, B; Miao, ZM; Ntsekhe, M; Núñez, JE; Pfeffer, MA; Sim, D; Solomon, SD; Steg, PG; van der Meer, P; Zhou, Y | 1 |
| Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Piña, IL; Solomon, SD; Ward, JH | 1 |
| Kudryavtsev, AA; Makarovskaya, MV; Ryazanov, AS; Shikh, EV | 1 |
| Abraham, WT; Butt, JH; Desai, AS; Dewan, P; Dickstein, K; Ferreira, JP; Jhund, PS; Køber, L; McMurray, JJV; Packer, M; Petrie, MC; Rouleau, JL; Solomon, SD; Stewart, S; Swedberg, K; Zile, MR | 1 |
| Azushima, K; Tamura, K; Tsukamoto, S; Uehara, T; Wakui, H | 1 |
| Chen, J; Li, C; Liang, W; Pei, Y; Wang, Q; Yu, J | 1 |
| Akai, H; Munakata, Y; Numahata, T; Sawada, S; Tanji, Y; Watanabe, T | 1 |
| Bianchi, F; Cotugno, M; Fiori, E; Forte, M; Gallo, G; Magrì, D; Marchitti, S; Raffa, S; Ranieri, D; Rubattu, S; Sciarretta, S; Stanzione, R; Testa, M; Visco, V; Volpe, M | 1 |
| Alacapa, J; Alconera, CJ; Almirol, BJ; Caesar Delos Trinos, JP; Gerodias, F; Leong, RN; Lim, S; Mojica, VJ; Paredes, KP; Tamayo, RL; Tumanan-Mendoza, B | 1 |
| Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Myhre, PL; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH | 1 |
| Hu, WS; Lin, CL | 2 |
| Chen, BT; Chen, YN; Huang, XL; Wang, XJ | 1 |
| Barylski, M; Drożdż, J; Filipiak, KJ; Gorczyca-Głowacka, I; Kapłon-Cieślicka, A; Kasprzak, JD; Lelonek, M; Mamcarz, A; Ochijewicz, D; Ryś-Czaporowska, A; Sobczak-Kaleta, M; Starzyk, K; Szymański, FM; Wełnicki, M; Wożakowska-Kapłon, B | 1 |
| Braunwald, E; Claggett, BL; Desai, AS; Hernandez, AF; Kulac, IJ; Lefkowitz, M; McMurray, JJV; Mentz, RJ; Miao, ZM; Morrow, DA; Solomon, SD; Starling, RC; Vaduganathan, M; Velazquez, EJ; Ward, JH; Williamson, KM; Zieroth, S | 1 |
| Braunwald, E; Desai, AS; Hernandez, AF; Lepage, S; Mentz, RJ; Morrow, DA; Sarwat, S; Sharma, K; Solomon, SD; Starling, RC; Velazquez, EJ; Ward, JH; Williamson, KM; Zieroth, S | 1 |
| Lavie, CJ; Mehra, MR; Ventura, HO | 3 |
| Bhatt, AS; Desai, RJ; Lee, SB; Vaduganathan, M | 1 |
| Liu, Y; Ma, X; Sheng, Y; Sun, F; Yang, X | 1 |
| Pandya, A; Spahillari, A; Yan, BW | 1 |
| Fernández-Ruiz, I | 4 |
| Aspromonte, N; Bonanni, A; Camilli, M; Chiorazzo, G; Crea, F; Graziani, F; Iannaccone, G; Lanza, GA; Locorotondo, G; Lombardo, A; Mango, F; Massetti, M; Meucci, MC; Montone, RA; Natali, R; Russo, M | 1 |
| Chang, HY; Fong, MC; Huang, HT; Huang, JL; Ko, SL; Liao, CT; Lin, WY; Lo, HC; Wang, CY | 1 |
| Adamsson Eryd, S; Bodegård, J; Bozkurt, B; Cleland, JGF; Khordoc, C; Kishi, T; Lund, LH; Savarese, G; Thuresson, M; Vardeny, O; Zhang, R | 1 |
| Harada, N; Kato, T; Murakami, T; Yabe, D | 1 |
| Agostoni, P; Capovilla, T; De Martino, F; Dell'Aversana, S; Esposito, I; Filardi, PP; Galotta, A; Magrì, D; Mantegazza, V; Mapelli, M; Mattavelli, I; Nepitella, AA; Paolillo, R; Paolillo, S; Salvioni, E; Tamborini, G; Vignati, C | 1 |
| Ako, J; Eda, Y; Fujita, T; Iida, Y; Ikeda, Y; Ishii, S; Koitabashi, T; Nabeta, T; Oikawa, J; Takigami, Y; Yazaki, M | 1 |
| Bernhardt, R; Chapa, J; Damera, N; George, B; Lee, E; Rao, RA; Reese, L; Shah, C | 1 |
| Butler, J; Claggett, BL; Felker, GM; Januzzi, JL; Kulac, IJ; Liu, Y; McMurray, JJV; Myhre, PL; Piña, IL; Prescott, MF; Rouleau, JL; Solomon, SD; Ward, JH; Zile, MR | 1 |
| Adamson, C; Curtain, JP; Desai, AS; Docherty, KF; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Abrahamowicz, M; Behlouli, H; de Moura, CS; Pilote, L; Sohani, ZN | 1 |
| Abozied, O; Anderson, JH; Andi, K; Burchill, LJ; Connolly, HM; Egbe, AC; Jain, CC; Miranda, WR | 1 |
| Boonpala, P; Kalandakanond-Thongsong, S; Kijtawornrat, A; Kumphune, S; Panyasing, Y; Saengklub, N; Tantisuwat, L | 1 |
| Acquaro, M; Ghio, S; Greco, A; Pasotti, B; Rordorf, R; Sanzo, A; Savastano, S; Scelsi, L; Schirinzi, S; Seganti, A; Spolverini, M; Turco, A | 1 |
| Le Jemtel, TH; Samson, R | 1 |
| Bachórzewska-Gajewska, H; Dobrzycki, S; Zalewska-Adamiec, M | 1 |
| Cai, JL; Yu, J; Zhang, T | 1 |
| Blohm, JH; Brockmöller, J; Burgdorf, C; Hundack, L; Ivanoski, S; Januszewski, M; Remppis, BA | 1 |
| Chang, HY; Chen, YJ; Hou, CJ; Hsiao, CC; Hsu, CY; Hsu, NW; Huang, WH; Hung, CL; Hung, TC; Lin, YH; Su, CH; Sung, KT; Tsai, CT; Tsai, SY; Yeh, HI; Yun, CH | 1 |
| Agostoni, P; Banfi, C; Biondi, ML; Bonomi, A; Capra, N; Mapelli, M; Mattavelli, I; Palermo, P; Paolillo, S; Salvioni, E | 1 |
| Bellows, BK; Cohen, LP | 1 |
| Alencar, AKN | 1 |
| Ji, XP; Lin, ZW; Lyu, HX; Wu, AH | 1 |
| Alibaşiç, H; Aydin, S; Çiçek, M; Ekici, B; Koçak, A | 1 |
| Alarco, W; Figueroa, Y; Gómez-Mesa, JE; Magaña, A; Pow-Chon, F; Quesada, D; Ramos, CE; Rodríguez-García, D; Rossel, V; Saldarriaga, C; Speranza, M; Ventura-Umanzor, JR | 1 |
| Cao, P; Lv, Y; Peng, H; Yang, Q; Zhai, X | 1 |
| Ieda, M; Ishizu, T; Kawamatsu, N; Machino-Ohtsuka, T; Minami, K; Nakatsukasa, T; Sato, K; Terauchi, T; Yamamoto, M | 1 |
| Huang, Y; Li, X; Li, Y; Liu, Z; Wu, X | 1 |
| Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG | 1 |
| Aili, A; Bate, B; Chen, P; Dan, S; Guo, J; Han, Z; Hou, D; Hu, G; Kuransi, A; Nay, X; Qiqike, B; Xia, B; Xie, J; Zhu, M | 1 |
| Morita, H; Nakanishi, K | 1 |
| Chen, H; Cid-Ruzafa, J; Delgado, JF; Duong, M; Escobar, C; Gonzalez, V; Gutiérrez, M; Hernández, I; Hunt, PR; Justo, N; Palacios, B | 1 |
| Burnett, JC; Cappola, TP; Felker, GM; Hernandez, AF; Iyer, SR; Lyle, MA; Pereira, NL; Reddy, YNV; Redfield, MM; Scott, CG | 1 |
| Menachem, JN; Opotowsky, AR | 1 |
| Abellas-Sequeiros, M; Alonso-Salinas, GL; Del Prado Díaz, S; Del Rey, JM; Zamorano, JL | 1 |
| Erviti, J; Leache, L; Saiz, LC | 1 |
| López, GT; Malafarina, V; Rodil Fraile, R | 1 |
| Fabris, E; Ferrari, R; Frigerio, M; Merlo, M; Metra, M; Rapezzi, C; Sinagra, G | 1 |
| De Vecchis, R; Di Maio, M; Paccone, A | 2 |
| Anand, IS; Boytsov, SA; Claggett, B; Cleland, J; Comin-Colet, J; Desai, AS; Düngen, HD; Ge, J; Goncalvesova, E; Gong, J; Jhund, PS; Katova, T; Kerr Saraiva, JF; Lam, CSP; Lefkowitz, MP; Lelonek, M; Maggioni, AP; Martinez, F; McMurray, JJV; Merkely, B; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Senni, M; Shah, SJ; Shi, VC; Solomon, SD; van Veldhuisen, DJ; Zannad, F; Zhou, J; Zile, MR | 1 |
| Docherty, KF; McMurray, JJV | 1 |
| Chung, F; Han, J; Jackevicius, CA; Mody, FV; Nguyen, QL | 1 |
| Grigg, SE | 1 |
| Okunade, O | 1 |
| Albert, NM; Arnold, SV; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Hellkamp, A; Khariton, Y; McCague, K; Nassif, ME; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB | 1 |
| Balsam, P; Dąbrowski, R; Farkowski, MM; Gackowski, A; Grabowski, M; Jędrzejczyk-Patej, E; Kalarus, Z; Leszek, P; Nessler, J; Opolski, G; Ozierański, K; Przybylski, A; Sterliński, M | 1 |
| Aguiar, C; Cardoso, J; Ferrari, R; Fonseca, MC; Fucili, A; Moreira, JI; Rapezzi, C | 1 |
| Jorsal, A; McMurray, JJV; Nielsen, JC; Nielsen, RR; Pryds, K; Sommer, A; Wiggers, H | 1 |
| de Jong, LA; Jansen, DEMC; Postma, MJ; van der Pol, S; Vemer, P | 1 |
| Chang, HY; Chen, KC; Chong, E; Feng, AN; Fong, MC; Fu, HN; Huang, KC; Yin, WH | 1 |
| Castiello, A; Gavazzoni, M; Metra, M; Sciatti, E; Vizzardi, E | 1 |
| Akerman, CC; Beavers, JC | 1 |
| Addetia, K; Kalantari, S; Karagodin, I; Kim, G; Lang, R; Mor-Avi, V; Sayer, G; Tayazime, S; Uriel, N; Weinert, L; Yamat, M; Yu, DB | 1 |
| Meyer, P; Reny, JL; Russo-Vorms, L | 1 |
| Birkeland, K; Fombu, E; Grant, D; Heywood, JT; Khandwalla, RM; McCague, K; Owens, RL; Riebman, JB; Steinhubl, S | 1 |
| Heyse, A; Mahieu, E; Manhaeghe, L; Van Durme, F; Vanfraechem, C | 1 |
| Akin, I; Borggrefe, M; El-Battrawy, I | 1 |
| Adams, KF; Albert, NM; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Giblin, EM; Hernandez, AF; Hill, L; McCague, K; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB | 1 |
| Dauw, J; Dupont, M; Martens, P; Mullens, W; Somers, F; Van de Broek, H; Verluyten, L | 1 |
| Bover, R; De-Juan, J; Del Prado, S; Díez-Villanueva, P; Esteban-Fernández, A; Gómez-Bueno, M; López-Azor, JC; Manuel-Iniesta, Á; Martínez-Sellés, M; Pérez, Á; Valero-Masa, MJ; Vicent, L | 1 |
| Książczyk, M; Lelonek, M | 1 |
| Bayramoğlu, A; Dereli, S; Kaya, A | 1 |
| Alba, PR; Bress, AP; Choi, ME; Dodson, JA; He, T; King, JB; LaFleur, J; Levitan, EB; Mohanty, AF; Patterson, OV; Russo, PA; Vardeny, O | 1 |
| Anand, IS; Cikes, M; Claggett, B; Ge, J; Goncalvesova, E; Jackson, AM; Jhund, PS; Katova, T; Kosztin, A; Lam, CSP; Lefkowitz, MP; Lelonek, M; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Sabarwal, SV; Shah, AM; Shah, SJ; Shi, VC; Solomon, SD; Sweitzer, N; van Veldhuisen, DJ; Vardeny, O; Zannad, F; Zile, MR | 1 |
| A Pfeffer, M; Anand, I; Boytsov, S; Chen, CH; Desai, A; Kober, L; L Claggett, B; Lefkowitz, M; Linssen, G; Luis Arango, J; Lund, LH; McMurray, JJV; Merkely, B; Packer, M; Rizkala, A; Rouleau, J; Senni, M; Shi, V; Sibulo, A; Solomon, SD; Swedberg, K; Sweitzer, N; Vaduganathan, M; Vinereanu, D; Zile, M | 1 |
| Ajufo, E; Das, SR; Fonarow, GC; Navar, AM; Pandey, A; Sumarsono, A; Vaduganathan, M | 1 |
| Angeletti, S; Anguissola, GB; Bono, MC; Ciccozzi, M; Costantino, S; Locorriere, L; Pantano, AL; Spoto, S; Terracciani, F; Valeriani, E | 1 |
| Li, Y; Liu, Z; Wang, J | 1 |
| Bergdahl, E; Lindmark, K; Norberg, H | 2 |
| Chang, PC; Chou, CC; Chu, Y; Huang, YC; Lee, HL; Lin, SF; Wen, MS; Wo, HT | 1 |
| Chen, X; Fu, M; Schaufelberger, M | 1 |
| Abbate, A; Bonaventura, A; Del Buono, MG; Dixon, DL; Van Tassel, BW; Vecchié, A; Wohlford, GF | 1 |
| Lund, LH; Savarese, G | 1 |
| Bao, W; Belohlavek, J; Butylin, D; Chakrabarti, A; Fonseca, C; Lonn, E; Mueller, C; Noe, A; Pascual-Figal, D; Schwende, H; Senni, M; Straburzynska-Migaj, E; Wachter, R; Witte, KK | 1 |
| Wilcox, JE | 1 |
| Ambrosy, AP; Braunwald, E; Chakraborty, H; DeVore, AD; Duffy, CI; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| DeVore, AD; Hernandez, AF | 1 |
| Dunlay, SM; Sangaralingham, LR; Sangaralingham, SJ; Shah, ND; Tan, NY; Yao, X | 1 |
| Bhatt, AS; Butler, J; Vaduganathan, M | 1 |
| Cohen-Solal, A; Logeart, D | 1 |
| Gao, Y; Hao, W; Hou, A; Luan, B; Wang, L; Xing, C; Zhao, H | 1 |
| Barrios, V; Escobar, C; Manzano, L | 1 |
| Chang, HY; Yin, WH | 1 |
| Hryniewiecki, T; Kodziszewska, K; Kruszewski, M; Leszek, P; Pączek, L; Śmigielski, W; Sochanowicz, B | 1 |
| Chow, CL; Hannah, V; Nandal, S; Vaddadi, G; Van Gaal, W | 1 |
| Ayesta, A; Bover-Freire, R; de Juan-Bagudá, J; de la Cuerda, F; Díez-Villanueva, P; Esteban-Fernández, A; García-Aguado, M; Gómez-Bueno, M; Iglesias, D; Iniesta, ÁM; Martínez-Sellés, M; Perea-Egido, JÁ; Rojas-González, A; Salamanca, J; Vicent, L | 1 |
| Buckley, LF; Shah, AM | 1 |
| Abreu, J; Branco, L; Feliciano, J; Ferreira, RC; Galrinho, A; Moreira, RI; Pereira-da-Silva, T; Rio, P; Soares, RM; Timóteo, AT; Valentim Gonçalves, A | 1 |
| Bozkurt, B; Ezekowitz, J | 1 |
| Raina, A; Sokos, GG | 1 |
| Castro, A; Chaparro-Muñoz, M; López-Fernández, T; Lopez-Sendon, JL; Martín-Garcia, A; Martin-Garcia, AC; Martinez-Monzonis, A; Mitroi, C; Moliner, P; Sanchez, PL | 1 |
| Fu, M; Ljungman, C; Nordberg Backelin, C | 1 |
| Di Tano, G; Senni, M | 1 |
| Aguirre-Plans, J; Fernández-Fuentes, N; Jorba, G; Junet, V; Mas, JM; Oliva, B; Pujol, A; Ruiz, JL; Segú-Vergés, C | 1 |
| Cheng, S; Hamilton, MA; Kittleson, MM; Solomon, SD; Wolfson, AM; Zern, EK; Zile, MR | 1 |
| Gonçalves, FR; Polónia, J | 1 |
| Briasouli, A; Briasoulis, A; Fujisaki, T; Kuno, T; Takagi, H; Ueyama, H | 1 |
| Brännström, M; Hellström Ängerud, K; Holmlund, L; Lindmark, K; Sandberg, C | 1 |
| Chun, KH; Ha, J; Kang, SM; Kim, H; Lee, CJ; Lee, S; Lee, SH; Oh, J; Park, S | 1 |
| Carballo, D; Carballo, S; Garin, N; Marti, C; Serratrice, J; Stirnemann, J | 1 |
| Ahmad, T; Desai, NR; Kahn, PA; Riello, RJ | 1 |
| Abumayyaleh, M; Akin, I; Behnes, M; Borggrefe, M; El-Battrawy, I | 1 |
| Anand, IS; Anker, SD; Böhm, M; Claggett, BL; Lam, CSP; Lefkowitz, MP; McMurray, JJV; Pieske, B; Selvaraj, S; Shi, VC; Solomon, SD; Vaduganathan, M; Zannad, F | 1 |
| Acanfora, C; Acanfora, D; Bortone, AS; Casucci, G; Ciccone, MM; Goglia, F; Incalzi, RA; Maestri, R; Scicchitano, P; Uguccioni, M | 1 |
| Chang, PC; Chou, CC; Chu, Y; Lee, HL; Lin, SF; Wen, MS; Wo, HT | 1 |
| Claggett, BL; Jhund, PS; Lefkowitz, M; McMurray, JJV; Packer, M; Rizkala, A; Seferovic, P; Shi, V; Solomon, SD; Vaduganathan, M; Widimský, J | 1 |
| Abete, R; Chioffi, M; Grillo, M; Margonato, D; Mazzetti, S; Mortara, A; Passafaro, G; Pisani, M; Poggio, D; Rossi, J; Scifo, C | 1 |
| Anker, SD; Böhm, M; Kindermann, I; Lam, CSP; Laufs, U; Maack, C; Selejan, S; Tschöpe, C; Ukena, C; Voors, AA; Werner, C; Wintrich, J | 1 |
| Januzzi, JL; Myhre, PL | 1 |
| Anand, IS; Chopra, VK; Claggett, BL; Cunningham, JW; Janssens, S; Jhund, PS; Kober, L; Lam, CSP; Lefkowitz, MP; McMurray, JJV; Packer, M; Pfeffer, MA; Prescott, MF; Rouleau, J; Shah, SJ; Shi, VC; Solomon, SD; Vaduganathan, M; Zannad, F; Zile, MR | 1 |
| DeVore, AD; Fonarow, GC; Fudim, M; Heidenreich, PA; Hernandez, AF; Matsouaka, RA; Sayeed, S; Velazquez, EJ; Xu, H; Yancy, CW | 1 |
| Chen, X; Jin, C; Xiang, M; Xie, L | 1 |
| Agra-Bermejo, R; Alvarez Rodríguez, L; González-Juanatey, JR | 1 |
| Chin, KL; Liew, D; Wang, BH; Zomer, E | 1 |
| Bidaut, A; Bouali, Y; Donal, E; Gallard, A; Galli, E; Hubert, A; Laurin, C; Leclercq, C | 1 |
| Auria, F; Bonadies, D; Carrizzo, A; Ciccarelli, M; Citro, R; De Angelis, E; Galasso, G; Gigantino, A; Iaccarino, G; Loria, F; Polito, MV; Rispoli, A; Silverio, A; Vecchione, C; Vitulano, G | 1 |
| Chui, F; Dashwood, A; Gan, J; Laher, S; Rheault, H; Vale, C; Wong, YW | 1 |
| Berge, E; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA; Wyller, TB | 1 |
| Bewarder, Y; Böhm, M; Kindermann, I | 1 |
| Ackermann, G; Ahmed, K; Dieterle, T; Hullin, R; Meyer, I; Schaefer, S | 1 |
| He, LS; Huang, JQ; Lao, HY; Liu, XQ; Xia, C; Xiong, LJ | 1 |
| Claggett, B; Lefkowitz, M; McMurray, JJV; Minamisawa, M; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Suzuki, K; Swedberg, K; Zile, MR; Zucker, SD | 1 |
| Feng, H; Li, WJ; Liao, HH; Mou, SQ; Tang, QZ; Wu, HM; Xia, H; Zhang, N; Zhou, ZY | 1 |
| Aronovitz, MJ; Blanton, RM; Jaffe, IZ; Martin, GL; Pande, S; Richards, DA; Tam, K | 1 |
| Comin-Colet, J; Ecochard, L; Edelmann, F; Hussain, RI; Jaarsma, T; Piepoli, MF; Schorr, J | 1 |
| Barry, M; Doran, S; Kennedy, C; Smith, A | 1 |
| Butler, J; Camacho, A; Felker, GM; Januzzi, JL; Maisel, AS; Piña, IL; Prescott, MF; Rocha, R; Solomon, SD; Williamson, KM | 1 |
| Dauw, J; Martens, P; Mullens, W; Tersalvi, G | 1 |
| Chalikias, G; Tziakas, D | 1 |
| Ambrosy, AP; Chioncel, O | 1 |
| Biegus, J; Ponikowski, P; Zymliński, R | 1 |
| Newby, LK; Sen, S | 1 |
| Abete, R; De Ponti, R; Iacovoni, A; Marazzato, J; Mortara, A; Senni, M; Vecchi, AL | 1 |
| Baković, D; Barac, A; Čapkun, V; Duplančić, D; Eterović, D; Mirić, D; Sorić, T; Vuković, I | 1 |
| Estep, JD; Luthman, J; Randhawa, VK; Soltesz, EG; Starling, RC; West, L | 1 |
| Chen, X; Du, F; Gao, Z; Hua, H; Jing, X; Li, S; Sun, G; Sun, J; Xiao, Y; Xu, W | 1 |
| Liu, T; Roever, L; Tse, G; Wang, Y | 1 |
| Node, K; Tanaka, A | 2 |
| Claggett, BL; Cunningham, JW; McMurray, JJV; Solomon, SD; Vaduganathan, M | 2 |
| Wu, K; Zhao, S | 1 |
| Jackson, AM; Jhund, PS; McMurray, JJV; Solomon, SD | 1 |
| Ambrosy, AP; Braunwald, E; Desvigne-Nickens, P; DeVore, AD; Gilotra, NA; Givertz, MM; Gorodeski, EZ; Greene, SJ; Gupta, D; Hernandez, AF; Lala, A; Lewis, GD; Mahr, C; Mann, DL; McNulty, SE; Mohammed, SF; Redfield, MM; Shah, P; Starling, RC; Vader, JM | 1 |
| Ates, B; Colak, C; Ermis, N; Ozhan, O; Parlakpinar, H; Ulutas, Z; Vardi, N | 1 |
| Ioannou, A; Mandal, AKJ; Metaxa, S; Missouris, CG; Simon, S | 2 |
| Balsam, P; Grabowski, M; Opolski, G; Ozierański, K; Tymińska, A | 1 |
| Bengtsson, O; Claggett, BL; Desai, AS; Dewan, P; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjostrand, M; Solomon, SD | 1 |
| Maksutovic, NM; Thornby, KA | 1 |
| Maurer, SJ; Tutarel, O | 1 |
| Chang, PC; Chou, CC; Chu, PH; Hsiao, FC; Huang, CY; Wang, CL; Wen, MS | 1 |
| Ammendola, E; D'Alterio, G; Gravino, R; Limongelli, G; Masarone, D; Melillo, E; Pacileo, G; Petraio, A; Valente, F; Vastarella, R; Verrengia, M | 1 |
| Chiang, LM; Claggett, BL; Cunningham, JW; Lefkowitz, MP; McMurray, JJV; O'Meara, E; Pfeffer, MA; Prescott, MF; Redfield, MM; Rizkala, AR; Rouleau, J; Shah, SJ; Shi, VC; Solomon, SD; Zannad, F; Zile, MR | 1 |
| Bayes-Genis, A; Lupón, J; Núñez, J | 1 |
| Gronda, E; Iacoviello, M; Napoli, C | 1 |
| Almenar-Bonet, L; Batalla-Monedero, M; López-Vilella, R; Pérez-Roselló, V; Sánchez-Lázaro, I; Sierra-San Miguel, P | 1 |
| Chen, G; Deng, Z; Fang, Y; Kang, H; Qin, G; Wang, K; Zhang, J; Zhang, X | 1 |
| Agostoni, P; Bonomi, A; de Martino, F; Gugliandolo, P; Magini, A; Mapelli, M; Mattavelli, I; Paolillo, S; Rovai, S; Salvioni, E; Sassi, V; Vignati, C | 1 |
| Chilbert, MR; Ciriello, DN; Rogers, KC; Rovelli, R; Woodruff, AE | 1 |
| Branzi, G; Caravita, S; Cerea, P; Ciambellotti, F; Malfatto, G; Munforti, C; Parati, G; Ravaro, S; Villani, A | 1 |
| Benson, L; Dahlström, U; Fudim, M; Hage, C; Linde, C; Lund, LH; Lundberg, A; Rosano, GMC; Savarese, G; Schrage, B; Thorvaldsen, T | 1 |
| Bonow, RO; Hernandez, AF; Yancy, CW | 1 |
| Braunwald, E; Fonarow, GC; Gaziano, TA; Morrow, DA; Solomon, SD; Velazquez, EJ | 1 |
| Ahmad, T; Desai, NR | 1 |
| Bao, W; Butylin, D; Noè, A; Pascual-Figal, D; Prescott, MF; Schwende, H; Senni, M; Wachter, R | 1 |
| Berg, DD; Braunwald, E; DeVore, AD; Duffy, CI; Gurmu, Y; Lala, A; Morrow, DA; Pinney, SP; Velazquez, EJ | 1 |
| Allen, LA; Dickert, N; Doermann Byrd, K; Matlock, DD; Venechuk, GE | 1 |
| Arslan, U; Çoksevim, M; Dereli, S; Doğduş, M; Kaya, A; Yenerçağ, M | 1 |
| Ängerud, KH; Bergdahl, E; Lindmark, K; Norberg, H | 1 |
| Eworuke, E; Huang, TY; Kolonoski, J; Menzin, TJ; Welch, EC | 1 |
| Anand, IS; Claggett, BL; Cleland, JGF; Desai, AS; Janssens, S; Kober, L; Lefkowitz, MP; Mc Causland, FR; McGrath, MM; McMurray, JJV; Pfeffer, MA; Pieske, B; Rouleau, JL; Selvaraj, S; Shi, VC; Solomon, SD; van Veldhuisen, DJ; Zile, MR | 1 |
| Dani, SS; Ganatra, S; Vaduganathan, M | 1 |
| Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; McCague, K; Meng, X; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| Ahmed, T; Gottlieb, SS | 1 |
| Hu, P; Jin, D; Ke, Z; Wu, Y; Zhang, K; Zhang, Y | 1 |
| Frljak, S; Vrtovec, B; Zorz, N | 1 |
| Al-Khatib, SM; Blumer, V; Felker, GM | 1 |
| Costanzo, MR | 2 |
| Ambrosy, AP; Berardi, C; Braunwald, E; Chakraborty, H; DeVore, AD; Duffy, CI; Morrow, DA; Mulder, HS; O'Brien, TX; Velazquez, EJ | 1 |
| Chatterjee, NA; Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJV; Packer, M; Rohde, LE; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Vaduganathan, M; Zile, M | 1 |
| Mandal, AKJ; Missouris, CG | 1 |
| Castrodeza, J; Couto-Mallón, D; Diez-López, C; Dobarro, D; Gómez-Bueno, M; Gonçalves, A; González-Costello, J; McKenzie, S; Melendo-Viu, M; Ortiz, C; Tobar, J | 1 |
| Aliyev, ER; Brauer, M; Park, S; Shafrin, J; Shen, X | 1 |
| Abbas, CA; Bapat, D; Butler, J; Camacho, A; Felker, GM; Ibrahim, NE; Januzzi, JL; Maisel, AS; Piña, IL; Prescott, MF; Solomon, SD | 1 |
| Danzi, GB; De Maria, R; Di Tano, G; Loffi, M; Verde, S | 1 |
| Birkeland, K; Fombu, E; Grant, D; Heywood, JT; Khandwalla, RM; Owens, RL; Steinhubl, SR | 1 |
| Abshire, M; Alexy, T; Barringhaus, KG; Blanco, R; Briasoulis, A; DeVore, AD; Dhingra, R; Duffy, CI; Dunlay, SM; Eckman, PM; Espinoza, J; Gupta, B; Hernandez, AF; Lala, A; Lowes, BD; Mentz, RJ; O'Brien, EC; Rodgers, JE; Shen, X; Simon, MA; Stehlik, J; Thomas, L; Vilaro, J; Wells, QS; Xu, H | 1 |
| Docherty, KF; McMurray, JJV; Solomon, SD; Vaduganathan, M | 1 |
| Elsayed, H; Ganesananthan, S; Morgan, A; Parkes, A; Phillips, J; Shah, N; Shah, P; Yousef, Z | 1 |
| Lelonek, M | 2 |
| Hu, J; Huo, J; Jiang, W; Shan, Q; Wang, X; Wu, Y; Zhou, X | 1 |
| Chan, H; Chng, BLK; Gao, F; Hon, JS; Sim, KLD; Teo, LYL; Zheng, Y | 1 |
| Celli, D; Colombo, R; Galo, J | 1 |
| Bosso, G; Botta, A; Carbone, V; Carella, G; Cittadini, A; De Luca, M; Del Buono, A; Di Giovanni, G; Fimiani, B; Guardasole, V; Guarnaccia, F; Lapice, E; Martedì, E; Memoli, G; Oliva, D; Oliviero, U; Romano, G; Valvano, A; Zito, GB | 1 |
| Aimo, A; Bayes-Genis, A; Emdin, M; Georgiopoulos, G; Lombardi, CM; Passino, C; Pateras, K; Stamatelopoulos, K | 1 |
| Alves, S; Capilé, E; Feliciano, J; Ferreira, RC; Galrinho, A; Gonçalves, AV; Moreira, RI; Pereira-da-Silva, T; Rio, P; Silva, S; Soares, R | 1 |
| Bozkurt, B; Gillette, M | 1 |
| Cheng, S; Hua, W; Zhang, N | 1 |
| Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY | 1 |
| Balas, B; Bruce Wirta, S; Engelhard, J; Fonseca, AF; Kap, E; Klebs, S; Schlienger, R; Wachter, R | 1 |
| Malfatto, G; Parati, G; Villani, A | 1 |
| Haynes, R; Judge, PK | 1 |
| Albert, NM; Butler, J; Duffy, CI; Fonarow, GC; Hellkamp, A; Khariton, Y; Nassif, ME; Spertus, JA; Thomas, L | 1 |
| Dickert, NW; Moore, MA; Morris, AA; Rao, BR; Shore, S; Smith, GH; Speight, CD | 1 |
| Kadler, KE; Lewis, GA; Miller, CA; Schelbert, EB | 1 |
| Claggett, BL; Cunningham, JW; Solomon, SD; Zile, MR | 1 |
| Butler, J; Camacho, A; Claggett, BL; Desai, AS; Felker, GM; Ibrahim, NE; Januzzi, JL; Maisel, AS; Piña, IL; Prescott, MF; Solomon, SD; Williamson, KM | 1 |
| Abbas, C; Burnett, JC; Butler, J; Camacho, A; Felker, GM; Ibrahim, NE; Iyer, SR; Januzzi, JL; Maisel, AS; Murphy, SP; Piña, IL; Prescott, MF; Solomon, SD | 1 |
| Huang, J; Nie, D; Qian, J; Rong, S; Xiong, B; Yao, Y | 1 |
| Emdin, M; Giannoni, A; Masotti, S; Musetti, V; Passino, C; Prontera, C; Sciarrone, P; Senni, M; Valleggi, A; Vergaro, G | 1 |
| Bu, FL; Feinberg, JB; Hecht Olsen, M; Jakobsen, JC; Nielsen, EE; Raymond, I; Steensgaard-Hansen, F | 1 |
| Christophy, A; Heywood, JT; Jer, D; Kuo, RS; Mohan, RC; Pandey, AC; Srivastava, AV; Yoo, DH | 1 |
| Schwartzmann, P | 1 |
| Elston, C; Gengler, B; Kester, J; Montepara, C; Rerick, L | 1 |
| Battistoni, A; Bauersachs, J; Bayés-Genís, A; Butler, J; Cohen-Solal, A; Deichl, AS; Gallo, G; Khan, MS; Pieske, B; Saito, Y; Volpe, M; Zieroth, S | 1 |
| Allen, LA; Dickert, NW; Matlock, DD; Mitchell, AR; Moore, MA; Morris, AA; Pierce, KJ; Speight, CD; Venechuk, GE | 1 |
| Gallinoro, E; Golino, P; Palladino, A; Papa, AA | 1 |
| Bapat, D; Butler, J; Camacho, A; Felker, GM; Ibrahim, NE; Januzzi, JL; Khan, MS; Maisel, AS; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH | 1 |
| Hanoman, H; Mohammed, SR; Pinto Pereira, LM; Teelucksingh, S | 1 |
| Comin-Colet, J; Dosantos, R; Edelmann, F; Ferber, P; Hussain, RI; Jaarsma, T; Piepoli, MF | 1 |
| Maggioni, AP | 1 |
| Albert, CL; Donnellan, E; Estep, JD; Faulkenberg, KD; Il'giovine, ZJ; Martyn, T; Menon, V; Nissen, SE; Randhawa, VK; Starling, RC; Wilson Tang, WH | 1 |
| Cao, Y; Chen, A; Chen, M; Fan, Y; Guan, X; Li, J; Liu, Y; Yang, D | 1 |
| Bianco, C; Caccamo, M; Fang, W; Kido, K; Sokos, G | 2 |
| Fang, KF; Huang, YX; Jie, H; Li, BH; Lin, PH; Zhang, YH | 1 |
| Ferreira, JP; McCausland, FR; Packer, M; Patel, RB; Rossignol, P; Shah, SJ; Solomon, SD; Stockbridge, N; Ter Maaten, JM; Thompson, A; Vaduganathan, M; Zannad, F | 1 |
| Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Huang, JL; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY | 2 |
| El Nozahi, M; Rezq, A; Saad, M | 1 |
| Dormiani, K; Homayouni Moghadam, F; Nasr-Esfahani, MH; Poorgolizadeh, E; Rezaei, N | 1 |
| McMurray, JJV | 1 |
| Bouma, BJ; Egorova, AD; Jongbloed, MRM; Kiès, P; Nederend, M; Schalij, MJ; Tops, LF; Vliegen, HW; Zandstra, TE | 1 |
| Ferrara, F; La Porta, R; Vitiello, A | 1 |
| Casale, M; Correale, M; Crea, P; Dattilo, G; de Gregorio, C; Katsiki, N; Laterra, G; Luzza, F; Morabito, C; Signorelli, SS; Vaccaro, V | 1 |
| Howlett, JG | 1 |
| Andresen, H; Bendiksen, BA; Bergo, KK; Cataliotti, A; Christensen, G; Espe, EK; Hasic, A; Hauge-Iversen, IM; Hussain, RI; Nordén, ES; Sjaastad, I; Veras, I | 1 |
| O'Connor, CM | 1 |
| Ramakrishna, S; Salazar, JW; Tseng, ZH | 1 |
| Rohde, LE; Solomon, SD | 1 |
| Elkayam, U; Fong, MW; Grazette, LP; Havakuk, O; Hwang, J; Kwong, HY; McLeod, JM; Shavelle, D; Tran, JS; Zile, MR | 1 |
| Lelonek, M; Nowakowska, I; Pawlak, A; Rubiś, P; Wiśniowska-Śmiałek, S | 1 |
| Al'Aref, SJ; Almarzooq, ZI; Butler, J; Devabhaktuni, SR; Fudim, M; Greene, SJ; Khan, MS; Mentz, RJ; Salah, HM | 1 |
| Ambrosy, AP; Fudim, M; Tai, A | 1 |
| Agrawal, R; Corda, S; Jindal, R; Proudfoot, C; Rajput, T; Senni, M; Studer, R | 1 |
| Borrelli, C; Emdin, M; Gentile, F; Giannoni, A; Passino, C; Sciarrone, P; Spiesshoefer, J; Vergaro, G | 1 |
| Forteza Albertí, JF; González Colino, R; Mas-Lladó, C; Noris Mora, M; Pasamar Márquez, L; Peral Disdier, V; Pericas, P; Ramis-Barceló, MF; Rossello, X; Valadrón, I | 1 |
| Anand, IS; Claggett, BL; Cleland, JGF; Desai, AS; Ferreira, JP; Kober, L; Lefkowitz, MP; Liu, J; McMurray, JJV; Packer, M; Pfeffer, MA; Rouleau, JL; Shah, SJ; Shi, VC; Solomon, SD; van Veldhuisen, DJ; Vardeny, O; Zannad, F; Zile, MR | 1 |
| Cavallari, I; Grigioni, F; Maddaloni, E | 1 |
| Arroyo Rivera, B; Bravo Calero, L; de Juan Bitriá, C; Del Castillo, H; Martí Sánchez, D; Miracle Blanco, Á; Rubio Campal, JM; Sánchez Borque, P; Taibo Urquia, M; Tuñón Fernández, J | 1 |
| Alphonse Mahrouse, M; Hashem, HMA; Mahmoud, ST; Moussa, BA | 1 |
| Cho, GY; Choi, W; Hwang, IC; Kim, HK; Kim, YJ; Lee, SP; Moon, MG; Park, JB; Yoon, YE | 1 |
| Alaarag, AF; Amin, OA | 1 |
| Desai, AS; Guo, W; Iimori, T; Ito, H; Kitamura, T; Momomura, SI; Ohishi, T; Saito, Y; Sakata, Y; Tsutsui, H; Yamamoto, K | 1 |
| Abumayyaleh, M; Akin, I; Aweimer, A; Borggrefe, M; El-Battrawy, I; Kummer, M; Kuschyk, J; Mügge, A; Pilsinger, C; Sattler, K | 1 |
| Cui, X; Han, D; He, W; Jin, Z; Liu, Z; Raphael, DM; Shangguan, J; Shen, D | 1 |
| Adams, V; Augstein, A; Barthel, P; Draskowski, R; Galli, R; Goto, K; Jannasch, A; Kirchhoff, V; Linke, A; Männel, A; Mittag, J; Schauer, A; Winzer, EB | 1 |
| Borghi, C; Perrone Filardi, P; Pontremoli, R | 1 |
| Bitto, R; Casale, M; Correale, M; Crea, P; Dattilo, G; DE Gregorio, C; DI Bella, G; Katsiki, N; Laterra, G; Luzza, F; Migliorato, A; Morabito, C; Vaccaro, V | 1 |
| Liu, X; Zhong, L | 1 |
| Anand, IS; Boytsov, SA; Chen, CH; Chopra, VK; Claggett, BL; Ge, J; Inubushi-Molessa, A; Jackson, AM; Jhund, PS; Køber, L; Lam, CSP; Lefkowitz, MP; Liu, J; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Tromp, J; Van Veldhuisen, DJ; Widimský, J; Zannad, F; Zile, MR | 1 |
| McMURRAY, JJV; Solomon, SD | 1 |
| Chen, Y; Cui, J; Liu, X; Pan, C; Pang, Z; Ren, Y; Tian, L; Yao, Z; Zhang, L | 1 |
| Beavers, JC; Orvin, NJ; Russell, SD | 1 |
| Doumas, M; Papadopoulos, C; Patoulias, D | 1 |
| Buonacera, A; Malatino, L; Stancanelli, B | 1 |
| Ahn, KJ; Chung, WJ; Jang, AY; Kim, DH; Kwan, J; Yu, J | 1 |
| Chen, C; Fang, C; Huang, Y; Ma, L; Zhang, Y; Zhou, H | 1 |
| Albert, NM; Arnold, SV; Butler, J; Chan, PS; DeVore, AD; Fonarow, GC; Hernandez, AF; Hill, L; Khariton, Y; Nassif, ME; Patterson, JH; Spertus, JA; Thomas, L; Thomas, M; Williams, FB | 1 |
| Felker, GM; Mann, DL | 1 |
| Bayes-Genis, A; Cediel, G; Codina, P; Domingo, M; Lupón, J; Núñez, J; Revuelta-López, E; Santesmases, J; Santiago-Vacas, E; Spitaleri, G; Zamora, E | 1 |
| Gronda, E; Iacoviello, M; Palazzuoli, A | 1 |
| Chen, C; Li, Y; Peng, Y; Wu, X | 1 |
| Aiglova, R; Cernicek, V; Danek, J; Gloger, V; Lazarova, M; Pavlu, L; Precek, J; Schee, A; Skala, T; Taborsky, M; Vicha, M | 1 |
| Butler, J; Desai, AS; Felker, GM; Januzzi, JL; McMurray, JJV; Solomon, SD | 1 |
| Bhatt, AS; Claggett, BL; Desai, AS; Lefkowitz, MP; Liu, J; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Vaduganathan, M; Vardeny, O; Zile, MR | 1 |
| Chiang, LM; Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJV; Minamisawa, M; Packer, M; Pfeffer, MA; Solomon, SD; Suzuki, K; Zile, MR | 1 |
| Brar, S; D'Albo, N; Dani, SS; Dey, A; Ganatra, S; Kim, YS; Shah, S | 1 |
| Bhatt, AS; Claggett, BL; Lefkowitz, MP; McMurray, JJV; Packer, M; Solomon, SD; Vaduganathan, M; Zile, MR | 1 |
| Chen, W; Dang, H; Li, Y; Liu, Y | 1 |
| Lam, CSP; Solomon, SD | 1 |
| Dietrich, EA; Park, H; Pepine, CJ; Riaz, M; Smith, SM | 1 |
| Abdul-Aziz, AA; Adie, SK; Ketcham, SW; Konerman, MC; Thomas, MP | 1 |
| Alpenglow, JK; Bunsawat, K; Ratchford, SM; Richardson, RS; Smith, AS; Stehlik, J; Wray, DW | 1 |
| Briasoulis, A; Kuno, T; Ueyama, H | 1 |
| Chandrsawang, A; Kaewkan, P; Nathisuwan, S; Rattanavipanon, W; Sotananusak, T; Yamaae, F; Yingchoncharoen, T | 1 |
| Abbate, A; Bhardwaj, H; Damonte, JI; Del Buono, MG; Markley, R; Salloum, FN; Trankle, CR; Turlington, J; Van Tassell, BW | 1 |
| da Silva, DNV; da Silva, TC; da Silva, VM; de Carvalho, WN; de Jesus, AGQ; de Melo, RMV; Figueiredo, CS; Passos, LCS; Viana, TT | 1 |
| Claggett, B; Gori, M; Jhund, P; Lam, CSP; Lefkowitz, M; Liu, J; Maggioni, AP; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Prescott, MF; Rouleau, J; Senni, M; Shi, V; Solomon, SD; Van Veldhuisen, DJ; Zannad, F; Zile, M | 1 |
| Abraham, WT; Adamson, P; Brett, ME; Costanzo, MR; Desai, AS; Heywood, JT; Lamba, S; Rathman, L; Raval, N; Shavelle, D; Sood, P; Stevenson, LW | 1 |
| Belarte-Tornero, LC; Farré, N; Mojón, D; Ruiz-Bustillo, S; Solé-González, E; Valdivielso-More, S | 1 |
| Bapat, D; Butler, J; Camacho, A; Felker, GM; Ibrahim, NE; Januzzi, JL; Maisel, A; Piña, IL; Solomon, SD; Ward, JH; Williamson, KM | 1 |
| Čepelová, J; Daněk, J; Malý, M | 1 |
| Hori, M; Imamura, T; Kinugawa, K; Ueno, H | 1 |
| Accogli, M; Ammendola, E; Antonicelli, R; Aspromonte, V; Brunetti, ND; Cannone, M; Carbone, A; Del Giorno, G; Dell'Era, G; Dello Russo, A; Floris, R; Gravellone, M; Guerra, F; Guido, A; Maglia, G; Nigro, G; Palmisano, P; Paolisso, P; Pellegrino, PL; Pimpini, L; Santoro, F; Stronati, G; Ziacchi, M | 1 |
| Rakugi, H; Yamamoto, K | 1 |
| Alhan, A; Altay, H; Altın, C; Ataş, AE; Baş, MM; Çakmak, HA; Demirkan, B; Dereli, S; Durakoğlugil, ME; Ekici, B; Fahri Erkan, A; Karavelioğlu, Y; Kılıçaslan, B; Kılıçaslan, F; Kıvrak, T; Küçük, M; Olgun, FE; Özkan, H; Şabanoğlu, C; Tengiz, İ; Yaman, M; Yenerçağ, M; Yiğit, Z; Zoghi, M | 1 |
| Camerotto, A; Cuppini, S; Mazza, A; Minuz, P; Rigatelli, G; Rubello, D; Schiavon, L; Torin, G; Townsend, DM | 1 |
| Daimon, S; Maeda, K; Yasuda, M | 1 |
| Ameri, P; Benenati, S; Canepa, M; Carmisciano, L; Giovinazzo, S; Metra, M; Porto, I; Senni, M; Sormani, MP; Toma, M; Tomasoni, D | 1 |
| Brunetti, ND; Correale, M; Di Biase, M; Diella, C; Ferraretti, A; Iacoviello, M; Mallardi, A; Mazzeo, P; Merolla, G; Romano, V; Tricarico, L | 1 |
| Allen, LA; Carnicelli, AP; Fonarow, GC; Greene, SJ; Greiner, MA; Hammill, BG; Hardy, NC; Lippmann, SJ; Mentz, RJ; O'Brien, EC; Peterson, PN; Shen, X; Yancy, CW | 1 |
| Jackevicius, CA; Krumholz, HM; Mody, FV; Ozaki, AF | 1 |
| Chun, KH; Ha, J; Kang, SM; Kim, H; Lee, CJ; Lee, S; Lee, SH; Oh, J; Park, S; Yoon, M | 1 |
| Anand, IS; Düngen, HD; Jackson, AM; Jhund, PS; Lam, CSP; Lefkowitz, MP; Linssen, G; Lund, LH; Maggioni, AP; McMurray, JJV; Pfeffer, MA; Rouleau, JL; Saito, Y; Saraiva, JFK; Senni, M; Solomon, SD; Vardeny, O; Wijkman, MO; Yilmaz, MB; Zile, MR | 1 |
| Gallo, G; Volpe, M | 1 |
| Ideishi, A; Kuwano, T; Miura, SI; Morita, H; Suematsu, Y; Tashiro, K | 1 |
| Chen, W; Dang, H; Li, Z; Liu, Y; Tang, L | 1 |
| Antonazzo, IC; De Ponti, F; Diemberger, I; Gatti, M; Raschi, E | 1 |
| Ademi, Z; Liew, D; Perera, K; Zomer, E | 1 |
| Goh, VJ; Hon, JS; Koh, N; Lim, CP; Sim, D; Teo, LLY; Teoh, CK | 1 |
| Chen, Y; Wu, Y | 1 |
| Birkeland, K; Dorn, J; Fombu, E; Grant, D; Heywood, JT; Khandwalla, R; Owens, RL; Steinhubl, SR | 1 |
| Choi, KH; Hwang, HS; Ji, E; Kang, DH; Kang, GH; Lee, S; Song, JM; Song, N | 1 |
| Gackowski, A; Gruchała, M; Gwizdała, A; Jankowska, EA; Kamiński, K; Lelonek, M; Leszek, P; Mizia-Stec, K; Nessler, J; Ponikowski, P; Rozentryt, P; Straburzyńska-Migaj, E | 1 |
| Curtis, LH; Fonarow, GC; Greiner, MA; Hammill, BG; Hardy, NC; Heidenreich, PA; Hernandez, AF; Laskey, WK; Lippmann, SJ; Luo, N; Mentz, RJ; Mi, X; O'Brien, EC; Turner, SJ; Yancy, CW | 1 |
| Guo, J; Wong, PC; Zhang, A | 1 |
| Gervasini, G; Robles, NR | 1 |
| Adams, KF; Giblin, EM; Patterson, JH; Pearce, N | 1 |
| Clerico, A; Di Tano, G | 1 |
| Chrysochoou, C; Georgiopoulos, G; Kalos, T; Kasiakogias, A; Katsiki, N; Konstantinidis, D; Oikonomou, D; Thomopoulos, C; Tousoulis, D; Tsioufis, C | 1 |
| Ayalasomayajula, S; Boggarapu, S; Langenickel, T; Pal, P; Sunkara, G | 1 |
| Chapman, RH; Heidenreich, PA; Ollendorf, DA; Pearson, SD; Sandhu, AT | 2 |
| Bellows, B; Bress, A; King, J | 1 |
| Butler, J; Hamo, CE; Papadimitriou, L | 2 |
| Armstrong, WM; Emmett, M; Packer, M; Rothstein, JM | 2 |
| Spellberg, B | 1 |
| Werner, BE | 1 |
| Vitting, KE | 1 |
| McCartney, M | 1 |
| Kitai, T; Krittanawong, C | 1 |
| De Biase, L; Emdin, M; Senni, M; Trimarco, B | 1 |
| Barghash, MH; Desai, AS | 1 |
| Fonarow, GC; Greiner, M; Heidenreich, PA; Hernandez, AF; Lippmann, SJ; Parikh, KS; Yancy, CW | 1 |
| Kittipibul, V; Perez, AL; Starling, RC; Tang, WHW | 1 |
| Gong, J; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Elkayam, U; Havakuk, O | 1 |
| Butler, J; Papadimitriou, L | 1 |
| Packer, M | 3 |
| Guglin, M | 1 |
| Flores, D; Kozhuharov, N; Mueller, C; Sabti, Z | 1 |
| Launay, JM; Logeart, D; Nougué, H; Solal, AC; Vodovar, N | 1 |
| Claggett, B; Seferovic, JP; Solomon, SD | 1 |
| Chrysant, SG | 1 |
| Bauersachs, J; Bavendiek, U; Kempf, T | 1 |
| Anand, IS; Desai, AS; Ge, J; Gong, J; Lam, CSP; Lefkowitz, MP; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Van Veldhuisen, DJ; Wang, W; Zannad, F; Zile, MR | 1 |
| Agrawal, H; Albaghdadi, A; Bramblett, T; Mukherjee, D; Teleb, M | 1 |
| Burrell, LM; Cherif, M; Clark, AL; Lang, CC; Singh, JSS; Squire, IB | 1 |
| Claggett, BL; Desai, AS; Lefkowitz, MP; Lewis, EF; Liu, J; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Aronow, WS; Shamliyan, TA | 1 |
| Clem, JR; Heins, J | 1 |
| Chien, FJ; Eisen, HJ; Kim, DH | 1 |
| Aguiar, C; Marques da Silva, P | 1 |
| Cortesi, PA; D'Angiolella, LS; Mantovani, LG; Pitotti, C; Ritrovato, D; Senni, M | 1 |
| Luo, N; Mentz, RJ; O'Brien, EC | 1 |
| Kherad, B; Krackhardt, F; Kresoja, KP; Schmidt, G; Spillmann, F; Tschöpe, C | 1 |
| Lindblad, AJ; McDonald, T; Sehn, E | 1 |
| Grimm, D; Krüger, M; Nielsen, PM; Simonsen, U; Wehland, M | 1 |
| Aziz, MIA; Bin-Chia Wu, D; Leong, KTG; Liang, L; Ng, K; Sim, D; Tan, D; Wei, YQ; Wong, R | 2 |
| Barbera, V; Bellasi, A; Cozzolino, M; De Pascalis, A; Di Lullo, L; Floccari, F; Mudoni, A; Rivera, R; Ronco, C; Santoro, A; Verdesca, S | 1 |
| Aichner, S; Albrecht, D; Bremerich, J; Delles, C; Freyhardt, P; Heye, T; Hrabak-Paar, M; Janka, R; Keicher, C; Khder, Y; Langenickel, T; Mayr, M; Ott, C; Schmieder, RE; Wagner, F; Yates, D | 1 |
| Bell, TD; Mazer, AJ; Miller, PE; Sachdev, V; Solomon, MA; Strich, JR; Wright, ME | 1 |
| Andries, G; Biswas, M; Khera, S; Yandrapalli, S | 1 |
| Gao, J; Goodchild, TT; Kapusta, DR; Lefer, DJ; Li, Z; Polhemus, DJ; Scarborough, AL; Smart, FW; Trivedi, RK; Varner, KJ; Xia, H | 1 |
| Metra, M | 1 |
| Chen, L; Li, C; Li, M; Liu, XC; Qiu, CG; Wang, W; Yan, KP | 1 |
| Bonnet, D; Burch, M; Bush, C; Canter, C; Chen, F; Halnon, N; Kantor, P; Kochilas, L; Rossano, J; Shaddy, R; Zhao, Z | 1 |
| Karim, MA; Khan, NAJ; Siddiqui, HU; Ullah, S | 1 |
| Butler, J; DeFilippis, EM; Vaduganathan, M | 1 |
| Anand, IS; Charney, A; Duino, V; McIntyre, HF; McMurray, JJV; Sarkar, A; Senni, M; Shi, V; Wachter, R | 1 |
| Ademi, Z; Deschaseaux, C; Hancock, E; Haroun, RH; Pfeil, AM; Schwenkglenks, M; Trueman, D | 1 |
| Kałużna-Oleksy, M; Kolasa, J; Lelonek, M; Migaj, J; Nessler, J; Pawlak, A; Straburzyńska-Migaj, E | 1 |
| Chen, CH; Desai, AS; Dukát, A; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Packer, M; Prescott, MF; Ramires, F; Rouleau, JL; Senni, M; Shi, VC; Solomon, SD; Swedberg, K | 1 |
| Belohlavek, J; Butylin, D; Carr, D; Noè, A; Pascual-Figal, D; Senni, M; Wachter, R | 1 |
| de Boer, RA; Koenders, JMA; Linssen, GCM; Meeder, JG; Ramos, IC; Rutten-van Mölken, MPMH; Versteegh, MM | 1 |
| Cameli, M; Curci, V; Di Tommaso, C; Mandoli, GE; Mondillo, S; Pagliaro, A; Pastore, MC; Reccia, R | 1 |
| Aspromonte, N; Valle, R | 1 |
| Aldemerdash, A; Berei, TJ; Hollis, IB; Hsu, CC; Rodgers, JE; Smith, KR; Vardeny, O | 1 |
| Briggs, A; Cowie, MR; Deschaseaux, C; Hancock, E; Haroun, R; Lacey, M; McMurray, JJV; Mumby-Croft, J; Taylor, M; Trueman, D; Woodcock, F | 1 |
| Lang, CC; Zaid Iskandar, M | 1 |
| Brink, D | 1 |
| Jing, W; Kashyap, ML; Khazaeli, M; Moradi, H; Nunes, A; Suematsu, Y; Vaziri, ND | 1 |
| Marketou, ME; Nakou, ES; Parthenakis, FI; Vardas, PE | 1 |
| Ariano, C; De Vecchis, R; Di Biase, G; Noutsias, M | 3 |
| Berge, E; Hua, TA; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA | 1 |
| Cyrille, N; Elyahu, AY; Ramakrishna, H; Renew, JR | 1 |
| Bayés-Genís, A; Domínguez, E; Mollar, A; Núñez, J; Palau, P; Sanchis, J | 1 |
| Kario, K | 1 |
| Adda, J; Akodad, M; Audurier, Y; Battistella, P; Belloc, C; Breuker, C; Castet-Nicolas, A; Chettouh, M; Cristol, JP; Curinier, C; Dupuy, AM; Fesler, P; Kalmanovich, E; Kuster, N; Lotierzo, M; Marques, S; Mercier, G; Roubille, C; Roubille, F; Solecki, K; Soltani, S; Verchere, A; Zerkowski, L | 1 |
| Claggett, BL; Desai, AS; Gong, J; Jhund, PS; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Mueller-Velten, G; Packer, M; Rouleau, JL; Shen, L; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Balas, B; Bruce Wirta, S; Calado, F; Dworak, M; Engelhard, J; Grunow, SS; Klebs, S; Proenca, CC; Schindler, M; Schlienger, R; Viriato, D; Wachter, R | 1 |
| Dunlay, SM; Sangaralingham, LR; Sangaralingham, SJ; Shah, ND; Yao, X | 1 |
| Colaco, NA; Kazi, DS | 1 |
| Beliën, H; Dupont, M; Martens, P; Mullens, W | 1 |
| Berdague, P; Bourdin, A; Dupuis, M; Galinier, M; Jaffuel, D; Mallet, JP; Molinari, N; Pathak, A; Ricci, JE; Roubille, F | 1 |
| Goodchild, TT; Koiwaya, H; Lefer, DJ; Li, Z; Polhemus, DJ; Scarborough, A; Trivedi, RK; Yoo, D | 1 |
| Kitzman, DW; Packer, M | 1 |
| Edelmann, F; Knosalla, C; Mörike, K; Muth, C; Prien, P; Störk, S | 1 |
| Kabbach, G; Khalil, P; Mukherjee, D; Said, S | 1 |
| Anand, IS; Chow, SL; Daniels, LB; Maisel, AS; McCullough, PA | 1 |
| Atwood, A; DiDomenico, RJ; Harrington, RL; Kumar, VM; Rigoni, GC; Touchette, DR; Zueger, PM | 1 |
| Chandra, A; Claggett, BL; Desai, AS; Katova, T; Lefkowitz, MP; Lewis, EF; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; Hernandez, AF; McCague, K; Morrow, DA; Rocha, RA; Velazquez, EJ | 1 |
| Hirsh Raccah, B; Matok, I; Muszkat, M; Perlman, A | 1 |
| Chiang, LM; Claggett, B; McMurray, JJV; O'Meara, E; Packer, M; Prescott, MF; Rouleau, JL; Solomon, SD; Zile, MR | 1 |
| Butler, J; Fombu, E; Januzzi, JL; Maisel, A; McCague, K; Piña, IL; Prescott, MF; Riebman, JB; Solomon, S | 1 |
| Ambrosy, AP; Velazquez, EJ | 1 |
| Beliën, H; Dupont, M; Martens, P; Mullens, W; Vandervoort, P | 1 |
| Kaplan, A; Modgill, V; Senni, M; Shi, V; Streefkerk, H; Zhou, W | 1 |
| Antol, DD; Casebeer, AW; DeClue, RW; Russo, PA; Stemkowski, S | 1 |
| Aguiar, C; Freitas, P; Mendes, M; Rodrigues, G; Tralhão, A; Ventosa, A | 1 |
| Liu, RC | 1 |
| Ayesta, A; Bover-Freire, R; De-Juan, J; Díez-Villanueva, P; Esteban-Fernández, A; García-Aguado, M; Gómez-Bueno, M; González-Saldívar, H; Iglesias, D; Iniesta, ÁM; Martínez-Sellés, M; Perea-Egido, JA; Rojas-González, A; Vicent, L | 2 |
| Stewart Coats, AJ | 1 |
| Albert, NM; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Hernandez, AF; McCague, K; Mi, X; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB | 1 |
| Dupont, M; Lambeets, S; Lau, CW; Martens, P; Mullens, W | 1 |
| Gori, M; Lombardi, CM; Metra, M; Sciatti, E; Senni, M | 1 |
| Störk, S | 1 |
| Davis, LE; Lu, BN | 1 |
| Chiu, MH; Howlett, JG; Kuriachan, VP; Sharma, NC | 1 |
| Chrisant, M; Das, BB; Scholl, F; Vandale, B | 1 |
| Anand, IS; Anavekar, N; Anker, SD; Arango, JL; Arenas, JL; Atar, D; Ben-Gal, T; Boytsov, SA; Chen, CH; Chopra, VK; Cleland, J; Comin-Colet, J; Duengen, HD; Echeverría Correa, LE; Filippatos, G; Flammer, AJ; Galinier, M; Ge, J; Godoy, A; Goncalvesova, E; Gong, J; Janssens, S; Katova, T; Køber, L; Lam, CSP; Lefkowitz, MP; Lelonek, M; Linssen, G; Lund, LH; Maggioni, AP; Martinez, F; McMurray, JJV; Merkely, B; Milicic, D; O'Meara, E; Oh, BH; Packer, M; Perrone, SV; Pfeffer, MA; Pieske, B; Ranjith, N; Redfield, MM; Rizkala, AR; Rouleau, JL; Saito, Y; Saraiva, JF; Seferovic, PM; Senni, M; Shah, S; Shi, VC; Sibulo, AS; Sim, D; Solomon, SD; Sweitzer, NK; Taurio, J; Van Veldhuisen, DJ; Vinereanu, D; Vrtovec, B; Widimský, J; Yilmaz, MB; Zannad, F; Zhou, J; Zile, MR; Zweiker, R | 1 |
| Ghafar, MZ; Mulkerrin, EC; O'Keeffe, ST; Sharkey, AT | 1 |
| Cristino, J; Lee, D; Ng, C; Tan, J; Tang, I; Trueman, D | 1 |
| Malafarina, V; Rodil Fraile, R; Tiberio López, G | 1 |
| Guo, W; Ito, H; Kitamura, T; Momomura, SI; Ohishi, T; Okino, N; Saito, Y; Tsutsui, H; Yamamoto, K | 1 |
| Gandjour, A; Ostwald, DA | 1 |
| Dargad, RR; Parekh, JD; Prajapati, MR | 1 |
| Bösch, C; Dobner, S; Hunziker, L; Martinelli, M; Rhyner, D; Schnegg, B; Suter, T; Wieser, M; Wigger, O | 1 |
| Rickenbacher, P | 1 |
| Abdurrob, A; Balas, B; Bruce Wirta, S; Calado, F; Chang, CL; Gagne, JJ; Najafzadeh, M; Rogers, JR; Schlienger, RG; Tsacogianis, T; Turner, SJ; Wang, SV | 1 |
| Zacà, V | 1 |
| Carbonell, P; Gasol, M; López, P; Molina, A; Pontes, C; Vicente, M | 1 |
| Bouabdallaoui, N; Claggett, B; McMurray, JJV; O'Meara, E; Packer, M; Prescott, MF; Rouleau, JL; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Ahn, R; Prasad, V | 1 |
| Baliga, RR | 1 |
| Aspromonte, N; De Maria, R; Di Lenarda, A; Di Tano, G; Frigerio, M; Gabrielli, D; Gulizia, MM; Iacoviello, M; Mortara, A; Murrone, A; Nardi, F; Oliva, F; Pontremoli, R; Scherillo, M; Senni, M; Urbinati, S | 1 |
| Bocchi, EA; Rassi, S; Veiga Guimarães, G | 1 |
| Wollert, KC | 1 |
| Adda, J; Agullo, A; Akodad, M; Batistella, P; Huet, F; Kalmanovitch, E; Roubille, C; Roubille, F | 1 |
| Albert, NM; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Hernandez, AF; Hill, CL; McCague, K; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB | 1 |
| Claggett, B; Gandhi, PU; Januzzi, JL; Lefkowitz, MP; Liu, J; McMurray, JJV; Packer, M; Pieske, B; Prescott, MF; Shah, AM; Shi, V; Solomon, SD; Voors, A; Zile, MR | 1 |
| Bayes-Genis, A; Sarrias, A | 1 |
| Bhagat, AA; Butler, J; Fonarow, GC; Greene, SJ; Vaduganathan, M | 1 |
| Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| D'Elia, E; Gori, M; Senni, M | 1 |
| Le Bras, A | 1 |
| Claggett, BL; Desai, AS; Fonarow, GC; McMurray, JJV; Packer, M; Rouleau, JL; Solomon, SD; Srivastava, PK; Swedberg, K; Zile, MR | 1 |
| Danhof, M; Giraudel, J; Mochel, JP; Peyrou, M; Rigel, DF; Teng, CH | 1 |
| Arrigo, M; Beauvais, F; Cohen-Solal, A; Launay, JM; Logeart, D; Nougué, H; Pezel, T; Picard, F; Sadoune, M; Vodovar, N | 1 |
| Du, AX; Ezekowitz, JA; Hanninen, M; McAlister, FA; Oudit, GY; Paterson, DI; Shanks, M; Thomas, J; Westerhout, CM | 1 |
| Cole, R; Jensen, BC; Pal, J; Sauer, AJ; Sharma, N; Vader, J; Yehya, A | 1 |
| Hong, GR; Kang, DH; Kim, JJ; Kim, MS; Lee, S; Park, SJ; Park, SW; Shin, SH; Song, JM; Yun, SC | 1 |
| Allen, LA; Dickert, NW; Markham, DW; Mitchell, AR; Moore, M; Morris, AA; Shore, S; Smith, GH; Speight, CD | 1 |
| Okutucu, S; Oto, A; Sabanoglu, C | 1 |
| Brito, D; Ferreira, J; Fonseca, C; Franco, F; Morais, J; Silva Cardoso, J | 1 |
| Appadurai, V; Malpas, T; Nicolae, M; Thoreau, J | 1 |
| Chang, CL; Curtis, LH; Fonarow, GC; Greiner, MA; Hammill, BG; Hardy, NC; Heidenreich, PA; Hernandez, AF; Laskey, WK; Lippmann, SJ; Luo, N; Mentz, RJ; O'Brien, EC; Peterson, PN | 1 |
| Jarcho, J | 1 |
| Ter Maaten, JM | 1 |
| Claggett, B; Desai, AS; Kachadourian, J; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Vardeny, O; Zile, MR | 1 |
| Ahern, D; Cassagnol, M; Fuzaylova, I; Lam, C; Makaryus, AN; Talreja, O | 1 |
| Claggett, B; Lefkowitz, M; McMurray, JJV; O'Meara, E; Packer, M; Prescott, MF; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Ferreira, JP; Zannad, F | 1 |
| Ceyssens, W; Dupont, M; Luwel, E; Martens, P; Mullens, W; Nuyens, D; Rivero-Ayerza, M; Van Herendael, H; Vercammen, J | 1 |
| Coughlan, JJ; Daly, A; Liston, R; Mross, T; O'Connor, A; Wafer, M | 1 |
| Fonarow, GC; Srivastava, PK | 1 |
| Álvarez-García, J; Brossa, V; Fluvià-Brugues, P; López López, L; Mesado, N; Mirabet, S; Moliner-Abós, C; Pamies Besora, J; Pirla, MJ; Rivas-Lasarte, M; Roig, E; Solé-González, E | 1 |
| Desai, VK; Jaffe, AS; Pereira, NL | 1 |
| Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJV; Myhre, PL; Packer, M; Rouleau, JL; Shi, V; Solomon, SD; Swedberg, K; Vaduganathan, M; Zile, MR | 1 |
| Dalmaso, SG; Marchitto, N; Mobilia, P; Raimondi, G; Sindona, F | 1 |
| Castello, L; De Giusti, M; Dito, E; Parisi, C; Proietti, F; Tomai, F | 1 |
| Bilato, C; Paolini, C; Pellizzari, CA; Perrone, C; Randon, ML | 1 |
| Bentivenga, C; Berardi, E; Borghi, C; Cosentino, ER; Degli Esposti, D; Dugato, V; Fg Cicero, A; Landolfo, M; Magri, G; Miceli, R; Spinardi, L | 1 |
| Pemberton, C; Richards, AM; Yandle, T | 1 |
| Mboumi, K; Severini, D | 1 |
| Calò, L; Fusco, A; Lanzillo, C; Lino, S; Martino, A; Minati, M; Monzo, L; Tota, C | 1 |
| D'Agostino, A; Dini, FL; Fabiani, I; Galeotti, GG; Mazzola, M; Pugliese, NR; Zywicki, V | 1 |
| Caivano, M; Gubelli, S | 1 |
| Apple, FS; Burnett, JC; Gaggin, HK; Ibrahim, NE; Iyer, S; Januzzi, JL; McCarthy, CP; Mukai, R; Shrestha, S; Szymonifka, J | 1 |
| Anand, IS | 1 |
| Benson, L; Dahlström, U; Jhund, PS; Lund, LH; McMurray, JJV; Simpson, J | 1 |
| Kuster, GM; Pfister, O | 1 |
| Ambrosy, AP; Braunwald, E; Desai, AS; DeVore, AD; Duffy, CI; Gurmu, Y; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ | 1 |
| deKemp, RA; Hu, X; Klein, R; Mikush, N; Pfau, D; Renaud, JM; Sinusas, AJ; Thorn, SL; Tirziu, D; Wu, X; Young, LH; Zhang, J | 1 |
| Balas, B; Engelhard, J; Fonseca, AF; Kap, E; Klebs, S; Kostev, K; Schlienger, R; Wachter, R; Wirta, SB | 1 |
| Chang, HC; Chang, HY; Chen, CN; Chong, E; Feng, AN; Fong, MC; Hsueh, CW; Huang, KC; Lai, WT; Yin, WH | 1 |
| Cook, EA; Shipman, D; Wooster, J | 1 |
| Burke, RM; Lighthouse, JK; Mickelsen, DM; Small, EM | 1 |
| Albert, NM; Buysman, EK; Chang, C; Swindle, JP | 1 |
| Daubert, JC; Donal, E; Hage, C; KapŁon-CieŚlicka, A; Linde, C; LÖfstrÖm, U; Lund, LH; Oger, E | 1 |
| Ali, RH; Dizaye, K | 1 |
| Balmforth, C; Jhund, PS; Lefkowitz, M; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shen, L; Shi, V; Simpson, J; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Aboulhosn, J; Lin, J; Lluri, G; Miner, P; Reardon, L; Whalen, K | 1 |
| Atallah, B; Bader, F; Cherfan, A; El Banna, M; Gabra, G; Hamour, I; Hisham, M; Kalagieh, O; Sadik, ZG; Soliman, M | 1 |
| Braunwald, E; DeVore, AD; Duffy, CI; Gurmu, Y; McCague, K; Morrow, DA; Prescott, MF; Rocha, R; Velazquez, EJ | 1 |
| Bursa, N; Okutucu, S | 1 |
| Hong, SH; Kim, H; Kim, S; Lee, EK; Park, SK | 1 |
| Aguiar, C; Anker, SD; Coats, A; Crespo-Leiro, MG; Filippatos, G; Kapelios, CJ; Lainscak, M; Laroche, C; Leszek, P; Lund, LH; Maggioni, AP; McDonagh, T; Murin, J; Piepoli, MF; Rosano, G; Ruschitzka, F; Savarese, G; Seferovic, P; Zanolla, L | 1 |
| A L Buraiki, J; Bao, W; Belohlavek, J; Butylin, D; Bøhmer, E; Cavusoglu, Y; Chaaban, S; Fernandez, A; Fonseca, C; Gniot, J; Goncalvesova, E; Kobalava, Z; Lelonek, M; Lonn, E; Mozheiko, M; Mueller, C; Noè, A; Pascual-Figal, D; Pouleur, AC; Schwende, H; Senni, M; Straburzynska-Migaj, E; Tribouilloy, C; Wachter, R; Witte, KK | 1 |
| Haslam, A; Prasad, V | 1 |
| Bosotti, L; Bursi, F; Carugo, S; Massironi, L; Santangelo, G; Tombolini, E; Toriello, F; Torta, D; Valli, F | 1 |
| Burnier, M; Kjeldsen, SE; Narkiewicz, K; Oparil, S | 1 |
| Emdin, M; Passino, C; Vergaro, G | 1 |
| Aimo, A; Emdin, M; Maisel, AS | 1 |
| Ambrosy, AP; DeVore, AD; Velazquez, EJ | 1 |
| Alcalde, RO; Alonso-Martín, C; Arbòs, CM; Bruña, V; Devesa, C; Fernández-Avilés, F; Juárez, M; Martínez-Sellés, M; Méndez-Zurita, F; Pamies, J; Sousa-Casasnovas, I; Vicent, L; Viñolas, X | 1 |
| Chen, Q; Li, D; Lu, C; Wang, Y; Xu, T; Zhou, R | 1 |
| Ewert, P; Hager, A; Maurer, SJ; Pujol Salvador, C; Schiele, S; Tutarel, O | 1 |
| Alexanian, C; Cannon, CP; Doros, G; Ibrahim, NE; Januzzi, JL; Ponirakis, A; Russo, P; Song, Y | 1 |
| Hryniewiecki, TT; Kodziszewska, K; Leszek, P; Sochanowicz, B; Witold, Ś | 1 |
| Abbate, A; Bonaventura, A; Van Tassel, BW; Vecchié, A; Wohlford, GF | 1 |
| Chen, R; DeJong, C; Dudley, RA; Kazi, DS; Tseng, CW | 1 |
| Anand, IS; Chandra, A; Claggett, BL; Ge, J; Lam, CSP; Lefkowitz, MP; Lewis, EF; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Vaduganathan, M; Van Veldhuisen, DJ; Wang, W; Zannad, F; Zile, MR | 1 |
| Artemieva, MM; Bloshchitsyna, MN; Feygina, EE; Katrukha, AG; Medvedeva, NA; Postnikov, AB; Semenov, AG; Tamm, NN | 1 |
| Cottone, S; Geraci, G; Mulè, G; Nardi, E; Sorce, A | 1 |
| Beck-da-Silva, L; Rohde, LE | 1 |
| Apple, FS; Daniels, LB; Jaffe, A; Januzzi, J; Omland, T; Ordonez-Llanos, J | 1 |
| Ambrosy, AP; Chioncel, O; Fudim, M | 1 |
| Amurthur, B; Anand, IS; Ardell, JL; DiCarlo, LA; Gregory, DD; KenKnight, BH; Libbus, I; Mittal, S; Monteiro, R; Premchand, RK; Sharma, K | 1 |
| Bobadilla, G; Bravo, C; Duarte, M; Guardamagna, C; Muñoz, P; Rossel, V; Verdugo, F | 1 |
| Dorhout, B; van der Meer, P; Voors, AA | 1 |
| Atar, D; Burnett, JC; Kompa, AR; Krum, H; Sangaralingham, SJ; von Lueder, TG; Wang, BH | 1 |
| Cohn, JN; Gimpelewicz, C; Hua, TA; Kandra, A; Krum, H; Latini, R; Lesogor, A; Massie, B; Tognoni, G; Zalewski, A | 1 |
| Solomon, SD; Tacheny, T; Vardeny, O | 1 |
| Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K | 1 |
| Claggett, B; Gupta, DK; Kraigher-Krainer, E; Lefkowitz, MP; McMurray, JJ; Packer, M; Pieske, B; Santos, A; Shah, AM; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Anand, IS; Cohn, JN; Kuskowski, M; Rector, TS; Snider, J | 1 |
| Bransford, T; Claggett, B; Jhund, PS; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, B; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD | 1 |
| Desai, AS; Gong, J; Lefkowitz, M; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Gislason, GH; Kristensen, SL; Køber, L; Lamberts, M; Selmer, C; Torp-Pedersen, C; von Kappelgaard, LM | 1 |
| Ambrosio, G; Anker, SD; Díez, J; Edelmann, F; Filippatos, GS; Fraser, AG; Gavazzi, A; Gheorghiade, M; Guazzi, M; Hummel, SL; Lam, CS; Levy, D; Maggioni, AP; Metra, M; Paulus, WJ; Pfeffer, MA; Pieske, BM; Senni, M; Smiseth, OA; Solomon, SD; Stewart Coats, AJ; Stough, WG; Tschöpe, C | 1 |
| Baigent, C; Haynes, R; Judge, P; Landray, MJ | 1 |
| Jessup, M | 1 |
| Desai, AS; Gong, J; Lefkowitz, MP; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Fox, KA; Jessup, M; Komajda, M; McMurray, JJ; Packer, M | 1 |
| Claggett, BL; Jhund, PS; Kraigher-Krainer, E; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, BM; Prescott, MF; Shah, AM; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Miller, R; Solomon, SD; Vardeny, O | 1 |
| Hampton, T | 1 |
| Andersen, K; Arango, JL; Arnold, JM; Bělohlávek, J; Böhm, M; Boytsov, S; Burgess, LJ; Cabrera, W; Calvo, C; Chen, CH; Desai, AS; Duarte, YC; Dukat, A; Erglis, A; Fu, M; Gomez, E; Gong, J; Gonzàlez-Medina, A; Hagège, AA; Huang, J; Katova, T; Kiatchoosakun, S; Kim, KS; Kozan, Ö; Lefkowitz, MP; Llamas, EB; Martinez, F; McMurray, JJ; Mendoza, I; Merkely, B; Mosterd, A; Negrusz-Kawecka, M; Packer, M; Peuhkurinen, K; Ramires, FJ; Refsgaard, J; Rizkala, AR; Rosenthal, A; Rouleau, JL; Senni, M; Shi, VC; Sibulo, AS; Silva-Cardoso, J; Solomon, SD; Squire, IB; Starling, RC; Swedberg, K; Teerlink, JR; Vanhaecke, J; Vinereanu, D; Wong, RC; Zile, M | 1 |
| Krum, H | 1 |
| Andersen, K; Arango, JL; Arnold, M; Bayram, E; Bĕlohlávek, J; Böhm, M; Boytsov, S; Burgess, L; Cabrera, W; Chen, CH; Desai, A; Erglis, A; Fu, M; Gomez, E; Gong, J; Gonzalez, A; Greenlaw, N; Hagege, AA; Katova, T; Kiatchoosakun, S; Kim, KS; Lefkowitz, M; Martinez, F; McMurray, J; Mendoza, I; Merkely, B; Mosterd, A; Negrusz-Kawecka, M; Packer, M; Peuhkurinen, K; Ramires, F; Refsgaard, J; Rizkala, A; Rouleau, J; Senni, M; Shi, V; Sibulo, AS; Silva-Cardoso, J; Solomon, S; Squire, I; Starling, RC; Swedberg, K; Teerlink, JR; Vinereanu, D; Wong, R; Zile, MR | 1 |
| Bodey, F; Hopper, I; Krum, H | 1 |
| Pitt, B; Rossignol, P; Zannad, F | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N | 1 |
| Ferrari, L; Sada, S | 1 |
| Swedberg, K | 1 |
| Bramlage, P; Ferrero, C; Gomez, T; Minguet, J; Sutton, G | 1 |
| İkitimur, B; Karadağ, B; Kılıçkıran Avcı, B; Öngen, Z | 1 |
| Califf, R; Claggett, B; Køber, L; Lam, CS; Lewis, E; Liu, J; McEntegart, M; McMurray, JJ; Pfeffer, M; Rouleau, J; Skali, H; Solomon, S; Velazquez, E | 1 |
| Claggett, B; Gori, M; Lefkowitz, MP; Liu, LC; McMurray, JJ; Packer, M; Pieske, B; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Pieske, B; Tschöpe, C | 1 |
| McMurray, JJ | 3 |
| Braunwald, E | 2 |
| Alves, C; Carballo, S; Darbellay, P; Lebowitz, D; Moret, M; Sabeh, N | 1 |
| Gradman, AH | 1 |
| Gallagher, B; Patel, Y; Pham, AQ | 1 |
| Brahimi, A; Chen, F; Claggett, B; Desai, AS; Finn, PV; Gong, J; Hartley, LH; Lefkowitz, M; Liu, J; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, JL; Shi, V; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Lang, CC; Singh, JS | 1 |
| Battistoni, A; Rubattu, S; Tocci, G; Volpe, M | 1 |
| Fabbri, LM; Roversi, S; Tonelli, R | 1 |
| Buggey, J; DeVore, AD; Mentz, RJ; Velazquez, EJ | 1 |
| Bayram, E; Chen, CH; Desai, AS; Fu, M; Jhund, PS; Lefkowitz, MP; McMurray, JJ; Negrusz-Kawecka, M; Packer, M; Rizkala, AR; Rosenthal, A; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Traynor, K | 1 |
| Li, GP; Li, LF; Liang, YZ; Liu, T; Qi, WW; Xu, G; Ye, L | 1 |
| Andersen, MB; Grimm, D; Pietsch, J; Simonsen, U; Wehland, M | 1 |
| Fath, R | 2 |
| Macdonald, PS | 1 |
| Morrow, T | 1 |
| Bress, AP; King, JB; Munger, MA; Reese, AD | 1 |
| Krum, H; von Lueder, TG | 1 |
| Mills, J; Vardeny, O | 1 |
| Desai, AS; Gong, J; Jhund, PS; Lefkowitz, MP; Martinez, F; McMurray, JJV; Mosterd, A; Packer, M; Ramires, F; Rizkala, AR; Rouleau, JL; Senni, M; Shi, VC; Silva Cardoso, J; Simpson, J; Solomon, SD; Squire, I; Swedberg, K; Zile, MR | 1 |
| Nguyen, E; Weeda, ER; White, CM | 1 |
| Claggett, B; Jhund, P; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| DeKosky, ST; Feldman, AM; Haller, JA | 1 |
| Gori, M; Senni, M | 1 |
| Ayalasomayajula, S; Gevorkyan, H; Hinder, M; Jhee, S; Langenickel, TH; Pal, P; Rajman, I; Tsubouchi, C; Valentin, MA | 1 |
| Amirbegishvili, IM; Averkov, OA; Babaeva, LA; Kobalava, ZhD; Kotovskaya, YV; Merai, I; Moisfev, VS; Pavlikova, EP | 1 |
| Hayes, WJ; Wachholtz, CD | 1 |
| Ollendorf, DA; Pearson, SD; Sandhu, AT | 1 |
| Køber, L | 1 |
| Arimura, T; Goto, M; Imaizumi, S; Iwata, A; Kuwano, T; Matsuo, Y; Miura, S; Saku, K; Suematsu, Y; Yahiro, E | 1 |
| Baicu, CF; Claggett, BL; Jhund, PS; Lefkowitz, M; McMurray, JJ; Pieske, B; Prescott, MF; Shi, V; Solomon, SD; Voors, AA; Zile, MR | 1 |
| Cardoso, JS; Desai, AS; Jhund, PS; Kristensen, SL; Lefkowitz, MP; Martinez, F; McMurray, JJ; Merkely, B; Packer, M; Preiss, D; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Squire, I; Starling, RC; Swedberg, K; Zile, MR | 1 |
| Giannitsis, E; Huber, K; Jaffe, AS; Lindahl, B; Mair, J; Möckel, M; Müller, C; Plebani, M; Thygesen, K | 1 |
| Aksnes, TA; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M | 1 |
| Correia, LC; Rassi, A | 1 |
| Katrukha, AG; Semenov, AG | 1 |
| McCormack, PL | 1 |
| Gu, Y; Liu, XY; Wang, H; Wu, J; Zhang, MJ; Zhu, PF | 1 |
| Claggett, B; Desai, AS; Dukat, A; Kozan, Ö; Lefkowitz, MP; McMurray, JJ; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Starling, RC; Swedberg, K; Zile, M | 1 |
| Latini, R; Masson, S; Staszewsky, L | 1 |
| Korabathina, R; Wojnowich, K | 1 |
| Bruhn, C | 1 |
| Brown, NJ; Hubers, SA | 1 |
| Albrecht, D; Averkov, O; Ayalasomayajula, S; Chandra, P; Jordaan, P; Kobalava, Z; Kotovskaya, Y; Langenickel, TH; Moiseev, V; Pal, P; Pavlikova, E; Prescott, MF; Rajman, I | 1 |
| Ansara, AJ; Koehler, JM; Kolanczyk, DM | 1 |
| Fonarow, GC; Gordin, JS | 1 |
| Coats, AJ; Lainscak, M | 1 |
| Bellows, BK; Bress, AP; King, JB; Nelson, RE; Shah, RU | 1 |
| Einecke, D | 1 |
| Wise, J | 1 |
| Gong, J; Jhund, PS; Lefkowitz, MP; McMurray, JJ; Okumura, N; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 2 |
| Anand, I; Andreka, P; Charney, A; Chen, F; Cosmi, F; Fischer, S; Galve, E; Gelev, V; Gogia, H; Gómez-Doblas, JJ; Majercak, I; Martinez-Selles, M; McIntyre, HF; McMurray, JJ; Nociar, J; Radomska, M; Reimund, B; Reyes, A; Sarkar, A; Senni, M; Shehova-Yankova, N; Sokolova, B; Volterrani, M; Wachter, R; Yilmaz, MB; Zilahi, Z | 1 |
| Patel, S; Veltri, K | 1 |
| Jhund, PS; McMurray, JJ | 1 |
| Oliveira, GH; Robinson, MR | 1 |
| Greenberg, B; Hsiao, R | 1 |
| Vilela-Martin, JF | 1 |
| Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Teerlink, JR; Vardeny, O; Zile, MR | 1 |
| Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, J; Shi, V; Solomon, S; Swedberg, K; Zile, M | 1 |
| Lippi, G; Sanchis-Gomar, F | 1 |
| Claggett, B; Fonarow, GC; Hernandez, AF; McMurray, JJ; Solomon, SD | 1 |
| Gori, M; Piepoli, M; Senni, M; Volterrani, M | 1 |
| Claggett, B; Desai, A; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Anand, IS; Cohn, JN; Florea, VG; Rector, TS | 1 |
| Claggett, BL; Desai, AS; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, JL; Shi, V; Solomon, SD; Starling, R; Swedberg, K; Teerlink, J; Zile, MR | 1 |
| Mentz, RJ; O'Brien, EC | 1 |
| Fu, M; Lund, LH; Swedberg, K | 1 |
| Chan, WW; Claggett, B; Deschaseaux-Voinet, C; Fonarow, GC; Gaziano, TA; McMurray, JJ; Rouleau, JL; Solomon, SD; Turner, SJ; Zile, MR | 1 |
| Ahmed, A; Banach, M; Bielecka-Dabrowa, A; Misztal, M; Pietrucha, T; Rysz, J; Sakowicz, A; von Haehling, S | 1 |
| Parker, JD; Ross, HJ | 1 |
| Hein, L; Lother, A | 1 |
| Rosenberg, K | 1 |
| Bistola, V; Farmakis, D; Karavidas, A; Parissis, J | 1 |
| Cameron, SJ; Howell, EH | 1 |
| Chaggar, PS; Orsborne, C; Shaw, SM; Williams, SG | 1 |
| Brozena, S; Jessup, M; Owens, AT | 1 |
| Adhyaru, B; Raj, L | 1 |
| Blumenthal, RS; Gilotra, NA; Hsu, S; Lewsey, S; Mathews, L; Nwabueze, C; Okwuosa, IS; Princewill, O; Russell, SD | 1 |
| Desai, AS; Vaduganathan, M | 1 |
| Díez, J | 1 |
| Cook, JC; Patterson, JH; Rodgers, JE; Tran, RH | 1 |
| Brandenburg, VM; Marx, N; Rocca, HB | 1 |
| Ezekowitz, JA | 1 |
| Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, JL; Shi, V; Solomon, SD; Swedberg, K; Vardeny, O; Zile, MR | 1 |
| Lin, JX; Lin, LM; Wu, MF; Wu, Y | 1 |
| Cannon, JA; Chen, F; Gong, J; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJ; Packer, M; Rouleau, JL; Shen, L; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Hua, Y; Kelly, DJ; Liew, D; Liu, B; Reid, C; Wang, BH; Wang, I; Zhou, Y | 1 |
| Alfonso Manterola, F; Almenar Bonet, L; Ariza Solé, A; Arribas Ynsaurriaga, F; Bover Freire, R; Bueno, H; Coca Payeras, A; Díaz Molina, B; Evangelista Masip, A; Ferreira González, I; González Juanatey, JR; Jiménez Navarro, M; Lambert Rodríguez, JL; López de Sá, E; López Fernández, S; Manito Lorite, N; Marin Ortuño, F; Martín Asenjo, R; Mirabet Pérez, S; Pascual Figal, D; Pérez de Isla, L; Rodríguez Padial, L; Ruilope Urioste, LM; San Román Calvar, JA; Sánchez Fernández, PL; Segovia Cubero, J; Sionis Green, A; Sionis, A; Varela Román, A; Vázquez García, R; Zamorano Gómez, JL | 1 |
| Huynh, K | 1 |
| Claggett, BL; Desai, AS; Gong, J; McMurray, JJ; Packer, M; Prescott, MF; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR | 1 |
| Cheng, J | 1 |
| Callan, PD; Clark, AL | 1 |
| Campbell, DJ | 2 |
| Sabbah, HN | 1 |
| Khder, Y; Lefkowitz, MP; McMurray, JJV; Shi, V | 1 |
| Guo, W; Ito, H; Momomura, S; Ohishi, T; Okino, N; Saito, Y; Tsutsui, H; Yamamoto, K | 1 |
| Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z | 1 |
| Teerlink, JR; Tyler, JM | 1 |
| Bruno, RM; Taddei, S | 1 |
| Böhm, M; Gong, J; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Young, R; Zile, MR | 1 |
| Boutari, C; Doumas, M; Faselis, C; Imprialos, K; Kokkinos, P; Stavropoulos, K | 1 |
| Banerjee, D; Kang, G | 1 |
| Clark, AL; Cleland, JGF; Dierckx, R; Kazmi, S; MacNamara, A; Pellicori, P; Shah, P; Urbinati, A; Zhang, J | 1 |
| Riddell, E; Vader, JM | 1 |
| Rodgers, JE | 1 |
| Kobalava, ZD; Lukina, OI; Villevalde, SV | 1 |
| Degener, F; Postma, MJ; van der Pol, S; Vemer, P | 1 |
| Baumhäkel, M; Böhm, M; Müller, U | 1 |
| Fu, L; Gao, Y; Han, Y; Li, Y; Ma, D; Shen, J; Wang, F; Wang, Y; Xie, R; Zhou, P | 1 |
| Jiang, B; Liu, ZH; Qu, FZ | 1 |
| Baumhäkel, M; Müller, U | 1 |
| Feldman, D; Wexler, R | 1 |
| Califf, RM; Maggioni, AP; McMurray, JJ; Moukarbel, GV; Pfeffer, MA; Scheiman, JM; Signorovitch, JE; Solomon, SD; Velazquez, EJ; White, HD | 1 |
| Andrews, CD; Brunel, P; MacDonald, TM; Parthasarathy, HK; Pieske, B; Struthers, AD; Weisskopf, M | 1 |
| Anand, IS; Bishu, K; Cohn, JN; Ishani, A; Kuskowski, MA; Rector, TS | 1 |
| Anand, IS; Cohn, JN; Holwerda, NJ; Kuskowski, M; Rector, TS; Thomas, S | 1 |
| Bailey, J; Black, HR; Samuel, R; Zappe, D | 1 |
| Han, LH; Jiang, B; Jiang, WP; Li, HX; Liu, ZH; Qu, FZ; Zou, C | 1 |
| Iannazzo, S; Pradelli, L; Zaniolo, O | 1 |
| Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B | 1 |
| Bellocci, F; Crea, F; Giubilato, G; Ierardi, C; Pieroni, M; Santangeli, P; Vitulano, N | 1 |
| McMurray, JJ; Swedberg, K | 2 |
| Bourgoun, M; Califf, RM; Ghali, JK; Hassanein, AH; Hung, CL; Køber, L; Pfeffer, MA; Shin, SH; Solomon, SD; Uno, H; Velazquez, EJ; Verma, A | 1 |
| Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Vahtola, E | 1 |
| Bernheim, A; Brunner-La Rocca, HP; Kiowski, W; Kuster, GM; Morgenthaler, NG; Mueller, B; Nietlispach, F; Rickli, H; Riesen, W; Rüter, F; Schindler, R; Schuetz, P | 1 |
| Belenkov, Y; Califf, RM; Finn, PV; Kenchaiah, S; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Shamshad, F; Soler-Soler, J; Solomon, SD; Swedberg, K; Varshavsky, S; Velazquez, EJ | 1 |
| Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH | 1 |
| Allhoff, T; Anand, IS; Cohn, JN; Drexler, H; Jantzen, F; Kempf, T; Kuskowski, M; Rector, TS; Tapken, H; Wollert, KC | 1 |
| Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, J; Signorovitch, JE; Solomon, SD; Swedberg, K; Thune, JJ; Velazquez, E | 1 |
| Ruilope, LM; Segura, J | 1 |
| Anand, IS; Angelici, L; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Prescott, M; Solomon, S; Tognoni, G | 1 |
| Akhtari, S; Andalib, A; Curnew, G; Leclerc, JM; Rigal, R; Tardif, JC; Vaillancourt, M | 1 |
| Adams, F; Birkenfeld, AL; Engeli, S; Jordan, J; Schroeder, C | 1 |
| Aparasu, RR; Ashton, CM; Chen, H; Desai, RJ; Deswal, A; Johnson, ML; Mehta, HB; Morgan, RO | 1 |
| Biala, A; Finckenberg, P; Korpi, A; Levijoki, J; Loytainen, M; Martonen, E; Mervaala, E | 1 |
| Maksimov, ML; Mochkin, IA; Starodubtsev, AK | 1 |
| Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H | 1 |
| Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H | 1 |
| Joffe, MM; Yang, W | 1 |
| Clark, AL; Cleland, JG | 1 |
| Bransford, T; Gong, J; Kraigher-Krainer, E; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, B; Shah, A; Shi, V; Solomon, SD; Takeuchi, M; Voors, A; Zile, M | 1 |
| Crunkhorn, S | 1 |
| Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T | 1 |
| Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM | 1 |
| Adourian, A; Anand, IS; Cohn, JN; Kuskowski, M; Muntendam, P; Rector, TS | 1 |
| Califf, RM; Giles, T; Haffner, SM; Hernandez, AF; Krum, H; Leiter, LA; Martinez, FA; Mazzone, T; McMurray, JJ; Rutten, GE; Standl, E; Sun, JL; Thomas, L; Tognoni, G; Wong, YW | 1 |
| Lee, TH | 1 |
| Cherubini, A; Di Lenarda, A; Perkan, A; Salvatore, L; Sinagra, G | 1 |
| Gordon, A; Helmers, C; Löfdahl, P; Pantev, E; Rydberg, E; Willenheimer, R | 1 |
| Barlera, S; Benza, RL; Chiang, YT; Cohn, JN; Gottlieb, SO; Kleemann, TD; Latini, R; Rosconi, F; Staszewsky, L; Vandervoort, PM; Volpi, A; Wong, M | 1 |
| Anand, I; Cohn, JN; Gottlieb, SO; Latini, R; Maggioni, AP; Tognoni, G | 1 |
| Greenberg, BH | 1 |
| Inagaki, K; Iwanaga, Y; Kihara, Y; Mochly-Rosen, D; Onozawa, Y; Sarai, N; Takenaka, H | 1 |
| Cohn, JN | 3 |
| Anand, I; Bevilacqua, M; Cardano, P; Chiang, YT; Cohn, JN; Dunselman, PH; Holwerda, NJ; Judd, D; Latini, R; Maggioni, AP; Masson, S; Salio, M; Tognoni, G | 1 |
| Hollenberg, NK | 1 |
| Anand, IS; Chiang, YT; Cohn, JN; Fisher, LD; Glazer, RD; Latini, R; Maggioni, AP; Masson, S; Tognoni, G | 1 |
| Komajda, M | 2 |
| Kohno, M | 1 |
| Kubota, T; Takeshita, A | 1 |
| Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Carson, P; Cohn, JN; Tognoni, G | 1 |
| Terra, SG | 1 |
| Califf, RM; Edwards, S; Gallo, P; Henis, M; Kober, L; Leimberger, JD; Maggioni, AP; McMurray, JV; Pfeffer, MA; Rouleau, JL; Sellers, MA; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Hashimoto, R; Kawahara, S; Matsuzaki, M; Umemoto, S | 1 |
| Ghali, JK | 1 |
| Jermendy, G; Matos, L; Winkler, G | 1 |
| Bertocchi, F; Ceconi, C; De Tommasi, E; Ferrari, R; Francolini, G; Guida, P; Iacoviello, M; Massari, F; Pitzalis, MV; Rizzon, P; Romito, R | 1 |
| Vachiéry, JL | 1 |
| Deswal, A; Mann, DL | 1 |
| Califf, RM; Edwards, S; Henis, M; Køber, L; Leimberger, JD; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Sellers, MA; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, H; Zelenkofske, S | 1 |
| Latini, R; Maggioni, AP; Masson, S; Staszewsky, L | 1 |
| Goa, KL; Wellington, K | 1 |
| Doi, M; Kobayashi, S; Kohno, M; Matsuzaki, M; Oda, T; Ohkusa, T; Okuda, S; Tokuhisa, T; Yamamoto, T; Yano, M | 1 |
| Hukai, D; Ishii, C; Kanamori, T; Ohbayashi, Y; Ohnishi, M; Ohno, K; Okabayashi, T; Ozawa, T; Sakaguchi, T; Sichiri, G; Tanaka, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yokohama, H | 1 |
| Pfeffer, M | 1 |
| McAnulty, JH | 1 |
| Lai, KN; Lam, KY; Leung, JC; Li, PS; Wing-Hon Lai, K; Yu, CM | 1 |
| Liebson, PR | 1 |
| Schlosshan, D; Tan, LB; Williams, SG | 1 |
| Anzai, T; Hashimoto, K; Himeno, H; Imai, K; Kawana, M; Kitakaze, M; Koretsune, Y; Maruyama, S; Masaoka, Y; Matsubara, H; Matsuoka, T; Miyao, Y; Miyatake, K; Miyauchi, T; Nakamura, Y; Nomura, F; Okamoto, H; Ozono, K; Sekiya, M; Shinohara, H; Shintani, U; Shiraki, T; Takaoka, H; Tsutamoto, T; Yasumura, Y; Yokoya, K; Yokoyama, H | 1 |
| Crijns, HJ; Folkeringa, RJ; Pinto, YM | 1 |
| Aknay, N; Anand, I; Barlera, S; Cohn, JN; Glazer, R; Hester, A; Latini, R; Staszewsky, L; Wong, M | 1 |
| Angeli, F; Verdecchia, P | 1 |
| Califf, RM; Friedman, JY; Gnanasakthy, A; Reed, SD; Schulman, KA; Velazquez, EJ | 1 |
| Birkenhäger, WH; Staessen, JA | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ | 1 |
| Dahlöf, B; Kanae, K; Mochizuki, S; Shimizu, M; Tajima, N; Taniguchi, I; Yoshida, S | 1 |
| Nguyen, A; Sharma, S | 1 |
| Croom, KF; Keating, GM | 1 |
| Aknay, N; Carson, P; Chiang, YT; Cohn, JN; Farsang, C; Glazer, RD; Krum, H; Maggioni, AP | 1 |
| Aknay, N; Anand, I; Baruch, L; Cohn, JN; Glazer, RD; Hester, A; Heywood, JT; Krum, H; Vanhaecke, J | 1 |
| Ripley, TL | 1 |
| Aknay, N; Baruch, L; Feliciano, N; Goedel-Meinen, L; Hester, A; Hofmann, M; Majahalme, SK; Prescott, MF | 1 |
| Anand, I; Barlera, S; Carbonieri, E; Cohn, J; Gonzini, L; Latini, R; Maggioni, AP; Opasich, C; Tavazzi, L | 1 |
| Komuro, I; Kuwabara, Y | 1 |
| Erhardt, LR | 1 |
| Barlera, S; Carson, PE; Cerè, E; Cohn, JN; Glazer, R; Latini, R; Maggioni, AP; Masson, S; Singh, SN; Tognoni, G | 1 |
| Cohn, JN; Giardini, A; Glazer, R; Hester, A; Majani, G; Opasich, C; Tavazzi, L; Tognoni, G | 1 |
| Allsbrook, JS; Califf, RM; Masselink, LE; McMurray, JJ; Pfeffer, MA; Radeva, JI; Reed, SD; Schulman, KA; Sellers, MA; Velazquez, EJ; Weinfurt, KP | 1 |
| Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K | 1 |
| Aknay, N; Anand, IS; Chiang, YT; Cohn, JN; Florea, VG; Glazer, RD; Hester, A; Kuskowski, MA; Latini, R; Maggioni, AP; Opasich, C; Rector, TS | 1 |
| Cerulli, A; Frech, FH; Smith, DG | 1 |
| Anand, IS; Cohn, JN; Florea, VG; Glazer, R; Hester, A; Kuskowski, MA; Latini, R; Masson, S; Mocarelli, P; Rector, T; Signorini, S | 1 |
| Hatori, T; Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV | 1 |
| Barrios Alonso, V; Calderón Montero, A; Escobar Cervantes, C | 1 |
| Temple, R | 1 |
| Aylward, PE; Barvik, S; Califf, RM; Dalby, AJ; Huang, Z; Marin-Neto, JA; McMurray, JJ; Murin, J; Nordlander, RO; Pfeffer, MA; van Gilst, WH; Weaver, WD; White, HD; Zannad, F | 1 |
| Liu, DS; Ye, JF | 1 |
| Drexler, H; Landmesser, U | 1 |
| Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tan, LB; Tognoni, G; Vago, T; Wong, M | 1 |
| Kjeldsen, SE; Mistry, NB; Westheim, AS | 1 |
| Anand, I; Carretta, E; Cohn, J; Glazer, R; Ingrillì, F; Krum, H; Latini, R; Maggioni, AP; Masson, S; Pettinati, G; Tognoni, G | 1 |
| Battegay, E; Calvo-Vargas, C; Cieśliński, A; Degaute, JP; Holwerda, NJ; Hua, T; Julius, S; Kjeldsen, S; Kobalava, J; Laragh, JH; McInnes, GT; Pedersen, OL; Plat, F; Rudyatmoko, FP; Siamopoulos, KC; Störset, O; Weber, M; Zanchetti, A | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Skvortsov, AA; Sychev, AV | 2 |
| Anavekar, NS; Arnold, JM; Bourgoun, M; Ghali, JK; Køber, L; Pfeffer, MA; Skali, H; Solomon, SD; Thune, JJ; Velazquez, EJ | 1 |
| Aylward, PG; Califf, RM; Kober, L; McMurray, JJ; Pfeffer, MA; Pieper, KS; Skali, H; Solomon, SD; Stephenson, K; Van de Werf, F; Velazquez, EJ; White, HD | 1 |
| Ott, P | 1 |
| Behlouli, H; Hudson, M; Humphries, K; Pilote, L; Sheppard, R; Tu, JV | 1 |
| Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kondo, T; Li, L; Li, Y; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Ohno, T; Okada, H; Takemura, G | 1 |
| Dahlöf, B; Ikewaki, K; Kanae, K; Kawai, M; Mochizuki, S; Ogawa, K; Ohta, M; Okazaki, F; Seki, S; Shimizu, M; Tajima, N; Taniguchi, I; Taniguchi, M; Yamada, T; Yoshida, S; Yoshikawa, M | 1 |
| Mitsuyama, S | 2 |
| Akazawa, H; Komuro, I; Kudo, Y | 1 |
| Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Omvik, P; Rostrup, M | 1 |
| Bissessor, N; White, H | 1 |
| Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S | 1 |
| Deswal, A; Mann, DL; Ramasubbu, K | 1 |
| Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tognoni, G; Wong, M | 1 |
| Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ | 1 |
| Gaballa, MA; Goldman, S; Guarraia, D; Johnson, N; Thai, H | 1 |
| Havranek, EP | 1 |
| Califf, RM; Francis, GS; Huang, Z; Lewis, EF; McMurray, JJ; Pfeffer, MA; Prisant, LM; Thomas, KL; Velazquez, EJ; Weaver, WD | 1 |
| Burrell, LM; Johnston, CI | 1 |
| Clair, MJ; de Gasparo, M; Hebbar, L; Iannini, JP; Krombach, RS; Melton, DM; Mukherjee, R; O, SJ; Spinale, FG; Whitebread, S | 1 |
| Clair, MJ; Cox, MH; de Gasparo, M; Hebbar, L; Iannini, JP; Melton, DM; Mukherjee, R; Spinale, FG; Thomas, PB; Whitebread, S | 1 |
| Bolshakova, TD; Fomina, IG; Kazakov, EN; Lyusov, VA; Mazayev, VP; Olbinskaya, LI; Orlov, VA; Spormann, DO; Sulimov, VA; Sullivan, J; Zvereva, TV | 1 |
| Clair, MJ; de Gasparo, M; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Spinale, FG; Whitebread, S; Zellner, JL | 1 |
| Clair, MJ; de Gasparo, M; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Rios, G; Spinale, FG; Whitebread, S | 1 |
| Leary, AC; Lim, PO; MacDonald, TM; McMahon, AD; Shiels, P | 1 |
| Anand, I; Baruch, L; Cohen, IS; Cohn, JN; Judd, D; Ziesche, S | 1 |
| Kirk, JK | 1 |
| Cohn, JN; Glazer, RD; Hester, A; Spormann, D; Tognoni, G | 1 |
| Bohlender, J; Dietz, R; Haass, M; Höhnel, K; Luft, FC; Scheuermann, M; Thibault, G; Willenbrock, R | 1 |
| van Veldhuisen, DJ; Voors, AA | 1 |
| Coca, A; Giner, V | 1 |
| Califf, RM; Cohn, JN | 1 |
| Pfeffer, MA | 1 |
| Petkun, W | 1 |
| Cukon, S; Ennezat, PV; Hammer, A; Infeld, J; Jorde, UP; Le Jemtel, TH; Lisker, J; Sonnenblick, EH; Suryadevara, V | 1 |
| Bonarjee, VV; Dickstein, K | 1 |
| Clair, MJ; de Gasparo, M; Hendrick, JW; King, MK; Mandel, J; McElmurray, JH; Mukherjee, R; New, RB; Sampson, AC; Spinale, FG | 1 |
| Cohn, JN; Glazer, R; Spormann, D; Tognoni, G | 1 |
| Iwao, H; Izumi, Y; Kawano, H; Kim, S; Kimoto, M; Yoshiyama, M; Zhan, Y | 1 |
| Kulbertus, H | 1 |
| Thürmann, PA | 1 |
| Miller, AB; Srivastava, P | 1 |
| Hayashida, W; Yasaka, A | 1 |
| Fruhwald, FM; Kickenweiz, E; Klein, W; Zweiker, R | 1 |
| De Gasparo, M; Domergue, V; Fornes, P; Giudicelli, JF; Richer, C | 1 |
| Auer, JW; Berent, R; Eber, B | 1 |
| Ogihara, T; Rakugi, H | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Lipicky, R | 1 |
| Cohn, JN; Tognoni, G | 1 |
| Piérard, L | 1 |
| Baicu, SC; deGasparo, M; Goldberg, AT; Hendrick, JW; Joffs, C; King, MK; Krombach, RS; Multani, MM; Sample, JA; Spinale, FG | 1 |
| Barlera, S; Höglund, C; Latini, R; Staszewsky, L; Volpi, A; Wong, M | 1 |
| Haddy, FJ | 1 |
| Cayley, WE | 1 |
| Forfar, JC; Munir, S | 1 |
229 review(s) available for valsartan and Cardiac Failure
| Article | Year |
|---|---|
Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hospitalization; Humans; Hyperkalemia; Hypotension; Mortality; Renal Insufficiency; Risk Assessment; Stroke Volume; Valsartan | 2021 |
Efficacy of medication therapy for patients with chronic kidney disease and heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Stroke Volume; Valsartan | 2022 |
Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm Disorders.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome; Valsartan | 2021 |
Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Glucose; Heart Failure; Humans; Network Meta-Analysis; Sodium; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant article.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.
Topics: Aminobutyrates; Atrial Fibrillation; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Randomized Controlled Trials as Topic; Valsartan | 2022 |
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diuretics; Drug Combinations; Enalapril; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents | 2022 |
Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Glucose; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Pyrimidines; Sodium; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Effectiveness of sacubitril-valsartan in patients with cancer therapy-related cardiac dysfunction: a systematic review of clinical and preclinical studies.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Heart Failure; Humans; Neoplasms; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Function, Left | 2022 |
Sacubitril/Valsartan Off-Label Uses for Heart Failure.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Heart Defects, Congenital; Heart Failure; Humans; Neprilysin; Off-Label Use; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiac Myosins; Chronic Disease; Glucose; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Sodium; Sodium-Glucose Transporter 2; Soluble Guanylyl Cyclase; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiology; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Angiotensin receptor-neprilysin inhibitors for hypertension-hemodynamic effects and relevance to hypertensive heart disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Hypertension; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan | 2022 |
New therapies for the treatment of heart failure with preserved ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review.
Topics: Cost-Benefit Analysis; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2023 |
A narrative review on sacubitril/valsartan and ventricular arrhythmias.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
The Efficacy and Safety of Sacubitril-Valsartan for the Treatment of Heart Failure in Adults: A Meta-Analysis.
Topics: Adult; Aminobutyrates; Heart Failure; Humans; Tetrazoles; Valsartan | 2023 |
Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Female; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycemic Control; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review.
Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials.
Topics: Aminobutyrates; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Heart Failure; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Valsartan | 2022 |
Sacubitril/valsartan: An antiarrhythmic drug?
Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cardiology; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2022 |
Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Calcium Channel Blockers; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Evaluating the evidence for sacubitril/valsartan across the continuum of heart failure.
Topics: Aminobutyrates; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan | 2022 |
Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2023 |
Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Prospective Studies; Quality of Life; Renin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Valsartan | 2022 |
Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Heart Failure; Humans; Hypotension; Quality of Life; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Hypoglycemia; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis.
Topics: Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Efficacy and safety of low-dose sacubitril/valsartan in heart failure patients: A systematic review and meta-analysis.
Topics: Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2023 |
Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Heart Failure; Humans; Incidence; Valsartan | 2023 |
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Stroke Volume; Treatment Outcome; Valsartan | 2023 |
Effects of Sacubitril-Valsartan in Patients With Various Types of Heart Failure: A Meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2023 |
Do Elderly Patients with Heart Failure and Reduced Ejection Fraction Benefit from Pharmacological Strategies for Prevention of Arrhythmic Events?
Topics: Aged; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Humans; Prognosis; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Enzyme Inhibitors; Heart Failure; Humans; Kidney; Neprilysin; Receptors, Angiotensin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Sacubitril/valsartan-induced liver injury: A case report and literature review.
Topics: Adult; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chemical and Drug Induced Liver Injury, Chronic; Drug Combinations; Female; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan | 2019 |
[« ARNI » (Angiotensin Receptor-Neprilysin Inhibitor): when, for whom and how?]
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Cognition; Drug Combinations; Enalapril; Heart Failure; Humans; Kidney; Neprilysin; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Recent advances in the treatment of chronic heart failure.
Topics: Aminobutyrates; Amyloid Neuropathies, Familial; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hemodynamics; Humans; Iron Deficiencies; Mitral Valve Insufficiency; Monitoring, Physiologic; Sodium-Glucose Transporter 2; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2020 |
The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neurosecretory Systems; Renin-Angiotensin System; Sympathetic Nervous System; Tetrazoles; Valsartan; Vasopressins | 2019 |
Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Heart Failure; Hospitalization; Humans; Irbesartan; Mineralocorticoid Receptor Antagonists; Mortality; Network Meta-Analysis; Perindopril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Spironolactone; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Valsartan | 2020 |
LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Evidence-Based Medicine; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
Cost-effectiveness analyses of sacubitril-valsartan for heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Impact of Sacubitril-Valsartan on Markers of Glomerular Function.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Glomerular Filtration Rate; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Angiotensin Receptor Neprilysin Inhibitors-2019 Update.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Evidence-Based Medicine; Heart Failure; Humans; Neprilysin; Patient Safety; Protease Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Recovery of Function; Risk Assessment; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Heart Failure; Humans; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan | 2022 |
A Systematic Review on the Use of Sacubitril/Valsartan Initiated Prior to Discharge in Hospitalized Patients With Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Patient Discharge; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2021 |
Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Stroke Volume; Treatment Outcome; Valsartan | 2020 |
Inpatient Initiation of Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Heart Failure; Hospitalization; Humans; Inpatients; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Valsartan | 2021 |
Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Valsartan | 2020 |
Heart failure with preserved ejection fraction after the PARAGON-HF trial results: current knowledge and future directions.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Female; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Clinical Trials as Topic; Cognition Disorders; Drug Combinations; Heart Failure; Humans; Neprilysin; United States; United States Food and Drug Administration; Valsartan | 2021 |
Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Network Meta-Analysis; Pyrimidines; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan | 2021 |
Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Defibrillators, Implantable; Dose-Response Relationship, Drug; Drug Combinations; Electrocardiography; Heart Failure; Humans; Stroke Volume; Valsartan | 2021 |
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left | 2021 |
Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Global Health; Heart Failure; Humans; Neprilysin; Randomized Controlled Trials as Topic; Survival Rate; Valsartan | 2020 |
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Valsartan | 2021 |
Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Brain Diseases; Chemotherapy-Related Cognitive Impairment; Drug Combinations; Heart Failure; Humans; Hypertension; Neprilysin; Valsartan | 2021 |
Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cause of Death; Drug Combinations; Heart Failure; Hospitalization; Humans; Mortality; Natriuretic Peptide, Brain; Peptide Fragments; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Asia; Biphenyl Compounds; Drug Combinations; Europe; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2021 |
Renal protection in chronic heart failure: focus on sacubitril/valsartan.
Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Valsartan; Young Adult | 2021 |
Mechanisms and Models in Heart Failure: A Translational Approach.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Development; Enzyme Activators; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Models, Biological; Natriuretic Peptides; Neprilysin; Pyrimidines; Sodium-Glucose Transporter 2 Inhibitors; Soluble Guanylyl Cyclase; Stroke Volume; Urea; Valsartan; Ventricular Remodeling | 2021 |
Recent advances in pharmacological treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotonic Agents; Drug Combinations; Ferric Compounds; Heart Failure; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Iron Deficiencies; Maltose; Pyrimidines; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea; Valsartan; Vasodilator Agents; Ventricular Remodeling | 2021 |
Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Diseases; Pharmacovigilance; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan | 2021 |
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Enalapril; Enzyme Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Neprilysin; Ramipril; Severity of Illness Index; Stroke Volume; Valsartan; Ventricular Dysfunction, Left | 2021 |
Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan | 2021 |
Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Diseases; Renin-Angiotensin System; Tetrazoles; Valsartan | 2017 |
Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Combinations; Heart Failure; Humans; Hypertension; Life Style; Prognosis; Risk Factors; Stroke Volume; Sympathectomy; Tetrazoles; Valsartan | 2017 |
Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biphenyl Compounds; Drug Combinations; Drug Interactions; Heart Failure; Humans; Liver Diseases; Renal Insufficiency; Tetrazoles; Valsartan | 2017 |
Heart Failure Guidelines on Pharmacotherapy.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Diuretics; Drug Combinations; Heart Failure; Humans; Hydralazine; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Nitrates; Practice Guidelines as Topic; Severity of Illness Index; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents | 2017 |
Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.
Topics: Alzheimer Disease; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Pharmacogenetics; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2017 |
First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2017 |
Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval: The Need to Close the Gap.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Heart Failure; Humans; Tetrazoles; United States; United States Food and Drug Administration; Valsartan | 2017 |
Angiotensin Receptor-Neprilysin Inhibition.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Recovery of Function; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
"Fast Track" Development and Approval Process for Heart Failure Therapeutics.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Approval; Drug Combinations; Drug Discovery; Heart Failure; Humans; Ivabradine; Tetrazoles; United States; United States Food and Drug Administration; Valsartan | 2017 |
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Clinical Trials as Topic; Cough; Cyclic GMP; Diuresis; Drug Combinations; Heart Failure; Heart Ventricles; Humans; Hypertension; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan; Vasodilation | 2017 |
[New pharmacologic therapies for chronic heart failure].
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Digitalis Glycosides; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2017 |
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Heart Failure with Preserved Ejection Fraction: Entresto a Possible Option.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart; Heart Failure; Humans; Irbesartan; Perindopril; Tetrazoles; Valsartan | 2017 |
Sacubitril/valsartan: beyond natriuretic peptides.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptides; Tetrazoles; Valsartan | 2017 |
Benefits and Harms of Sacubitril in Adults With Heart Failure and Reduced Left Ventricular Ejection Fraction.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2017 |
Pharmacologic Management for Heart Failure and Emerging Therapies.
Topics: Aminobutyrates; Benzazepines; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Glucosides; Heart Failure; Humans; Ivabradine; Neuregulin-1; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Urea; Valsartan | 2017 |
Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2017 |
[Acute and chronic heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Resynchronization Therapy; Chronic Disease; Defibrillators, Implantable; Diuretics; Drug Combinations; Extracorporeal Membrane Oxygenation; Guideline Adherence; Heart Failure; Heart-Assist Devices; Infusions, Intravenous; Iron; Tetrazoles; Valsartan | 2017 |
The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Hypertension; Imidazoles; Natriuretic Peptides; Neprilysin; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
[Neprilysin inhibition and chronic kidney disease].
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Diuresis; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Models, Biological; Molecular Targeted Therapy; Natriuresis; Natriuretic Peptides; Neprilysin; Proteinuria; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valsartan | 2017 |
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
Topics: Aminobutyrates; Angiotensin II Type 2 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Patient Selection; Practice Guidelines as Topic; Protease Inhibitors; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
What will be the impact of sacubitril/valsartan in clinical practice?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Decision-Making; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Heart Failure; Humans; Patient Selection; Recovery of Function; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2018 |
PARADIGM-HF Trial: Secondary Analyses Address Unanswered Questions.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Humans; Prospective Studies; Tetrazoles; Valsartan | 2018 |
Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Tetrazoles; Valsartan | 2017 |
Heart failure treatment: Keeping up with best practices.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Cardiac Rehabilitation; Cardiac Resynchronization Therapy; Cardiovascular Agents; Defibrillators, Implantable; Diuretics; Drug Combinations; Echocardiography; Heart Failure; Heart-Assist Devices; Humans; Ivabradine; Obesity; Physician's Role; Physicians, Family; Sleep Apnea, Obstructive; Stroke Volume; Tetrazoles; Valsartan | 2018 |
B-Natriuretic Peptide Pathway Modulation for the Management of Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Disease Management; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Signal Transduction; Stroke Volume; Tetrazoles; Valsartan | 2018 |
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Topics: Aged; Aging; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Stroke Volume; Systole; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Obesity; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Entresto, a New Panacea for Heart Failure?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Molecular Structure; Tetrazoles; Valsartan | 2018 |
Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2018 |
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Heart Rate; Humans; Natriuretic Peptides; Neprilysin; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Stroke Volume; Sympathetic Nervous System; Tetrazoles; Valsartan | 2018 |
Sacubitril/valsartan: from a large clinical trial to clinical practice.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Decision-Making; Clinical Trials as Topic; Drug Combinations; Evidence-Based Medicine; Heart Failure; Humans; Neprilysin; Patient Selection; Practice Guidelines as Topic; Protease Inhibitors; Research Design; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Sacubitril/Valsartan: potential treatment for paediatric heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Child; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2018 |
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2018 |
[Pharmacological therapy of heart failure with reduced ejection fraction].
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Output, Low; Combined Modality Therapy; Diuretics; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Ivabradine; Life Style; Mineralocorticoid Receptor Antagonists; Stroke Volume; Tetrazoles; Valsartan | 2018 |
[Heart failure with "mid-range" ejection fraction: a new clinical entity?]
Topics: Aged; Aminobutyrates; Benzimidazoles; Biomarkers; Biphenyl Compounds; Comorbidity; Coronary Disease; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Natriuretic Peptides; Perindopril; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone; Stroke Volume; Survival Rate; Syndrome; Tetrazoles; Valsartan | 2018 |
Sacubitril/Valsartan: The Newest Neurohormonal Blocker for Guideline-Directed Medical Therapy for Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Guideline Adherence; Heart Failure; Humans; Tetrazoles; Valsartan | 2018 |
Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2019 |
Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Decision-Making; Deprescriptions; Drug Combinations; Drug Substitution; Heart Failure; Hospitalization; Humans; Medication Adherence; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Practical guidance on the use of sacubitril/valsartan for heart failure.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Cost of Illness; Drug Combinations; Evidence-Based Medicine; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Practice Guidelines as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2019 |
Sacubitril/valsartan: A practical guide.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Practice Guidelines as Topic; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Chronic heart failure: advances in pharmacological treatment and future perspectives.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Health Care Costs; Heart Failure; Humans; Models, Statistical; Republic of Korea; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2019 |
Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Remodeling; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Remodeling; Walk Test | 2019 |
The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
Topics: Alternative Splicing; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Designer Drugs; Drug Combinations; Drug Therapy, Combination; Endothelin-1; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Natriuretic Peptides; Neprilysin; Peptidyl-Dipeptidase A; Protease Inhibitors; Receptors, Angiotensin; Renin-Angiotensin System; Snake Venoms; Tetrazoles; Valsartan | 2013 |
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiotonic Agents; Clinical Trials as Topic; Diabetic Angiopathies; Diuretics; Drug Combinations; Exercise Therapy; Heart Failure; Homeostasis; Humans; Hypertension, Pulmonary; Iron Deficiencies; Mineralocorticoid Receptor Antagonists; Molecular Targeted Therapy; Obesity; Observational Studies as Topic; Patient Selection; Phenotype; Phosphodiesterase 5 Inhibitors; Sodium Channel Blockers; Stroke Volume; Tetrazoles; Valsartan; Vascular Stiffness | 2014 |
Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Natriuresis; Nephrology; Neprilysin; Proteinuria; Pyridines; Renin-Angiotensin System; Tetrazoles; Thiazepines; Treatment Outcome; Valsartan | 2015 |
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Tetrazoles; Valsartan | 2014 |
Neprilysin inhibitors preserve renal function in heart failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Kidney; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2015 |
Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Registries; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Time Factors; Valsartan | 2014 |
Heart failure therapies in 2014: Mixed results for heart failure therapies.
Topics: Aminobutyrates; Anemia, Iron-Deficiency; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotonic Agents; Diuretics; Drug Combinations; Heart Failure; Humans; Spironolactone; Tetrazoles; Valsartan | 2015 |
LCZ696 : a new paradigm for the treatment of heart failure?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Clinical Trials, Phase II as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Prospective Studies; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2015 |
Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2014 |
Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2015 |
The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Design; Heart Failure; History, 20th Century; Humans; Neprilysin; Physiology; Renin-Angiotensin System; Research Design; Tetrazoles; Valsartan | 2015 |
LCZ696: the next step in improving RAS inhibition?
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; ras Proteins; Renin-Angiotensin System; Tetrazoles; Valsartan | 2015 |
LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Rats; Tetrazoles; Valsartan | 2015 |
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Hypertension; Indans; Natriuretic Peptide, Brain; Neprilysin; Propionates; Pyridines; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Stroke Volume; Tetrazoles; Thiazepines; Valsartan | 2015 |
Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Discovery; Heart Failure; Humans; Hypertension; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2015 |
Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2015 |
Sacubitril/valsartan (Entresto) for heart failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiotonic Agents; Disease Progression; Drug Combinations; Drug Interactions; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2015 |
LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Molecular Structure; Natriuretic Peptides; Neprilysin; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Neprilysin; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valsartan | 2015 |
Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Drug Design; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2015 |
New medical therapies for heart failure.
Topics: Amides; Aminobutyrates; Atrial Natriuretic Factor; Biphenyl Compounds; Digoxin; Drug Combinations; Fumarates; Heart Failure; Humans; Natriuretic Peptides; Peptide Fragments; Snake Venoms; Tetrazoles; Valsartan | 2015 |
A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Ivabradine; Neprilysin; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan | 2016 |
Sacubitril-Valsartan for the Treatment of Heart Failure: Effectiveness and Value.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2016 |
Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Heart Failure; Heart Function Tests; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Medication Therapy Management; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Heart Failure Update: Outpatient Management.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiotonic Agents; Cardiovascular Agents; Diet, Sodium-Restricted; Digoxin; Diuretics; Drug Combinations; Exercise Therapy; Fatty Acids, Omega-3; Female; Heart Failure; Heart Transplantation; Hospice Care; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan; Vasodilator Agents | 2016 |
[Angiotensin-receptor- and neprilysin-inhibition: a new option against heart failure].
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Drug Combinations; Enzyme Inhibitors; Heart Failure; Hospitalization; Humans; Neprilysin; Tetrazoles; Valsartan | 2016 |
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Topics: Abnormalities, Drug-Induced; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Bradykinin; Contraindications; Drug Combinations; Drug Costs; Drug Synergism; Enalapril; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Failure; Humans; Hyperkalemia; Hypertension; Kidney; Multicenter Studies as Topic; Natriuretic Peptides; Neprilysin; Pregnancy; Prodrugs; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Thiazepines; Valsartan | 2016 |
Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2016 |
New medications for heart failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Benzazepines; Biphenyl Compounds; Cyclic Nucleotide-Gated Cation Channels; Drug Combinations; Heart Failure; Heart Rate; Humans; Ivabradine; Neprilysin; Practice Guidelines as Topic; Protease Inhibitors; Recovery of Function; Signal Transduction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Ivabradine; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular System; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Patient Selection; Protease Inhibitors; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Contemporary clinical trial updates in heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Rate; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction | 2016 |
Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Quality of Life; Tetrazoles; Valsartan | 2016 |
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2016 |
Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Valsartan | 2016 |
Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan | 2017 |
Pharmacology of heart failure: From basic science to novel therapies.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Guanylate Cyclase; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Myosins; Neprilysin; Practice Guidelines as Topic; Renin-Angiotensin System; Tetrazoles; Valsartan | 2016 |
Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2016 |
Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan | 2016 |
The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2017 |
Neprilysin Inhibitors: Emerging Therapy for Heart Failure.
Topics: Alzheimer Disease; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Patient Selection; Pyridines; Stroke Volume; Tetrazoles; Thiazepines; Valsartan | 2017 |
An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).
Topics: Adrenergic beta-Antagonists; American Heart Association; Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Atrial Natriuretic Factor; Benzazepines; Biphenyl Compounds; Calcium Channel Blockers; Cardiology; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Drug Combinations; Erythropoietin; Evidence-Based Medicine; Fumarates; Heart Failure; Hematinics; Humans; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Societies, Medical; Stroke Volume; Tetrazoles; United States; Valsartan; Vasodilator Agents | 2016 |
The ABCs of managing systolic heart failure: Past, present, and future.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Resynchronization Therapy Devices; Defibrillators, Implantable; Digoxin; Diuretics; Drug Combinations; Evidence-Based Medicine; Exercise; Heart Failure; Heart-Assist Devices; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Practice Guidelines as Topic; Systole; Tetrazoles; Valsartan | 2016 |
Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Chronic Disease; Drug Combinations; Endothelin-1; Heart Failure; Humans; Natriuretic Agents; Natriuretic Peptide, Brain; Neprilysin; Receptors, Atrial Natriuretic Factor; Renin-Angiotensin System; Sympathetic Nervous System; Tetrazoles; Valsartan | 2017 |
Evolving therapies for the management of chronic and acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Disease Management; Drug Combinations; Ferric Compounds; Heart Failure; Humans; Ivabradine; Maltose; Tetrazoles; Valsartan | 2016 |
[Sacubitril / Valsartan in patients with diabetes and heart failure].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Complications; Dose-Response Relationship, Drug; Drug Combinations; Evidence-Based Medicine; Heart Failure; Humans; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Agents; Contraindications; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Hypertension; Myocardial Infarction; Renal Insufficiency, Chronic; Tetrazoles; Valsartan | 2016 |
Heart failure - what's new and what's changed?
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Complications; Drug Combinations; Heart Failure; Humans; Positive-Pressure Respiration; Practice Guidelines as Topic; Sleep Apnea, Central; Tetrazoles; Valsartan | 2016 |
Long-term neprilysin inhibition - implications for ARNIs.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biological Availability; Biphenyl Compounds; Blood Pressure; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Silent disease progression in clinically stable heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Apoptosis; Atrial Natriuretic Factor; Biphenyl Compounds; Calcium; Disease Progression; Diuretics; Drug Combinations; Fibrosis; Heart Failure; Humans; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Natriuretic Agents; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stress, Mechanical; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2017 |
Sacubitril/Valsartan (LCZ696) in Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
The safety of sacubitril-valsartan for the treatment of chronic heart failure.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Chronic Disease; Drug Combinations; Enalapril; Heart Failure; Humans; Risk Factors; Tetrazoles; Valsartan | 2017 |
Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Naphthyridines; Neprilysin; Tetrazoles; Valsartan | 2017 |
Neprilysin Inhibitors in Cardiovascular Disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2017 |
Heart failure guidelines: What's new?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Drug Combinations; Guideline Adherence; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Potential Expanded Indications for Neprilysin Inhibitors.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2017 |
Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Costs; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan | 2017 |
[A Breakthrough in the Treatment of Patients With Heart Failure With Reduced Ejection Fraction: the Clinical Significance of the PARADIGM HF-Trial].
Topics: Angiotensin Receptor Antagonists; Clinical Trials as Topic; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Valsartan: more than a decade of experience.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Hypotension; Meta-Analysis as Topic; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2009 |
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2009 |
Dual-acting angiotensin receptor-neprilysin inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Volume; Endopeptidases; Heart Failure; Humans; Hypertension; Neprilysin; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Vasoconstriction | 2011 |
[Application of AT1-angiotensin II receptor blocker valsartan in clinical practice].
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Drug Monitoring; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Renal Insufficiency; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Water-Electrolyte Balance | 2011 |
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Benzazepines; Bosentan; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Heart Failure; Heart-Assist Devices; Humans; Metoprolol; Multicenter Studies as Topic; Placebos; Propanolamines; Prospective Studies; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2002 |
[Pharmacological treatment of heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Infusions, Intravenous; Pyridazines; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2003 |
[Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Losartan; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Failure; Humans; Hypertension; Japan; Losartan; Myocardial Infarction; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2003 |
[Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Complications; Heart Failure; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan for the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Valsartan: in chronic heart failure.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Agents; Drug Administration Schedule; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
VALUE: to the heart of the matter.
Topics: Antihypertensive Agents; Heart Failure; Humans; Hypertension; Risk Factors; Tetrazoles; Valine; Valsartan | 2004 |
Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Valsartan in chronic heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Drug Therapy, Combination; Female; Formularies, Hospital as Topic; Heart Failure; Humans; Liver Diseases; Male; Patient Education as Topic; Pregnancy; Randomized Controlled Trials as Topic; Renal Insufficiency; Tetrazoles; Valine; Valsartan | 2005 |
[Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Enalapril; Heart Failure; Humans; Indoles; Lisinopril; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2005 |
A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Drug Tolerance; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
[ARB II in chronic heart failure. Coincidences and divergences. Class effect?].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Losartan; Systole; Tetrazoles; Valine; Valsartan | 2005 |
Chronic heart failure: an overview of conventional treatment versus novel approaches.
Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cardiac Glycosides; Erythropoietin; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Pacemaker, Artificial; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2005 |
The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2006 |
Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Heart Failure; Humans; Long-Term Care; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
[Val-HeFT trial--evidence for valsartan in heart failure].
Topics: Adolescent; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2007 |
[ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Contraindications; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Myocardial Infarction; Severity of Illness Index; Survival Rate; Tetrazoles; Valine; Valsartan | 2007 |
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Anti-angiotensin therapy: new perspectives.
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Fumarates; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Imidazoles; Kidney Diseases; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1997 |
Angiotensin-II receptor antagonists: their place in therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 1999 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Diseases; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1999 |
Cardiac protection: evolving role of angiotensin receptor blockers.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Middle Aged; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2000 |
Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Prognosis; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2000 |
[Use of angiotensin II receptor blockaders in heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Heart Failure; Humans; Irbesartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2000 |
Valsartan: a novel angiotensin type 1 receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2000 |
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2001 |
[Angiotensin I receptor blockers for heart failure].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Austria; Benzimidazoles; Biphenyl Compounds; Contraindications; Cough; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2001 |
[Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2001 |
Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2001 |
196 trial(s) available for valsartan and Cardiac Failure
| Article | Year |
|---|---|
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Disease Progression; Drug Combinations; Drug Labeling; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Neprilysin; Retrospective Studies; Time Factors; United States; United States Food and Drug Administration; Valsartan; Ventricular Function, Left | 2021 |
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.
Topics: Adolescent; Adult; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female; Heart; Heart Failure; Humans; Male; Middle Aged; Valsartan; Young Adult | 2021 |
Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Prospective Studies; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Remodeling | 2021 |
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Valsartan | 2022 |
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Ramipril; Stroke Volume; Valsartan; Ventricular Dysfunction, Left | 2021 |
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Stroke Volume; Valsartan; Walk Test | 2021 |
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Sacubitril/Valsartan Can Reduce Atrial Fibrillation Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation.
Topics: Atrial Fibrillation; Catheter Ablation; Heart Failure; Humans; Recurrence; Treatment Outcome; Valsartan | 2023 |
Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Neprilysin; Peptide Fragments; Sitagliptin Phosphate; Tetrazoles; Valsartan | 2022 |
The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
Topics: Adiponectin; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Carotid Intima-Media Thickness; Drug Combinations; Endothelium; Heart Failure; Humans; Hypertension; Matrix Metalloproteinase 9; Natriuretic Peptide, Brain; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Ramipril; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial.
Topics: Aged; Aminobutyrates; Biomarkers; Biphenyl Compounds; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Troponin T; Valsartan | 2022 |
Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Blood Coagulation; Calcitonin Gene-Related Peptide; Delayed-Action Preparations; Drug Combinations; Heart Failure; Humans; Metoprolol; Superoxide Dismutase; Valsartan | 2022 |
Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide 1; Glucose Tolerance Test; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Neprilysin; Sitagliptin Phosphate; Tetrazoles; Valsartan | 2022 |
No Improved Patient-Oriented Outcomes With Sacubitril/Valsartan in Adults With Heart Failure and Preserved Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hyperkalemia; Hypotension; Pyrimidines; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2022 |
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Frailty; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Ramipril; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.
Topics: Aftercare; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Heart Failure; Humans; Patient Discharge; Stroke Volume; Tetrazoles; Valsartan | 2023 |
The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure.
Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Echocardiography; Enalapril; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2022 |
A study of the efficacy of sacubitril/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease.
Topics: Heart Diseases; Heart Failure; Humans; Pulmonary Arterial Hypertension; Stroke Volume; Valsartan; Ventricular Function, Left | 2023 |
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Furosemide; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2023 |
The Value of Sacubitril/Valsartan in Acute Anterior Wall ST-Segment Elevation Myocardial Infarction before Emergency Percutaneous Coronary Intervention.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Prospective Studies; Ramipril; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Health-related quality of life outcomes in PARAGON-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial.
Topics: Adolescent; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Child; Drug Combinations; Heart Failure; Humans; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2023 |
Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.
Topics: Adolescent; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Female; Heart Atria; Heart Failure; Humans; Hypertension; Male; Natriuretic Peptide, Brain; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Diseases; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2023 |
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial).
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2023 |
Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Perimenopause; Prospective Studies; Valsartan; Ventricular Remodeling | 2023 |
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2023 |
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Study on the Efficacy of Sacubitril/Valsartan in Patients with Heart Failure with Preserved Ejection Fraction Undergoing Peritoneal Dialysis.
Topics: Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left | 2023 |
Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
Topics: Adrenomedullin; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Microcirculation; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
Clinical benefits of angiotensin receptor-Neprilysin inhibitor in adults with congenital heart disease.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Defects, Congenital; Heart Failure; Humans; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Case-Control Studies; Drug Combinations; Echocardiography; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Topics: Aged; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Neprilysin; Quality of Life; Sex Factors; Single-Blind Method; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Optimizing heart failure treatment following cardiac resynchronization therapy.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
Activity Sensors to Evaluate the Effect of Sacubitril/Valsartan on Quality-of-Life in Heart Failure: rational and design of the AWAKE-HF study.
Topics: Accelerometry; Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Monitoring, Physiologic; Quality of Life; Tetrazoles; Valsartan; Young Adult | 2019 |
Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study.
Topics: Aftercare; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Patient Discharge; Valsartan | 2020 |
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Discharge; Peptide Fragments; Tetrazoles; Valsartan | 2020 |
The Impact of Sacrubitril/Valsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Treatment Outcome; Troponin T; Valsartan; Ventricular Function, Left | 2020 |
Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Drug Monitoring; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Outcome Assessment, Health Care; Peptide Fragments; Sex Factors; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Protein Precursors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.
Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Risk Assessment; Stroke; Time; Valsartan | 2020 |
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Liver; Prognosis; Stroke Volume; Valsartan | 2020 |
Rationale and study design of OUTSTEP-HF: a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in patients with heart failure with reduced ejection fraction.
Topics: Accelerometry; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Europe; Exercise; Heart Failure; Humans; Quality of Life; Stroke Volume; Valsartan | 2020 |
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Betacoronavirus; Biphenyl Compounds; Cardiotonic Agents; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Early Termination of Clinical Trials; Glomerular Filtration Rate; Heart Failure; Heart Transplantation; Heart-Assist Devices; Hospitalization; Humans; Hypotension; Natriuretic Peptide, Brain; Pandemics; Peptide Fragments; Pneumonia, Viral; SARS-CoV-2; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Europe; Glucosides; Heart Failure; Humans; North America; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan | 2020 |
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Female; Heart Failure; Humans; Male; Neprilysin; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Registries; Stroke Volume; Sweden; Valsartan | 2021 |
Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left | 2020 |
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Death; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valsartan | 2020 |
Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anterior Wall Myocardial Infarction; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Early Medical Intervention; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Postoperative Complications; Stroke Volume; Treatment Outcome; Valsartan | 2021 |
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Black or African American; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Valsartan | 2020 |
The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure.
Topics: Actigraphy; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Comorbidity; Double-Blind Method; Drug Combinations; Enalapril; Exercise; Female; Heart Failure; Humans; Male; Middle Aged; Severity of Illness Index; Sleep; Stroke Volume; Valsartan | 2021 |
OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Exercise; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
Topics: Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Diseases; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Ramipril; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Female; Heart Failure; Humans; Potassium; Stroke Volume; Valsartan | 2021 |
Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Japan; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Global Health; Heart Failure; Hospitalization; Humans; Male; Neprilysin; Quality of Life; Risk Factors; Stroke Volume; Valsartan | 2021 |
A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arterial Pressure; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Hormone Antagonists; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Oxidative Stress; Pulmonary Artery; Stroke Volume; Tetrazoles; Treatment Outcome; Troponin T; Valsartan | 2021 |
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study.
Topics: Aminobutyrates; Biphenyl Compounds; China; Drug Combinations; Female; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Heart Failure; Humans; Hypertension; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Sleep; Stroke Volume; Tetrazoles; Valsartan; Wakefulness | 2021 |
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Global Health; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Revascularization; Prospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Valsartan | 2017 |
Health-Related Quality of Life Outcomes in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Follow-Up Studies; Health Status; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2017 |
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Aorta; Aorta, Thoracic; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Essential Hypertension; Female; Heart Failure; Humans; Hypertrophy, Left Ventricular; Imidazoles; Magnetic Resonance Angiography; Male; Medication Adherence; Middle Aged; Neprilysin; Tetrazoles; Valsartan; Vascular Stiffness; Ventricular Remodeling | 2017 |
Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
Topics: Adolescent; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Infant, Newborn; Male; Myocardial Ischemia; Prospective Studies; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Cause of Death; Double-Blind Method; Drug Combinations; Drug Tolerance; Europe; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Survival Rate; Systole; Tetrazoles; Treatment Outcome; United States; Valsartan | 2018 |
Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Stroke Volume; Switzerland; Tetrazoles; Valsartan | 2017 |
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Uric Acid; Valsartan | 2018 |
Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.
Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Patient Discharge; Patient Readmission; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2018 |
Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Ivabradine; Male; Mineralocorticoid Receptor Antagonists; Patient Care Planning; Patient Readmission; Sodium Potassium Chloride Symporter Inhibitors; Tetrazoles; Valsartan | 2018 |
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Europe; Female; Heart Failure; Humans; Male; Middle Aged; Morbidity; Prospective Studies; Recurrence; Stroke Volume; Survival Rate; Tetrazoles; United States; Valsartan | 2018 |
Insights into implementation of sacubitril/valsartan into clinical practice.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Drug Combinations; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Neprilysin; Renin-Angiotensin System; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2018 |
Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Neprilysin; Polysomnography; Prospective Studies; Sleep Apnea Syndromes; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2018 |
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
Topics: Activities of Daily Living; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Exercise; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Social Behavior; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
Topics: Administration, Oral; Aged; Aminobutyrates; Biphenyl Compounds; Cardiac Output, Low; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Safety; Peptide Fragments; Prognosis; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Follow-Up Studies; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Protein Precursors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2018 |
Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Allergic Agents; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Assessment; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Stroke Volume; Valsartan; Ventricular Function, Left | 2018 |
Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction - Baseline Characteristics and Treatment of PARALLEL-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Japan; Male; Neprilysin; Randomized Controlled Trials as Topic; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Disease Progression; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Growth Differentiation Factor 15; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2018 |
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Output, Low; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Dat
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Double-Blind Method; Drug Combinations; Enalapril; Female; Follow-Up Studies; Heart Arrest; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Prognosis; Prospective Studies; Quebec; Stroke Volume; Survival Rate; Sweden; Tetrazoles; Time Factors; United Kingdom; United States; Valsartan | 2018 |
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Insufficiency; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Republic of Korea; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biological Availability; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Enalapril; Female; Furosemide; Heart Failure; Humans; Male; Medication Therapy Management; Middle Aged; Outcome Assessment, Health Care; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Cohort Studies; Drug Combinations; Enalapril; Extracellular Matrix; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2019 |
In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Hospital Mortality; Hospitalization; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2019 |
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Tetrazoles; Valsartan | 2019 |
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.
Topics: Aminobutyrates; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Risk; Survival Analysis; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria.
Topics: Aftercare; Aged; Heart Failure; Humans; Patient Discharge; Prognosis; Stroke Volume; Valsartan | 2020 |
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiomyopathy, Alcoholic; Cardiomyopathy, Dilated; Cardiotoxicity; Cardiovascular Diseases; Cause of Death; Dangerous Behavior; Diabetic Cardiomyopathies; Drug Combinations; Enalapril; Female; Heart Failure; Heart Valve Diseases; Hospitalization; Humans; Hypertension; Infections; Male; Middle Aged; Mortality; Myocardial Ischemia; Peripartum Period; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Virus Diseases | 2019 |
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cyclic GMP; Drug Combinations; Enalapril; Female; Heart Failure; Hemodynamics; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Tetrazoles; Treatment Outcome; Troponin; Valsartan | 2019 |
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Male; Neprilysin; Patient Discharge; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Vagus Nerve Stimulation; Valsartan; Ventricular Function, Left; Walk Test | 2019 |
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Echocardiography, Doppler, Color; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Neprilysin; Prognosis; Prospective Studies; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2014 |
Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Female; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Receptors, Cell Surface; Regression Analysis; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Glomerular Filtration Rate; Heart Atria; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2014 |
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2014 |
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Troponin T; Valine; Valsartan | 2014 |
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Valsartan | 2015 |
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Placebo Effect; Tetrazoles; Treatment Outcome; Valsartan | 2015 |
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Risk; Risk Factors; Sex Factors; Valsartan; Ventricular Dysfunction, Left | 2015 |
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Creatinine; Double-Blind Method; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2015 |
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Tetrazoles; Treatment Outcome; Valsartan | 2015 |
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cause of Death; Drug Combinations; Heart Failure; Humans; Middle Aged; Tetrazoles; Treatment Outcome; Valsartan; Young Adult | 2015 |
Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Blood Pressure; China; Clinical Protocols; Electrocardiography, Ambulatory; Fatty Acids, Monounsaturated; Fluvastatin; Heart Failure; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Myocardial Infarction; Prospective Studies; Recurrence; Research Design; Risk Assessment; Risk Factors; Shock, Cardiogenic; Time Factors; Treatment Outcome; Valsartan | 2015 |
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Global Health; Heart Failure; Humans; Male; Middle Aged; Morbidity; Neprilysin; Prognosis; Prospective Studies; Risk Assessment; Survival Rate; Tetrazoles; Valsartan; Young Adult | 2015 |
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
Topics: Adolescent; Adult; Aminobutyrates; Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood-Brain Barrier; Double-Blind Method; Drug Combinations; Female; Healthy Volunteers; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Young Adult | 2016 |
[First Experience of Clinical Application of LCZ696--an AT1-angiotensin Receptors and Neprilysin Inhibitor--in Patients With Chronic Heart Failure and Reduced Ejection Fraction].
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2015 |
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Proteins; Double-Blind Method; Drug Combinations; Female; Fibrosis; Galectin 3; Galectins; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Matrix Metalloproteinase 2; Middle Aged; Myocardium; Peptide Fragments; Procollagen; Prospective Studies; Receptors, Cell Surface; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Blood Glucose; Comorbidity; Diabetes Mellitus; Disease-Free Survival; Drug Combinations; Enalapril; Female; Glycated Hemoglobin; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prediabetic State; Prevalence; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Single-Blind Method; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Risk Factors; Valsartan | 2016 |
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Proportional Hazards Models; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biomarkers; Biphenyl Compounds; Chronic Disease; Drug Administration Schedule; Drug Combinations; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Russia; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
Topics: Aged; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Endpoint Determination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Protease Inhibitors; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2016 |
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Neprilysin; Renal Insufficiency; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Chi-Square Distribution; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Kidney; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Dropouts; Proportional Hazards Models; Prospective Studies; Risk Factors; Severity of Illness Index; Single-Blind Method; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2016 |
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Case-Control Studies; Disease Progression; Double-Blind Method; Drug Combinations; Drug Substitution; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Recovery of Function; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Patient Discharge; Patient Readmission; Prognosis; Prospective Studies; Stroke Volume; Tetrazoles; Time Factors; Valsartan | 2016 |
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiotonic Agents; Defibrillators, Implantable; Diuretics; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Electric Countershock; Enalapril; Heart Failure; Humans; Myocardial Revascularization; Proportional Hazards Models; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2016 |
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Hyperkalemia; Incidence; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Amnesia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Confusion; Delirium; Dementia; Disorders of Excessive Somnolence; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Proportional Hazards Models; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Prospective Studies; Single-Blind Method; Stroke Volume; Treatment Outcome; Valsartan | 2016 |
Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Asian People; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Research Design; Single-Blind Method; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2017 |
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Chronic Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Selection; Peptide Fragments; Retrospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2017 |
[Valsartan improves symptoms and quality of life in patients with chronic heart failure].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Data Interpretation, Statistical; Diastole; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Outpatients; Practice Guidelines as Topic; Prospective Studies; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2008 |
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Female; Gastrointestinal Hemorrhage; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2009 |
A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Exercise Tolerance; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Proteinuria; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Role of RAS inhibition in the regulation of Cu/Zn-SOD in the cardiac and peripheral arterial beds in humans.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Renin-Angiotensin System; Superoxide Dismutase; Tetrazoles; Valine; Valsartan | 2010 |
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Female; Follow-Up Studies; Heart Failure; Heart Rupture, Post-Infarction; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2010 |
Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Cystatin C; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Potassium; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biomarkers; Diabetic Angiopathies; Female; Growth Differentiation Factor 15; Heart Failure; Humans; Hypertension; Male; Middle Aged; Placebos; Prognosis; Regression Analysis; Risk Assessment; Risk Factors; Severity of Illness Index; Tetrazoles; Valine; Valsartan | 2010 |
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
Topics: Age Factors; Aged; Captopril; Cause of Death; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Recurrence; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2011 |
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Aged; Biomarkers; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Predictive Value of Tests; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2012 |
Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study.
Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan | 2012 |
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valine; Valsartan | 2012 |
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Galectin 3; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2013 |
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
Topics: Adiposity; Aged; Albuminuria; Biomarkers; Blood Glucose; Creatinine; Cyclohexanes; Double-Blind Method; Female; Glucose Metabolism Disorders; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Linear Models; Male; Middle Aged; Multivariate Analysis; Nateglinide; Nonlinear Dynamics; Obesity, Abdominal; Phenylalanine; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Waist Circumference | 2013 |
Safety and efficacy of valsartan versus enalapril in heart failure patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2002 |
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Survival Rate; Tetrazoles; Time; Valine; Valsartan | 2002 |
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Biomarkers; Double-Blind Method; Follow-Up Studies; Heart Failure; Humans; Kinetics; Natriuretic Peptide, Brain; Norepinephrine; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan | 2003 |
Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Stroke Volume; Sympathetic Nervous System; Tetrazoles; Treatment Outcome; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Effect of Valsartan on hospitalization: results from Val-HeFT.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2003 |
Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Disease Progression; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Lisinopril; Male; Middle Aged; Norepinephrine; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Coronary Disease; Delayed-Action Preparations; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Double-Blind Method; Heart Failure; Hospitalization; Humans; Risk Factors; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2004 |
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Synergism; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Failure; Heart Function Tests; Humans; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Receptors, Angiotensin; Renin; Tetrazoles; Valine; Valsartan | 2004 |
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.
Topics: Antihypertensive Agents; Echocardiography; Heart Failure; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Survival Analysis; Tetrazoles; United States; Valine; Valsartan; Ventricular Remodeling | 2004 |
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Follow-Up Studies; Health Care Costs; Health Resources; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Ischemia; Quality of Life; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2004 |
Heart attack patients with complications. Treat with valsartan, captopril, or both?
Topics: Aged; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Quality of Life; Risk Factors; Single-Blind Method; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adult; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Neurotransmitter Agents; Quality of Life; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left | 2004 |
Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial).
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Severity of Illness Index; Sex Distribution; Tetrazoles; United States; Valine; Valsartan | 2005 |
Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice.
Topics: Aged; Anemia; Antihypertensive Agents; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hemoglobins; Humans; Male; Middle Aged; Multivariate Analysis; Prevalence; Prognosis; Prospective Studies; Registries; Risk; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Placebos; Quality of Life; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People | 2005 |
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Topics: Ambulatory Care; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Costs; Global Health; Health Care Costs; Health Resources; Heart Failure; Hospital Costs; Hospitalization; Humans; Myocardial Infarction; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Heart Failure; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Morbidity; Multivariate Analysis; Prevalence; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan | 2005 |
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; C-Reactive Protein; Female; Heart Failure; Humans; Male; Middle Aged; Morbidity; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Tetrazoles; Valine; Valsartan | 2005 |
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Heart; Heart Failure; Humans; Male; Mediastinum; Middle Aged; Natriuretic Peptide, Brain; Observer Variation; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan | 2006 |
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Renin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2005 |
Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Captopril; Cardiovascular Diseases; Cause of Death; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2005 |
[Effects of benazepril combined with valsartan on congestive heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Female; Heart Arrest; Heart Failure; Humans; Hypertension; Male; Middle Aged; Proportional Hazards Models; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Follow-Up Studies; Heart Failure; Humans; Quinapril; Severity of Illness Index; Stroke Volume; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Exercise Test; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Quinapril; Stroke Volume; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Research Design; Risk Factors; Stroke Volume; Survival Analysis; Survivors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Endpoint Determination; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2007 |
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Tetrazoles; Valine; Valsartan | 2007 |
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cause of Death; Confidence Intervals; Creatinine; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Inflammation; Male; Middle Aged; Norepinephrine; Pulmonary Disease, Chronic Obstructive; Survival Rate; Tetrazoles; Treatment Outcome; Troponin T; Valine; Valsartan | 2007 |
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
Topics: Aged; Amiodarone; Captopril; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction | 2008 |
Valsartan in heart failure patients previously untreated with an ACE inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Hemodynamics; Humans; Least-Squares Analysis; Lisinopril; Male; Matched-Pair Analysis; Middle Aged; Renin-Angiotensin System; Tetrazoles; Time Factors; Valine; Valsartan | 1998 |
Angiotensin II receptor subtype I antagonism and diastolic cardiac filling in man.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Cardiovascular Agents; Cross-Over Studies; Diastole; Double-Blind Method; Echocardiography; Heart Failure; Hemodynamics; Humans; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 1999 |
Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Hemodynamics; Hormones; Humans; Lisinopril; Middle Aged; Single-Blind Method; Tetrazoles; Time Factors; Valine; Valsartan | 1999 |
Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Sex Factors; Tetrazoles; Valine; Valsartan | 2000 |
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Probability; Quality of Life; Stroke Volume; Survival Analysis; Tetrazoles; Valine; Valsartan | 2001 |
Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT).
Topics: Angiotensin Receptor Antagonists; Double-Blind Method; Echocardiography; Heart Failure; Humans; Quality Assurance, Health Care; Quality Control; Reproducibility of Results; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2002 |
708 other study(ies) available for valsartan and Cardiac Failure
| Article | Year |
|---|---|
Outcome Benefits Seen With 1 Year of Optimized Sacubitril/Valsartan for the Treatment of Systolic Heart Failure Managed by Pharmacists in a Cardiology Practice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cardiology; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Pharmacists; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Optimal Therapeutic Strategy Using Sacubitril/Valsartan in a Patient with Systolic Heart Failure and Chronic Kidney Disease - An Initial Case Report in Japan.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Japan; Male; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
Topics: Aftercare; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Patient Discharge; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2021 |
"Echocardiographic response" to sacubitril-valsartan: does it decrease defibrillation implantation, as well as the incidence of malignant arrhythmias?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Humans; Incidence; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Topics: Aftercare; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Medicare; Patient Discharge; Stroke Volume; Tetrazoles; United States; Valsartan | 2021 |
Adherence to Evidence-Based Therapies in Heart Failure: Deepening the Implementation Divide.
Topics: Aftercare; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Patient Discharge; Stroke Volume; Valsartan | 2021 |
Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Stroke Volume; Valsartan; Ventricular Function, Left; Ventricular Function, Right | 2021 |
An Expanded Heart Failure Indication for Sacubitril/Valsartan: Evolving the Evidence Bar.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Valsartan | 2021 |
Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Thailand; Valsartan | 2021 |
The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Hypertrophy; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left; Walk Test | 2022 |
Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
[ANMCO Position paper: Use of sacubitril/valsartan in hospitalized patients with acute heart failure].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; COVID-19; Drug Combinations; Heart Failure; Humans; Pandemics; Prospective Studies; SARS-CoV-2; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Are Post Hoc Analyses on Subgroups Sufficient to Support New Treatment Algorithms of Heart Failure? The Case of SGLT2 Inhibitors Associated with Sacubitril/Valsartan.
Topics: Algorithms; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan | 2022 |
Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
Topics: Aged; Aminobutyrates; Biosimilar Pharmaceuticals; Biphenyl Compounds; Chronic Disease; Defibrillators, Implantable; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Renin-Angiotensin System; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left; Veterans | 2021 |
Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Black People; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Retrospective Studies; Stroke Volume; Valsartan; White People | 2022 |
"Echocardiographic response" to sacubitril-valsartan: does it decrease defibrillation implantation, as well as the incidence of malignant arrhythmias? Response.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Humans; Incidence; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Spironolactone; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan; Ventricular Function, Left | 2022 |
Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Necrosis; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right; Ventricular Function, Left | 2022 |
Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients.
Topics: Aminobutyrates; Biphenyl Compounds; Echocardiography, Three-Dimensional; Heart Failure; Humans; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hypertension; Neprilysin; Pyrimidines; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Renal Dialysis; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Mortality; Nitrates; Practice Guidelines as Topic; Quality of Health Care; Stroke Volume; United States; United States Department of Veterans Affairs; Valsartan; Veterans | 2022 |
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
Topics: Aminobutyrates; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Ramipril; Valsartan | 2022 |
Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Female; Heart Failure; Humans; Male; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Variation in early diffusion of sacubitril/valsartan and implications for understanding novel drug diffusion.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Heart Failure; Humans; Medicare; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan | 2021 |
Impact of sacubitril/valsartan on systolic heart failure: Right heart location and clustering analysis.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cluster Analysis; Drug Combinations; Female; Heart Failure; Heart Failure, Systolic; Humans; Male; Middle Aged; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients.
Topics: Aminobutyrates; Atrial Fibrillation; Biphenyl Compounds; Cardiac Resynchronization Therapy; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rhabdomyolysis; Rosuvastatin Calcium; Stroke Volume; Tetrazoles; United States; Valsartan | 2022 |
Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Hemodynamics; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arabs; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Infant; Morbidity; Pilot Projects; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Valsartan Regulates PI3K/AKT Pathways through lncRNA GASL1 to Improve Isoproterenol-Induced Heart Failure.
Topics: Animals; Apoptosis; Carrier Proteins; Heart Failure; Humans; Isoproterenol; Male; Myocardium; Myocytes, Cardiac; Rats; RNA, Long Noncoding; Signal Transduction; Valsartan | 2022 |
Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Haemodynamic effects of sacubitril/valsartan in advanced heart failure.
Topics: Adult; Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Natriuretic Peptides; Stroke Volume; Valsartan; Vasodilator Agents | 2022 |
Efficacy and safety of sacubitril/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Outpatients; Retrospective Studies; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article 'Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline ch
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Arrest; Heart Failure; Humans; Myocardial Infarction; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan.
Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Hemodynamics; Humans; Prognosis; Stroke Volume; Valsartan | 2022 |
A new lead: Sacubitril-valsartan's unique benefit in HFrEF could lie with sympathoinhibition.
Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Pilot Projects; Stroke Volume; Valsartan | 2022 |
Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cardiotoxicity; Doxorubicin; Drug Combinations; Endoplasmic Reticulum Stress; Heart Failure; Male; Rats; Rats, Sprague-Dawley; Valsartan; Water | 2022 |
Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Valsartan | 2022 |
Sacubitril/valsartan-A new weapon for fighting the hypertension paradox.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Tetrazoles; Valsartan | 2022 |
Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Communicable Disease Control; COVID-19; Drug Combinations; Heart Failure; Humans; Pandemics; Prescriptions; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
[Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system blockade in heart failure patients - Part II: Mechanistic effects of sacubitril/valsartan, placement in current guidelines and use in clinical practice].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiology; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valsartan | 2022 |
Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Kidney; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Sacubitril/Valsartan and Rhabdomyolysis: Reanalysis of a Potential Safety Signal.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Rhabdomyolysis; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Optimal potassium levels in patients with heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Heart Failure; Humans; Potassium; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension: A case report.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Hypotension; Neprilysin; Renal Dialysis; Tetrazoles; Valsartan | 2022 |
Sacubitril/Valsartan Therapy for AF and HFpEF: Is the Glass Half Empty or Half Full?
Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Valsartan | 2022 |
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Fibrillation; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |
proANP Metabolism Provides New Insights Into Sacubitril/Valsartan Mode of Action.
Topics: Aminobutyrates; Atrial Natriuretic Factor; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; MicroRNAs; Neprilysin; Stroke Volume; Valsartan | 2022 |
Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients.
Topics: Angiotensin Receptor Antagonists; China; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Decision Support Techniques; Drug Combinations; Heart Failure; Humans; Medicare; Patient Discharge; Stroke Volume; Survival Analysis; United States; Valsartan | 2022 |
Relation of Household Income to Access and Adherence to Combination Sacubitril/Valsartan in Heart Failure: A Retrospective Analysis of Commercially Insured Patients.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Dysfunction, Left | 2022 |
Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril-valsartan.
Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension.
Topics: Aminobutyrates; Arterial Pressure; Biphenyl Compounds; Heart Failure; Humans; Hypertension, Pulmonary; Neprilysin; Quality of Life; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Diastole; Disease Models, Animal; Drug Combinations; Heart Failure; Mice; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction | 2022 |
Valsartan and sacubitril combination treatment enhances collagen production in older adult human skin cells.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Collagen; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cholesterol; Cross-Sectional Studies; Drug Combinations; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, HDL; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Triglycerides; Valsartan | 2022 |
Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Creatinine; Drug Combinations; Heart Failure; Humans; Hypertension; Natriuretic Peptide, Brain; Retrospective Studies; Tetrazoles; Uric Acid; Valsartan | 2022 |
Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Proteomics; Sex Characteristics; Valsartan | 2022 |
Sacubitril/Valsartan for heart failure: A protocol for systematic review and meta-analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Meta-Analysis as Topic; Neprilysin; Stroke Volume; Systematic Reviews as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25 000 Medicare beneficiaries.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cohort Studies; Drug Combinations; Heart Failure; Humans; Medicare; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan | 2022 |
[Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Heart Failure; Humans; Hypertension; Metabolic Syndrome; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Utilization of sacubitril-valsartan for right ventricular failure in a patient with arrhythmogenic right ventricular cardiomyopathy.
Topics: Adult; Aminobutyrates; Arrhythmogenic Right Ventricular Dysplasia; Biphenyl Compounds; Cardiomyopathies; Contrast Media; Diuretics; Drug Combinations; Female; Gadolinium; Heart Failure; Humans; Valsartan | 2022 |
Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Creatinine; Drug Combinations; Heart Failure; Humans; Kidney; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus; Enalapril; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemia; Insulins; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A Single or Double-Edged Effect?
Topics: Aldosterone; Aminobutyrates; Anti-Inflammatory Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Cathepsin G; COVID-19 Drug Treatment; Cytokines; Gastrin-Releasing Peptide; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptides; Neprilysin; Renin; Respiratory Distress Syndrome; Tetrazoles; Valsartan | 2022 |
Sacubitril/Valsartan in Advanced Heart Failure: Shattering the Paradigm to Focus on Real LIFE.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2022 |
Sacubitril-Valsartan Ameliorates Heart Failure by Inhibiting Cardiac Remodeling Potentially via MAPK/ERK Signaling.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Heart Failure; Tetrazoles; Valsartan; Ventricular Remodeling | 2022 |
Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure.
Topics: Animals; Dipeptidyl Peptidase 4; Heart Failure; Male; Rats; Rats, Wistar; Renin-Angiotensin System; Valsartan; Vildagliptin | 2022 |
Recovery of complete left bundle branch block in a dilated cardiomyopathy patient after treatment with sacubitril/valsartan: A case report.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Bundle-Branch Block; Cardiomyopathy, Dilated; Drug Combinations; Heart Failure; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotoxicity; Drug Combinations; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Cost-benefit analysis of sacubitril/valsartan in a Medicaid population.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Medicaid; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2022 |
[Chinese expert consensus on clinical application of angiotension-neprilysin inhibitor in patients with heart failure].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; China; Consensus; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Sacubitril/valsartan adherence… because the best is sometimes difficult to replace the good.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial.
Topics: Aftercare; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Kidney; Patient Discharge; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Pyrimidines; Stroke Volume; Tetrazoles; Valsartan | 2022 |
The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Fibrosis; Heart Failure; Hypertension; Myocardial Infarction; Rats; Rats, Inbred SHR; Tetrazoles; Valsartan | 2022 |
Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995-2021.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Bibliometrics; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan | 2022 |
Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy.
Topics: Arrhythmias, Cardiac; Bundle-Branch Block; Cardiac Resynchronization Therapy; Electrocardiography; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment? Authors' reply.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotoxicity; Drug Combinations; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Valsartan | 2022 |
[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].
Topics: Aminobutyrates; Amyloidosis; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Hypertrophy, Left Ventricular; Natriuretic Peptide, Brain; Phenotype; Spironolactone; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
Topics: Aldosterone; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Guanylate Cyclase; Heart Failure; Hospitalization; Humans; Ivabradine; Natriuretic Peptides; Potassium; Renin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan | 2022 |
Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Renal Insufficiency, Chronic; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Use and Out-of-Pocket Cost of Sacubitril-Valsartan in Patients With Heart Failure.
Topics: Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Health Expenditures; Heart Failure; Humans; Medicare; Retrospective Studies; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Dysfunction, Left | 2022 |
Sacubitril/valsartan (LCZ696) ameliorates hyperthyroid-induced cardiac hypertrophy in male rats through modulation of miR-377, let-7 b, autophagy, and fibrotic signaling pathways.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Autophagy; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Epigenesis, Genetic; Fibrosis; Heart Failure; Hyperthyroidism; Male; MicroRNAs; Neprilysin; Rats; Rats, Wistar; Signal Transduction; Thyroxine; Valsartan | 2022 |
Letter to the Editor regarding to 'Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control'.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Glucagon-Like Peptide-1 Receptor; Glycemic Control; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Neuroendocrine hormone status and diuretic response to atrial natriuretic peptide in patients with acute heart failure.
Topics: Atrial Natriuretic Factor; Diuretics; Heart Failure; Humans; Neurosecretory Systems; Valsartan; Vasopressins | 2022 |
Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction.
Topics: Cost-Benefit Analysis; Defibrillators, Implantable; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Sacubitril/Valsartan Improves Sexual Function and Fibrosis of the Clitoral and Vaginal Tissues in Female Spontaneously Hypertensive Rats: Erratum.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Female; Fibrosis; Heart Failure; Rats; Rats, Inbred SHR; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Reverse Remodeling Assessed by Left Atrial and Ventricular Strain Reflects Treatment Response to Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Neprilysin; Predictive Value of Tests; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Drug Combinations; Glycogen; Heart Failure; Hyperglycemia; Mice; Rats; Stroke Volume; Tetrazoles; Valsartan | 2022 |
[Do West African cardiologists adhere to the guidelines for the management of heart failure ?]
Topics: Aminobutyrates; Biphenyl Compounds; Cardiologists; Cross-Sectional Studies; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2022 |
Implication of sacubitril/valsartan on N-terminal pro B-type natriuretic peptide levels in hypertensive patients.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Hypertension; Natriuretic Peptide, Brain; Retrospective Studies; Tetrazoles; Valsartan | 2022 |
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Outpatients; Prospective Studies; Registries; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Preoperative Preparation With Valsartan/Sacubitril in a Patient With Cardiac Paraganglioma and Catecholamine-Induced Cardiomyopathy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathies; Catecholamines; Drug Combinations; Heart Failure; Humans; Paraganglioma; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.
Topics: Antioxidants; Calcium; Collagen; Heart Failure; Hemodynamics; Humans; Isoproterenol; Myocardial Infarction; Ramipril; Simendan; Valsartan | 2023 |
Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Troponin T; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2022 |
[Management of chronic heart failure: state of the art according to the 2021 guideline].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Outpatients; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Drug Combinations; Heart Failure; Humans; Hypertension; Hypotension; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2023 |
Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Mitral Valve Insufficiency; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Heart Failure; Histone-Lysine N-Methyltransferase; Methyltransferases; Myocardial Infarction; Neprilysin; Osteopontin; Rats; Repressor Proteins; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF).
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan | 2023 |
Effect of sacubitril/valsartan on cognitive impairment in colchicine-induced Alzheimer's model in rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cognitive Dysfunction; Colchicine; Drug Combinations; Heart Failure; Male; Neurodegenerative Diseases; Rats; Rats, Wistar; Tetrazoles; Valsartan | 2023 |
Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.
Topics: Adolescent; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Female; Heart Failure; Humans; Male; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
Topics: Aminobutyrates; Atrial Natriuretic Factor; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Guanosine Monophosphate; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Natriuretic Peptide, Brain; Stroke Volume; Troponin T; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2022 |
Guideline-Directed Medical Therapy: Even a Little Is Better Than None.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Sacubitril-Valsartan and Heart Function in End-stage Kidney Disease.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Kidney Failure, Chronic; Stroke Volume; Valsartan | 2022 |
The HF-POL study - the first real-life multicenter study of Polish patients with heart failure and left ventricular ejection fraction >40%: Study rationale and design.
Topics: Heart Failure; Humans; Poland; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction.
Topics: Biomarkers; Fibroblasts; Glycogen Synthase Kinase 3; Heart Failure; Humans; Interleukin-6; Matrix Metalloproteinase 9; Proto-Oncogene Proteins c-akt; Sodium-Glucose Transporter 2; Spironolactone; Stroke Volume; Valsartan | 2023 |
Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Male; Mineralocorticoid Receptor Antagonists; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Doxorubicin; Fibrosis; Heart Failure; Inflammation; Kidney; Kidney Diseases; Mice; Stroke Volume; Tolvaptan; Valsartan; Ventricular Function, Left | 2022 |
Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry.
Topics: Aged; Atrial Fibrillation; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2023 |
Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status.
Topics: Aged; Biomarkers; Female; Health Status; Heart Atria; Heart Failure; Humans; Male; Stroke Volume; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Congenitally Corrected Transposition of the Great Arteries; Drug Combinations; Female; Heart Failure; Heart Ventricles; Humans; Male; Prospective Studies; Quality of Life; Stroke Volume; Tetrazoles; Transposition of Great Vessels; Valsartan | 2023 |
Short term effect of sacubitril/valsartan on comprehensive geriatric assessment in chronic heart failure: a real life analysis.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Female; Geriatric Assessment; Heart Failure; Humans; Male; Stroke Volume; Tetrazoles; Valsartan | 2023 |
The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
Topics: Aged; Atrial Fibrillation; Diabetes Mellitus; Heart Failure; Humans; Stroke Volume; Tachycardia, Ventricular; Tetrazoles; Troponin I; Valsartan; Ventricular Function, Left | 2023 |
Renal Safety of de Novo Angiotensin-Neprilysin Inhibition in Older Adults: Insights From a Population-Based Analysis.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2023 |
Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Starting sacubitril-valsartan is safe in patients with transthyretin cardiac amyloidosis and impaired ejection fraction.
Topics: Aminobutyrates; Amyloidosis; Biphenyl Compounds; Heart Failure; Humans; Prealbumin; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2023 |
Renal Safety of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enzyme Inhibitors; Heart Failure; Humans; Hyperkalemia; Kidney; Potassium; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Comparison of the population of Polish patients participating in the TRANSITION study with the international population: a post hoc analysis.
Topics: Aftercare; Angiotensin Receptor Antagonists; Heart Failure; Humans; Male; Patient Discharge; Poland; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Effect of sacubitril/valsartan on natriuretic peptide in patients with compensated heart failure.
Topics: Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents; Ventricular Function, Left | 2023 |
The Real-World Price of Switching to an ARNI: A Case for De Novo Sacubitril/Valsartan Initiation.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Valsartan | 2023 |
Comprehensive analysis of the RNA transcriptome expression profiles and construction of the ceRNA network in heart failure patients with sacubitril/valsartan therapeutic heterogeneity after acute myocardial infarction.
Topics: Heart Failure; Humans; MicroRNAs; Myocardial Infarction; RNA, Circular; RNA, Messenger; Transcriptome; Valsartan | 2023 |
Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Characteristics of patients hospitalized for acute heart failure and discharged from an emergency medicine ward with sacubitril-valsartan: differences with patients in the PIONEER-HF and TRANSITION studies.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Emergency Medicine; Heart Failure; Humans; Patient Discharge; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Deconvolution of BNP and NT-proBNP Immunoreactivities by Mass Spectrometry in Heart Failure and Sacubitril/Valsartan Treatment.
Topics: Aminobutyrates; Biomarkers; Dyspnea; Heart Failure; Humans; Mass Spectrometry; Natriuretic Peptide, Brain; Peptide Fragments; Serine; Valsartan | 2023 |
Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Dialysis Solutions; Drug Combinations; Heart Failure; Humans; Hypertension; Peritoneal Dialysis; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2023 |
Safety and feasibility of angiotensin receptor neprilysin inhibitor in real-world patients with acute decompensated heart failure.
Topics: Aged; Aminobutyrates; Antihypertensive Agents; Biphenyl Compounds; Feasibility Studies; Female; Heart Failure; Humans; Male; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Next-Level Natriuretic Peptide Measurement.
Topics: Heart Failure; Humans; Mass Spectrometry; Natriuretic Peptide, Brain; Natriuretic Peptides; Peptide Fragments; Valsartan | 2023 |
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enzyme Inhibitors; Heart Failure; Humans; Kidney; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
Diuretic and renal effects of angiotensin receptor-neprilysin inhibitor in patients hospitalized for acute heart failure.
Topics: Antihypertensive Agents; Diuretics; Drug Combinations; Furosemide; Heart Failure; Humans; Kidney; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Pharmacology Focus: Sacubitril/Valsartan - A Review.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2022 |
Reply: Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril/valsartan and SGLT2i.
Topics: Female; Heart Failure; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2023 |
The dual inhibitor Sacubitril-valsartan ameliorate high-fat high-fructose-induced metabolic disorders in rats superiorly compared to valsartan only.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cattle; Drug Combinations; Heart Failure; Insulin; Metabolic Diseases; Rats; Tetrazoles; Valsartan | 2023 |
Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiologists; Cost-Benefit Analysis; Drug Combinations; Health Expenditures; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; East Asian People; Heart Failure; Humans; Hypotension; Neprilysin; Polymorphism, Genetic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System.
Topics: Aged; Biphenyl Compounds; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Delivery of Health Care; Drug Combinations; East Asian People; Heart Failure; Humans; Stroke Volume; Valsartan | 2023 |
The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Brain Ischemia; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Stroke; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study.
Topics: Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2023 |
LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4.
Topics: Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Glycogen Synthase Kinase 3 beta; Heart Failure; Hypertension, Pulmonary; Male; Mice; Molecular Docking Simulation; Valsartan; Ventricular Remodeling | 2023 |
Benefits of sacubitril/valsartan use in patients with chronic heart failure after cardiac valve surgery: a single-center retrospective study.
Topics: Heart Failure; Heart Valves; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2023 |
Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trial.
Topics: Europe; Europe, Eastern; Heart Failure; Humans; Myocardial Infarction; Valsartan | 2023 |
Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan | 2023 |
Angiotensin receptor-neprilysin inhibitors and cardiac remodeling.
Topics: Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2023 |
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atmosphere; Biphenyl Compounds; Comorbidity; Drug Combinations; Heart Failure; Humans; Hypertension; Multimorbidity; Stroke; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Marked Increase in Urinary C-peptide Levels after Treatment with Sacubitril/Valsartan in Patients with Type 2 Diabetes Mellitus and Hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; C-Peptide; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Atrial natriuretic peptide stimulates autophagy/mitophagy and improves mitochondrial function in chronic heart failure.
Topics: Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Heart Failure; Humans; Leukocytes, Mononuclear; Mitochondria; Mitophagy; Reactive Oxygen Species; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Budget Impact Analysis of Utilization of Sacubitril/Valsartan for the Treatment of Heart Failure With Reduced Ejection Fraction in the Philippines.
Topics: Aminobutyrates; Biphenyl Compounds; Enalapril; Heart Failure; Humans; Philippines; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptides; Phenotype; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Association of Heart Failure Patients With and Without Sacubitril-Valsartan Use With Incident Cancer Risk.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neoplasms; Risk; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
Clinical efficacy of enhanced external counter pulsation plus sacubitril/valsartan in the treatment of patients with chronic heart failure and the effect on ankle-arm index and cardiac function.
Topics: Angiotensin Receptor Antagonists; Ankle; Ankle Brachial Index; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Expert Testimony; Heart Failure; Humans; Poland; Prospective Studies; Stroke Volume; United States; Valsartan; Ventricular Function, Left | 2023 |
Angiotensin-Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: You Win Some, You Lose Some.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; United States; Valsartan | 2023 |
Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Glucose; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Dysfunction, Left | 2023 |
Sacubitril-valsartan shows benefit in heart failure with ejection fraction of >40.
Topics: Aminobutyrates; Heart Failure; Humans; Stroke Volume; Valsartan | 2023 |
Early improvement of strain imaging parameters predicts long-term response to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: An observational prospective study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Risk stratification for worsening renal function and renal decline in heart failure patients with reduced ejection fraction after sacubitril/valsartan treatment.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Kidney; Risk Assessment; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Glucose; Heart Failure; Hospitalization; Humans; Longitudinal Studies; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Peripheral Arterial Disease; Renal Insufficiency, Chronic; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Stroke Volume; United States; Valsartan | 2023 |
Impact of the angiotensin receptor-neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; C-Peptide; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2023 |
Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Exercise Tolerance; Heart Failure; Humans; Prognosis; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension.
Topics: Drug Combinations; Heart Failure; Humans; Hypotension; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Using Sacubitril/Valsartan to Decrease Health care Costs in Population Health Patients.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Health Care Costs; Heart Failure; Humans; Male; Medicare; Spironolactone; Stroke Volume; Tetrazoles; United States; Valsartan | 2023 |
Angiotensin Receptor-neprilysin Inhibitor Versus Renin-angiotensin System Inhibitor for Dementia Risk in Patients With Heart Failure.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Dementia; Enzyme Inhibitors; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Sex Differences in the Effectiveness of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril-Valsartan for the Treatment of Heart Failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Sex Characteristics; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Male; Mitral Valve Insufficiency; Rats; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Ventricular Remodeling | 2023 |
Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
Topics: Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tachycardia, Ventricular; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2023 |
Sacubitril-Valsartan in Heart Failure: The Hard Sell of Spending More to Save Later.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2023 |
The use of sacubitril / valsartan in Takotsubo syndrome with severe impairment of left ventricular systolic function.
Topics: Heart Failure; Humans; Takotsubo Cardiomyopathy; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Clinical and Hemodynamic Improvement in Pulmonary Hypertension After Switching to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Penalized Model-Based Unsupervised Phenomapping Unravels Distinctive HFrEF Phenotypes With Improved Outcomes Discrimination From Sacubitril/Valsartan Treatment Independent of MAGGIC Score.
Topics: Antihypertensive Agents; Female; Heart Failure; Humans; Male; Stroke Volume; Valsartan; Ventricular Function, Left | 2023 |
Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways.
Topics: Aged; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions.
Topics: Angiotensins; Cost-Benefit Analysis; Heart Failure; Humans; Neprilysin; Stroke Volume; Valsartan | 2023 |
Sacubitril/Valsartan: A Breakthrough in Heart Failure Management - Addressing Quality of Life and Mortality.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
[Titration strategy of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and hypotension].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Hypotension; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diuretics; Drug Combinations; Heart Failure; Humans; Neprilysin; Retrospective Studies; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left | 2023 |
Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensión Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC).
Topics: Angiotensin Receptor Antagonists; Cardiology; Consensus; Heart Failure; Humans; Hypertension; Quality of Life; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Dysfunction, Left | 2023 |
Development and validation of a sensitive and simple LC-MS/MS method for simultaneous quantitation of valsartan, sacubitril and sacubitrilat in pediatric population.
Topics: Adult; Antihypertensive Agents; Child; Chromatography, Liquid; Heart Failure; Humans; Reproducibility of Results; Tandem Mass Spectrometry; Tetrazoles; Valsartan | 2024 |
Longitudinal Changes in Natriuretic Peptides and Reverse Cardiac Remodeling in Patients with Heart Failure Treated with Sacubitril/Valsartan Across the Left Ventricular Ejection Traction Spectrum.
Topics: Heart Failure; Humans; Stroke Volume; Tetrazoles; Traction; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2023 |
Effect on the Quality of Life of Patients with Heart Failure and Reduced/Preserved Ejection Fraction Using Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cerebrovascular Disorders; Heart Failure; Humans; Irbesartan; Losartan; Myocardial Infarction; Retrospective Studies; Telmisartan; Tetrazoles; Valsartan | 2023 |
Sacubitril/Valsartan Cannot Improve Cardiac Function Compared with Valsartan in Patients Suffering Nonvalvular Atrial Fibrillation without Systolic Heart Failure.
Topics: Atrial Fibrillation; Biomarkers; Heart Failure; Heart Failure, Systolic; Humans; Stroke Volume; Tetrazoles; Valsartan | 2023 |
Natriuretic Peptides as Markers of Left Ventricular Reverse Remodeling After Angiotensin Receptor-Neprilysin Inhibitor Therapy.
Topics: Antihypertensive Agents; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Remodeling | 2023 |
Evolution of economic burden of heart failure by ejection fraction in newly diagnosed patients in Spain.
Topics: Angiotensin Receptor Antagonists; Drug Combinations; Financial Stress; Heart Failure; Humans; Retrospective Studies; Spain; Stroke Volume; Tetrazoles; Valsartan | 2023 |
The art of caring for adults with congenital heart disease in the face of imperfect data.
Topics: Adult; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2020 |
Sacubitril/valsartan and B-type natriuretic peptide value: recalculating route.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Tetrazoles; Valsartan | 2020 |
Medical journals and editorial quality control.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Multimorbidity; Periodicals as Topic; Quality Control; Tetrazoles; Valsartan | 2019 |
Response to: Medical journals and editorial quality control by Erviti et al.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Multimorbidity; Periodicals as Topic; Quality Control; Tetrazoles; Valsartan | 2019 |
In heart failure with reduced ejection fraction patients' left ventricular global longitudinal strain is enhanced after 1-year therapy with sacubitril/valsartan compared with conventional therapy with angiotensin-converting enzyme-inhibitors or AT1 blocke
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2019 |
PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Recovery of Function; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2019 |
Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Retrospective Studies; Tetrazoles; United States; United States Department of Veterans Affairs; Valsartan | 2019 |
Angiotensin- neprilysin inhibitors: should we initiate them in hospital for patients with acute decompensated heart failure?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Treatment Outcome; Valsartan | 2020 |
Choices in Heart Failure Treatment Goals: The Role of Patient-Reported Health Status.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Health Status; Heart Failure; Humans; Patient Reported Outcome Measures; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
The effect of sacubitril / valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Fail
Topics: Aminobutyrates; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiology; Death, Sudden, Cardiac; Drug Combinations; Female; Heart Failure; Humans; Male; Poland; Societies, Medical; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2019 |
ARNIs: balancing "the good and the bad" of neuroendocrine response to HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Neurosecretory Systems; Tetrazoles; Valsartan | 2020 |
Mechanisms of sacubitril-valsartan benefit in HFrEF.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Germany; Heart Failure; Humans; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Recovery of Function; Tetrazoles; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
The potential antiarrhythmic properties of sacubitril/valsartan: a case report.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Rate; Humans; Male; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2019 |
Risk Factors for Intolerance of Inpatient Sacubitril/Valsartan Initiation.
Topics: Adolescent; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Inpatients; Neprilysin; Prospective Studies; Retrospective Studies; Risk Factors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Echocardiographic evaluation of the effects of sacubitril-valsartan on vascular properties in heart failure patients.
Topics: Adult; Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Case-Control Studies; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Predictive Value of Tests; Prospective Studies; Protease Inhibitors; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Vascular Stiffness; Vasodilation | 2020 |
Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Retrospective Studies; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
Sacubitril/valsartan in heart failure and end-stage renal insufficiency.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Tetrazoles; Valsartan | 2019 |
The Risk for Sudden Cardiac Death and Effect of Treatment With Sacubitril/Valsartan in Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Black or African American; Cohort Studies; Drug Combinations; Drug Utilization; Female; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Neprilysin; Prognosis; Registries; Retrospective Studies; Risk Assessment; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Determinants of maximal dose titration of sacubitril/valsartan in clinical practice.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Valsartan | 2021 |
Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Effects of sacubutril/valsartan on nutritional status in heart failure with reduced ejection fraction.
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Drug Substitution; Female; Heart Failure; Humans; Male; Malnutrition; Middle Aged; Neprilysin; Nutrition Assessment; Nutritional Status; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Drug Combinations; Drug Substitution; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Valsartan; Ventricular Function, Left; Veterans Health Services | 2019 |
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Sex Factors; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Drug Utilization; Heart Failure; Humans; Ivabradine; Medicaid; Medicare Part D; Tetrazoles; United States; Valsartan | 2020 |
Use of sacubitril/valsartan in Marfan syndrome-related cardiomyopathy: The first case report.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Marfan Syndrome; Tetrazoles; Treatment Outcome; Valsartan; Young Adult | 2019 |
Efficacy of sacubitril valsartan sodium tablet for the treatment of chronic heart failure: A systematic review protocol of randomized controlled trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Research Design; Systematic Reviews as Topic; Tablets; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Drug Substitution; Female; Heart Failure; Humans; Male; Maximum Tolerated Dose; Middle Aged; Patient Safety; Prospective Studies; Renin-Angiotensin System; Risk Assessment; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2019 |
LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model.
Topics: Aminobutyrates; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; ERG1 Potassium Channel; Female; Heart Failure; Heart Rate; Heart Ventricles; Male; Myocardial Infarction; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channels, Voltage-Gated; Rats, Sprague-Dawley; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2019 |
The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016.
Topics: Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Drug Combinations; Eligibility Determination; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Patient Selection; Protease Inhibitors; Recovery of Function; Registries; Risk Assessment; Risk Factors; Stroke Volume; Sweden; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Dissecting the benefits of sacubitril-valsartan for heart failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Comorbidity; Drug Combinations; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Recovery of Function; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Early Implementation of Sacubitril/Valsartan for Patients With Heart Failure.
Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2020 |
From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
Topics: Adolescent; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Young Adult | 2020 |
Angiotensin-neprilysin inhibition in de novo heart failure - starting off strong.
Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Neprilysin; Tetrazoles; Valsartan | 2020 |
Is the glass half full or half empty after PARAGON-HF?
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Patient Readmission; Protease Inhibitors; Recovery of Function; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
Switching to sacubitril/valsartan or adding aldosterone antagonist: which first?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan | 2019 |
Response to "Grey Areas and Open Questions in Neprilysin Inhibition".
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Grey areas and open questions in neprilysin inhibition.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Tolerability and efficacy of sacubitril/valsartan in clinical practice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Quality of Life; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Biphenyl Compounds; Cardiac Resynchronization Therapy; Defibrillators, Implantable; Drug Combinations; Female; Heart Failure; Humans; Logistic Models; Male; Middle Aged; Outpatients; Prospective Studies; Recovery of Function; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Heart Failure With Preserved Ejection Fraction: Separating the Wheat From the Chaff.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Myocardial work improvement after sacubitril-valsartan therapy: a new echocardiographic parameter for a new treatment.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Contraction; Neprilysin; Predictive Value of Tests; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Substance and Substrate: LVEF and Sex Subgroup Analyses of PARAGON-HF and PARADIGM-HF Trials.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Tetrazoles; Valsartan | 2020 |
Effectiveness of sacubitril-valsartan in cancer patients with heart failure.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2020 |
Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Middle Aged; Retrospective Studies; Stroke Volume; Valsartan | 2020 |
[The PARAGON-HF trial: missed opportunity or first personalized therapy?]
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Precision Medicine; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Computer Simulation; Drug Combinations; Heart; Heart Failure; Humans; Neprilysin; Software; Stroke Volume; Systems Biology; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hypertension, Pulmonary; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Waiting Lists | 2020 |
Health-related quality of life in patients with heart failure eligible for treatment with sacubitril-valsartan.
Topics: Aminobutyrates; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Heart Failure; Humans; Quality of Life; Valsartan | 2020 |
Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Follow-Up Studies; Heart Failure; Humans; Prospective Studies; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2020 |
Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left | 2020 |
Adoption of sacubitril-valsartan in the Medicare population.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Medicare; Tetrazoles; United States; Valsartan | 2020 |
Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Valsartan; Ventricular Function, Left | 2020 |
Heart Failure With Preserved Ejection Fraction: The Quest for a Blood Pressure Goal.
Topics: Aminobutyrates; Biphenyl Compounds; Blood Pressure; Drug Combinations; Goals; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Tetrazoles; Valsartan | 2020 |
Sacubitril/Valsartan Therapy Ameliorates Ventricular Tachyarrhythmia Inducibility in a Rabbit Myocardial Infarction Model.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Myocardial Infarction; Rabbits; Stroke Volume; Tachycardia, Ventricular; Valsartan; Ventricular Function, Left | 2020 |
A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left | 2020 |
The Challenges of NT-proBNP Testing in HFpEF: Shooting Arrows in the Wind.
Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Valsartan; Wind | 2020 |
Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Clinical Decision-Making; Drug Combinations; Eligibility Determination; Evidence-Based Medicine; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Admission; Patient Selection; Peptide Fragments; Protease Inhibitors; Randomized Controlled Trials as Topic; Recovery of Function; Registries; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Sacubitril-Valsartan, a New Opportunity for Heart Failure with Recovered Ejection Fraction?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Australia; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Female; Follow-Up Studies; Forecasting; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Prognostic Usefulness of Myocardial Work in Patients With Heart Failure and Reduced Ejection Fraction Treated by Sacubitril/Valsartan.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Arterial Pressure; Biphenyl Compounds; Cardiotonic Agents; Case-Control Studies; Diuretics; Drug Combinations; Echocardiography; Female; Furosemide; Heart; Heart Failure; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Patient Readmission; Regression Analysis; Retrospective Studies; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2020 |
Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Australia; Biphenyl Compounds; Drug Combinations; Drug Tolerance; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Morbidity; Neprilysin; Prognosis; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Time Factors; Valsartan | 2020 |
Ejection fraction in heart failure revisited- where does the evidence start?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Introduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (THESEUS).
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Follow-Up Studies; Heart Failure; Humans; Primary Health Care; Prospective Studies; Retrospective Studies; Stroke Volume; Switzerland; Valsartan | 2020 |
Combination treatment of perifosine and valsartan showed more efficiency in protecting against pressure overload induced mouse heart failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Glycogen Synthase Kinase 3 beta; Heart Failure; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Organ Size; Phosphorylcholine; Pressure; Proto-Oncogene Proteins c-akt; Signal Transduction; Valsartan | 2020 |
Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cyclic GMP-Dependent Protein Kinase Type I; Drug Combinations; Guanosine Monophosphate; Heart Failure; Male; Mice; Mice, Inbred C57BL; Random Allocation; Valsartan; Ventricular Function, Left | 2020 |
Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Ireland; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Disease Progression; Drug Combinations; Heart Failure; Hospitalization; Humans; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Improving physical activity and exercise capacity in heart failure. Taking the first step is always the hardest.
Topics: Accelerometry; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Exercise; Exercise Tolerance; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Looking at the heart failure through the prism of liver dysfunction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Liver Diseases; Prognosis; Stroke Volume; Tetrazoles; Valsartan | 2020 |
In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure.
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Croatia; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/valsartan in patients post-left ventricular assist device implant: a single-centre case series.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart-Assist Devices; Humans; Stroke Volume; Valsartan | 2020 |
Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
Topics: Administration, Oral; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiomegaly; Chronic Disease; Disease Models, Animal; Dogs; Drug Combinations; Heart Failure; Myocardial Ischemia; Neprilysin; Protease Inhibitors; Rats, Sprague-Dawley; Recovery of Function; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
Sacubitril/valsartan in the treatment of cancer therapy-related cardiac dysfunction.
Topics: Adult; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Defects, Congenital; Heart Failure; Humans; Neoplasms; Tetrazoles; Valsartan | 2020 |
NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Reply: NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Letter by Wu and Zhao Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Tetrazoles; Valsartan | 2020 |
Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Tetrazoles; Valsartan | 2020 |
The Protective Effects of Compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Drug Therapy, Combination; Heart Failure; Heart Rate; Isoproterenol; Male; Myocardium; Rats, Wistar; Receptor, Angiotensin, Type 2; Stroke Volume; Sulfonamides; Thiophenes; Valsartan; Ventricular Function, Left | 2021 |
Comparison of the Effect of Sacubitril/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy.
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Ischemia; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Systole; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Feasibility Studies; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left | 2020 |
Expanding the indications for sacubitril/valsartan to unchartered territories.
Topics: Adult; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Defects, Congenital; Heart Failure; Humans; Tetrazoles; Valsartan | 2020 |
Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Receptors, Angiotensin; Stroke Volume; Taiwan; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Use of sacubitril/valsartan as 'bridge to transplant' in patients with end-stage hypertrophic cardiomyopathy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Hypertrophic; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/Valsartan as Antifibrotic Drug: Rejuvenating the Fibrosed HFpEF Heart.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Three cases of psychosis after use of sacubitril/valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Psychotic Disorders; Tetrazoles; Valsartan | 2021 |
Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Decision-Making; Disease Progression; Drug Combinations; Female; Heart Failure; Heart Transplantation; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Insufficiency; Neprilysin; Protease Inhibitors; Pulmonary Circulation; Recovery of Function; Retrospective Studies; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling | 2020 |
The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value?
Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost of Illness; Cost-Benefit Analysis; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
Quadruple Therapy Is the New Standard of Care for HFrEF.
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Standard of Care; Stroke Volume; Tetrazoles; Valsartan | 2020 |
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
Topics: Aftercare; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Patient Discharge; Peptide Fragments; Stroke Volume; Valsartan | 2020 |
Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Attitude of Health Personnel; Biphenyl Compounds; Clinical Decision-Making; Cost-Benefit Analysis; Decision Making, Shared; Decision Support Techniques; Drug Combinations; Drug Costs; Health Expenditures; Heart Failure; Humans; Neprilysin; Patient Participation; Protease Inhibitors; Stakeholder Participation; Valsartan | 2020 |
Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Echocardiography, Doppler, Pulsed; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Pulmonary Artery; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Vascular Stiffness; Ventricular Function, Left | 2021 |
A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Drug Substitution; Female; Heart Failure; Humans; Male; Medication Therapy Management; Models, Theoretical; Valsartan | 2021 |
Utilization of Sacubitril/Valsartan in Real-World Settings.
Topics: Adolescent; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Severity of Illness Index; Socioeconomic Factors; Valsartan; Young Adult | 2020 |
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Prospective Studies; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome; Uric Acid; Valsartan | 2020 |
Consider Everything When Prescribing Sacubitril/Valsartan: Perfection Is the Enemy of Good.
Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valsartan | 2020 |
Effects of sacubitril/valsartan in patients with left ventricular assist devices: Case series.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Proof of Concept Study; Valsartan | 2021 |
Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator.
Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2020 |
Similar Yet Different: Examining the Effects of Sacubitril/Valsartan by Race in the PIONEER-HF Trial.
Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Black or African American; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2020 |
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; North America; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Cause and duration of heart failure may impact on the response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Use of sacubitril-valsartan in blood pressure control with left ventricular assist devices.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Medicare; United States; Valsartan | 2020 |
Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Valsartan; Ventricular Remodeling | 2020 |
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions].
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care Facilities; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Biphenyl Compounds; Chronic Disease; Continuity of Patient Care; Coronavirus Infections; COVID-19; Delivery of Health Care; Disease Progression; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Pandemics; Pneumonia, Viral; Quarantine; Recurrence; SARS-CoV-2; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Telephone; Tetrazoles; Valsartan; Withholding Treatment | 2020 |
PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Case-Control Studies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Reported Outcome Measures; Peptide Fragments; Preliminary Data; Propensity Score; Prospective Studies; Quality of Life; Tetrazoles; Valsartan | 2020 |
Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Drug Substitution; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Quality of Life; Recovery of Function; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Asian People; Biphenyl Compounds; China; Drug Combinations; Exercise Tolerance; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Safety and Tolerability of Sacubitril/Valsartan Initiation in Inpatient Versus Outpatient Setting: A Retrospective Real World Study.
Topics: Aftercare; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Inpatients; Outpatients; Patient Discharge; Retrospective Studies; Stroke Volume; Valsartan | 2021 |
Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Italy; Male; Valsartan | 2021 |
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Middle Aged; Oxygen; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2020 |
Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Inpatients; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril/valsartan treatment.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany.
Topics: Adolescent; Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiologists; Drug Combinations; Germany; Heart Failure; Humans; Prescriptions; Primary Health Care; Referral and Consultation; Retrospective Studies; Valsartan | 2020 |
Should the LIFE Trial Assess Improvement in Ejection Fraction as a Primary Endpoint?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Heart failure features and sacubitril/valsartan effects.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2021 |
Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Health Status; Heart Failure; Humans; Prospective Studies; Quality of Life; Registries; Stroke Volume; Valsartan | 2021 |
Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions.
Topics: Adult; Aged; Aminobutyrates; Attitude of Health Personnel; Biphenyl Compounds; Cardiovascular Agents; Choice Behavior; Decision Making, Shared; Drug Combinations; Drug Costs; Female; Health Expenditures; Health Knowledge, Attitudes, Practice; Heart Failure; Humans; Interviews as Topic; Male; Middle Aged; Patient Participation; Patient Preference; Patient-Centered Care; Physician-Patient Relations; Tetrazoles; Valsartan | 2020 |
Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Reply: Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Middle Aged; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Renin profiling predicts neurohormonal response to sacubitril/valsartan.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cohort Studies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Renin; Stroke Volume; Valsartan | 2021 |
When and for Whom Should We Use SGLT2 Inhibitors in HFrEF?
Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N-terminal pro B-type natriuretic peptide levels.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Tolerance; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Retrospective Studies; Valsartan | 2021 |
Angiotensin Receptor-Neprilysin Inhibition Therapy and Improved Exercise Parameters in Heart Failure with Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Oxygen; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients.
Topics: Aged; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Hypotension; Inappropriate Prescribing; Male; Middle Aged; Neprilysin; Outpatients; Practice Guidelines as Topic; Protease Inhibitors; Recovery of Function; Retrospective Studies; Time Factors; Treatment Outcome; Valsartan | 2021 |
Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Colorado; Cost-Benefit Analysis; Decision Making, Shared; Decision Support Techniques; Drug Combinations; Drug Costs; Female; Georgia; Health Expenditures; Heart Failure; Humans; Interviews as Topic; Male; Middle Aged; Neprilysin; Patient Participation; Patient Satisfaction; Protease Inhibitors; Treatment Outcome; Valsartan | 2020 |
Beneficial effects of one-month sacubitril/valsartan treatment in a patient affected by end-stage dystrophinopathic cardiomyopathy.
Topics: Activities of Daily Living; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Dilated; Drug Combinations; Drug Monitoring; Dystrophin; Echocardiography; Exercise Tolerance; Heart Failure; Humans; Male; Middle Aged; Muscular Dystrophy, Duchenne; Stroke Volume; Symptom Assessment; Treatment Outcome; Valsartan | 2020 |
Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Chronic asymptomatic hyponatraemia following angiotensin receptor blocker-neprilysin inhibitor (ARNi) therapy: a case report.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Hyponatremia; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2022 |
How to appropriately update practicing clinicians on innovations in heart failure therapy waiting for the new version of the guidelines?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2021 |
Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Prospective Studies; Retrospective Studies; Tetrazoles; Valsartan; Vasodilator Agents | 2021 |
Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Fibrosis; Heart Failure; Hemodynamics; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocardial Contraction; Myocardial Infarction; Myocardium; Neprilysin; Protease Inhibitors; Renin; Tetrazoles; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left | 2021 |
Evaluating Sacubitril/Valsartan Dose Dependence on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Effect of sacubitril valsartan on cardiac function and endothelial function in patients with chronic heart failure with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Ivabradine; Stroke Volume; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide? Author's reply.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Sacubitril / valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Sacubitril/valsartan in the treatment of systemic right ventricular failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Retrospective Studies; Treatment Outcome; Valsartan; Ventricular Function, Right | 2021 |
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Biphenyl Compounds; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Drug Combinations; Heart Failure; Homeostasis; Humans; Inflammation; Models, Theoretical; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Receptor, Angiotensin, Type 2; Tetrazoles; Valsartan; World Health Organization | 2021 |
Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study.
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Biphenyl Compounds; Defibrillators, Implantable; Drug Combinations; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Natriuretic Peptide, Brain; Outpatients; Peptide Fragments; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Positive Recommendation for Angiotensin Receptor-Neprilysin Inhibitor: First Medication Approval for Heart Failure Without Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; United States; United States Food and Drug Administration; Valsartan | 2021 |
Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Heart Failure; Rats; Rats, Sprague-Dawley; Stroke Volume; Valsartan | 2021 |
Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF.
Topics: Advisory Committees; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Presumed Sudden Cardiac Deaths in the PARADIGM-HF Trial.
Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Valsartan | 2021 |
Reply: Presumed Sudden Cardiac Deaths in the PARADIGM-HF Trial.
Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Valsartan | 2021 |
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Retrospective Studies; Stroke Volume; Valsartan | 2021 |
Sacubitril/valsartan for heart failure with reduced ejection fraction: A first real-life observational study in Poland.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Poland; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Valsartan | 2021 |
Sacubitril-valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sleep Apnea, Central; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diastole; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan | 2021 |
Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril-valsartan: does money matter?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
Improvement in quality of life with sacubitril/ /valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Cardiac Resynchronization Therapy; Drug Combinations; Female; Heart Failure; Humans; Male; Neprilysin; Quality of Life; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Synchronized determination of the novel heart failure combination therapy containing sacubitril calcium and valsartan by a validated spectrofluorimetric method.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium; Drug Combinations; Heart Failure; Humans; Spectrometry, Fluorescence; Tetrazoles; Valsartan | 2021 |
Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Prognosis; Retrospective Studies; Stroke Volume; Valsartan | 2021 |
The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2021 |
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
Topics: Adolescent; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Prognosis; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Coronary Disease; Drug Combinations; Echocardiography; Heart Failure; Humans; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Connectin; Cyclic GMP; Diastole; Disease Models, Animal; Drug Combinations; Electrocardiography; Female; Fibrosis; Glycated Hemoglobin; Heart Failure; Muscle, Skeletal; Muscular Atrophy; Natriuretic Peptide, Brain; Peptide Fragments; Phosphorylation; Rats, Mutant Strains; Valsartan; Ventricular Function, Left | 2021 |
Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Outpatients; Quality of Life; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
Clinical Application of Sacubitril/Valsartan in Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Diuretics; Drug Combinations; Furosemide; Heart Failure; Humans; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2022 |
The evolution of guideline-directed medical therapy among decompensated HFrEF patients in sacubitril/valsartan era: Medical expenses and clinical effectiveness.
Topics: Aged; Aminobutyrates; Antihypertensive Agents; Biphenyl Compounds; Female; Health Expenditures; Heart Failure; Humans; Male; Middle Aged; Practice Guidelines as Topic; Propensity Score; Retrospective Studies; Stroke Volume; Treatment Outcome; Valsartan | 2021 |
Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
Topics: Aminobutyrates; Attention; Biphenyl Compounds; Drug Combinations; Glucose; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Symporters; Tetrazoles; Valsartan | 2021 |
Commentary to Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients.
Topics: Aminobutyrates; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2021 |
Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Health Status; Heart Failure; Humans; Quality of Life; Stroke Volume; Valsartan | 2021 |
In brief: Sacubitril/valsartan (Entresto) expanded indication.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Valsartan | 2021 |
Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
Topics: Aged; Aminobutyrates; Biomarkers; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Prognosis; Proportional Hazards Models; Stroke Volume; Valsartan | 2021 |
Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
Topics: Aminobutyrates; Biphenyl Compounds; Bisoprolol; Cardiac Rehabilitation; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Sodium; Stroke Volume; Tablets; Valsartan; Ventricular Function, Left | 2021 |
Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
Topics: Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Antihypertensive Agents; Czech Republic; Heart Failure; Humans; Losartan; Neprilysin; Perindopril; Ramipril; Retrospective Studies; Telmisartan; Valsartan | 2022 |
Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study.
Topics: Aminobutyrates; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Drug Combinations; Heart Failure; Hospitalization; Humans; Probability; Stroke Volume; Valsartan | 2021 |
Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Stroke Volume; Valsartan | 2021 |
Association of Body Mass Index With Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Body Mass Index; Cause of Death; Cohort Studies; Drug Combinations; Heart Failure; Humans; Male; Middle Aged; Overweight; Retrospective Studies; Risk Factors; Stroke Volume; Valsartan; West Virginia | 2021 |
Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study.
Topics: Adolescent; Adult; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Stroke Volume; Treatment Outcome; Valsartan | 2021 |
Characteristics of Heart Failure Patients With or Without Hypotension When Transitioning From Nitroprusside to Sacubitril-Valsartan.
Topics: Adult; Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Coronary Care Units; Diuretics; Drug Combinations; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Neprilysin; Nitroprusside; Protease Inhibitors; Retrospective Studies; Risk Factors; Treatment Outcome; Valsartan; Vasodilator Agents | 2021 |
Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Pilot Projects; Prospective Studies; Stroke Volume; Treatment Outcome; Valsartan | 2021 |
Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis.
Topics: Adult; Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Drug Utilization; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Pilot Projects; Practice Patterns, Physicians'; Protease Inhibitors; Recovery of Function; Retrospective Studies; Thailand; Time Factors; Treatment Outcome; Valsartan | 2021 |
Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Clinical Decision-Making; Disease Models, Animal; Drug Combinations; Evidence-Based Medicine; Heart Disease Risk Factors; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Protease Inhibitors; Protective Factors; Risk Assessment; Treatment Outcome; Valsartan | 2021 |
Clinical and echocardiographic characteristics after six months of sacubitril/valsartan in Chagas heart disease - A case series.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Troponin T; Valsartan; Ventricular Function, Left | 2021 |
Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Pulmonary Artery; Stroke Volume; Valsartan | 2021 |
Sacubitril-valsartan modifies the indication of cardiac implantable devices in patients with heart failure and reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Defibrillators, Implantable; Female; Heart Failure; Humans; Male; Valsartan | 2021 |
Monitoring the dynamics of clinical and laboratory markers of chronic heart failure during 12 months of sacubitril/valsartan treatment.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Quality of Life; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2021 |
Impact of Sacubitril/Valsartan on Right Heart Failure.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Valsartan | 2021 |
Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Comorbidity; Defibrillators, Implantable; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Valsartan; Ventricular Function, Left | 2021 |
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Female; Furosemide; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Retrospective Studies; Stroke Volume; Turkey; Valsartan; Ventricular Dysfunction, Left | 2021 |
The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Chronic Disease; Clinical Studies as Topic; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Male; Patient Readmission; Prognosis; Severity of Illness Index; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2020 |
Effect of sacubitril-valsartan on cardiac function in hemodialysis patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Kidney Failure, Chronic; Pilot Projects; Renal Dialysis; Treatment Outcome; Valsartan; Ventricular Function, Left | 2022 |
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure.
Topics: Aftercare; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Medicare; Patient Discharge; Stroke Volume; Tetrazoles; United States; Valsartan | 2021 |
National Trends in the Use of Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2021 |
Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2021 |
Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Stroke Volume; Tetrazoles; Valsartan | 2021 |
Angiotensin Receptor Blocker and Neprilysin Inhibitor Suppresses Cardiac Dysfunction by Accelerating Myocardial Angiogenesis in Apolipoprotein E-Knockout Mice Fed a High-Fat Diet.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Apolipoproteins; Biphenyl Compounds; Diet, High-Fat; Drug Combinations; Heart Failure; Male; Mice; Mice, Knockout; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Vascular Endothelial Growth Factor A | 2021 |
Clinical characteristics, prescription patterns, and persistence associated with sacubitril/valsartan adoption: A STROBE-compliant study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Valsartan | 2021 |
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan | 2021 |
Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis.
Topics: Australia; Clinical Trials as Topic; Cost-Benefit Analysis; Enalapril; Heart Failure; Humans; Valsartan | 2021 |
Angiotensin receptor-neprilysin inhibitor improves New York Heart Association class and N-terminal-pro B-type natriuretic peptide levels: initial experience in a Singapore single-centre cohort.
Topics: Angiotensin Receptor Antagonists; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; New York; Receptors, Angiotensin; Singapore; Stroke Volume; Valsartan | 2021 |
Reverse remodeling in a heart failure patient with cardiomegaly treated with sacubitril/valsartan: a case report.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Heart Failure; Humans; Percutaneous Coronary Intervention; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2021 |
Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cells, Cultured; Drug Combinations; Endothelial Cells; Heart Failure; Humans; Male; Mitral Valve; Mitral Valve Insufficiency; Myocardial Infarction; Myocardial Reperfusion Injury; Neprilysin; Rats; Rats, Sprague-Dawley; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiology; Drug Combinations; Heart Failure; Humans; Patient Care Management; Poland; Recovery of Function; Societies, Medical; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
Topics: Age Factors; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Neprilysin; Practice Patterns, Physicians'; Registries; Severity of Illness Index; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Diabetes: Sacubitril/valsartan improves glycaemic control.
Topics: Aminobutyrates; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Enalapril; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
The renal and cardiovascular effects of natriuretic peptides.
Topics: Aminobutyrates; Atrial Natriuretic Factor; Biphenyl Compounds; Disease Progression; Drug Combinations; Enalapril; Heart Failure; Humans; Kidney; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Natriuretic Peptides; Tetrazoles; Valsartan | 2017 |
[The relationship between natriuretic peptides and neprilysin pathways: the clinical simplification against the complexity of biological systems].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biological Phenomena; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Valsartan | 2017 |
Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Sacubitril-Valsartan in Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Sacubitril-Valsartan in Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Sacubitril-Valsartan in Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Sacubitril-Valsartan in Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Margaret McCartney: Only data can say if new is better.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Approval; Enalapril; Equivalence Trials as Topic; Heart Failure; Humans; United Kingdom; Valsartan | 2017 |
[Sacubitril/valsartan, a new and effective treatment for heart failure with reduced ejection fraction].
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).
Topics: Aged; Aged, 80 and over; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Practice Guidelines as Topic; Registries; Tetrazoles; Valsartan | 2017 |
Response by Dr Packer to the Letter of Dr Blankfield.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2018 |
Sacubitril/valsartan in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Sacubitril/valsartan in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Sacubitril/valsartan in PARADIGM-HF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Sacubitril/valsartan in PARADIGM-HF - Authors' reply.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
[Update on the clinical application of valsartan/sacubitril in patients with heart failure].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Evolving Pharmacologic Therapies for Heart Failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2017 |
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Middle Aged; Morbidity; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Sacubitril-valsartan: novel therapy for heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Tetrazoles; Valsartan | 2017 |
Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Markov Chains; Multivariate Analysis; Quality-Adjusted Life Years; Severity of Illness Index; Singapore; Stroke Volume; Survival Analysis; Tetrazoles; Valsartan | 2018 |
Use of sacubitril/valsartan in acute decompensated heart failure: a case report.
Topics: Acute Disease; Aminobutyrates; Angiotensin Receptor Antagonists; Anti-Retroviral Agents; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Heart Failure; Heart Ventricles; Humans; Middle Aged; Recovery of Function; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Pressure | 2018 |
Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney.
Topics: Aminobutyrates; Angiotensin II; Animals; Biphenyl Compounds; Bisoprolol; Blood Pressure; Drug Combinations; Echocardiography; Heart Failure; Kidney; Myocardium; Neprilysin; Nitrites; Norepinephrine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Artery; Renin; Reperfusion Injury; Sympathectomy; Tetrazoles; Valsartan; Ventricular Function, Left | 2017 |
Valsartan regulates TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure.
Topics: Animals; Antihypertensive Agents; Apoptosis; Cells, Cultured; Disease Models, Animal; Doxorubicin; Heart Failure; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; RNA, Long Noncoding; Smad Proteins; Transforming Growth Factor beta1; Valsartan | 2018 |
Sacubitril/Valsartan: Practice Changing Guideline in the Management of Congestive Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Practice Guidelines as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Decision-Making; Conservative Treatment; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Stroke Volume; Tetrazoles; Time Factors; Time-to-Treatment; Valsartan; Ventricular Remodeling | 2017 |
Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Outpatients; Patient Safety; Peptide Fragments; Poland; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2018 |
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeco
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Economics, Pharmaceutical; Enalapril; Female; Guidelines as Topic; Heart Failure; Humans; Male; Middle Aged; Models, Economic; Neprilysin; Netherlands; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Sacubitril/Valsartan in an Elderly Patient with Heart Failure: A Case Report.
Topics: Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Heart Ventricles; Humans; Male; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Sacubitril/Valsartan in Clinical Practice: The Italian Experience.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2017 |
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Colombia; Cost-Benefit Analysis; Denmark; Drug Combinations; Drug Costs; Heart Failure; Humans; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; United Kingdom; Valsartan; Ventricular Function, Left | 2018 |
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Disease Models, Animal; Drug Combinations; Fibrosis; Heart Failure; Male; Neprilysin; Random Allocation; Rats; Rats, Sprague-Dawley; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Uric acid is important, but there is something that matters even more: to deliver sacubitril/valsartan to eligible heart failure patients.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Uric Acid; Valsartan | 2018 |
The clinical relevance of drug-drug interaction between co-trimoxazole and sacubitril/valsartan treatment in a heart failure patient: a case report and overview of mechanisms and management in clinical practice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Anti-Bacterial Agents; Biphenyl Compounds; Drug Combinations; Drug Interactions; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Trimethoprim, Sulfamethoxazole Drug Combination; Valsartan | 2018 |
Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Eligibility Determination; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Morbidity; Population Surveillance; Retrospective Studies; Stroke Volume; Survival Rate; Sweden; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction : A retrospective cohort study.
Topics: Aminobutyrates; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stroke; Valsartan | 2018 |
Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Exercise Tolerance; Female; Heart Failure; Humans; Male; Neprilysin; Pilot Projects; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Body Mass Index; Comorbidity; Drug Combinations; Electronic Health Records; Female; Germany; Glycated Hemoglobin; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies; Sex Factors; Tetrazoles; Valsartan | 2018 |
Cognitive performance of patients with chronic heart failure on sacubitril/valsartan : A retrospective cohort study.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cognition; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Young Adult | 2018 |
From Molecules to Markets: Broadening the Focus of Cardiovascular Innovation.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2018 |
Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Drug Combinations; Female; Heart Failure; Humans; Male; Outpatients; Pharmacists; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Heart Failure; Hypertension; Male; Myocardium; Natriuretic Peptides; Neprilysin; Nitric Oxide; Protease Inhibitors; Rats, Inbred SHR; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2018 |
In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization : A retrospective cohort study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2019 |
Chronic Heart Failure.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Resynchronization Therapy; Diuretics; Drug Combinations; Germany; Guidelines as Topic; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan | 2018 |
Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Heart Failure; Hospitalization; Humans; Markov Chains; Quality-Adjusted Life Years; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cognition; Cognition Disorders; Dementia; Drug Combinations; Female; Heart Failure; Humans; Incidence; Male; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan | 2018 |
Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2018 |
Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Belgium; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography, Doppler; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2018 |
An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan; Ventricular Dysfunction, Left | 2018 |
Is the PARADIGM-HF cohort representative of the real-world heart failure patient population?
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Reproducibility of Results; Tetrazoles; Valsartan | 2018 |
Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Health Status; Heart Failure; Humans; Kidney; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Protease Inhibitors; Randomized Controlled Trials as Topic; Recovery of Function; Registries; Risk Factors; Spain; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2018 |
Sacubitril/valsartan: Can haemodynamic monitoring help with up-take?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamic Monitoring; Tetrazoles; Valsartan | 2018 |
Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Observational Studies as Topic; Patient Selection; Protease Inhibitors; Randomized Controlled Trials as Topic; Recovery of Function; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2018 |
Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions.
Topics: Aged; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Belgium; Biphenyl Compounds; Drug Combinations; Drug Prescriptions; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Incidence; Male; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Needs Assessment; Outcome and Process Assessment, Health Care; Quality-Adjusted Life Years; Stroke Volume; Survival Analysis; Tetrazoles; Thailand; Valsartan; Ventricular Dysfunction, Left | 2018 |
Renal effects of sacubitril/valsartan in patients with diabetes.
Topics: Aminobutyrates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan | 2018 |
Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
A Case of Palpitations Due to T-Wave Oversensing Caused by Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Electrocardiography; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Angiotensin receptor neprilysin inhibitors in older patients with heart failure.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2019 |
RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Sacubitril-valsartan in heart failure and multimorbidity patients.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Drug Combinations; Female; Heart Failure; Humans; Male; Neprilysin; Retrospective Studies; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Budgets; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2018 |
Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Electronic Health Records; Heart Failure; Humans; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Cost-Benefit Analysis; Defibrillators, Implantable; Drug Combinations; Drug Costs; Electric Countershock; Female; Health Care Costs; Heart Failure; Hospital Costs; Hospitalization; Humans; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2018 |
A Drug Utilization Study of Sacubitril/Valsartan in Catalonia.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Utilization; Female; Heart Failure; Humans; Male; Middle Aged; Prevalence; Spain; Tetrazoles; Valsartan | 2019 |
Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Evidence-Based Medicine; Heart Failure; Humans; Neprilysin; Practice Patterns, Physicians'; Protease Inhibitors; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Tetrazoles; Treatment Outcome; United States; United States Food and Drug Administration; Valsartan | 2018 |
Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2018 |
[ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Contraindications, Drug; Drug Combinations; Early Termination of Clinical Trials; Heart Failure; Humans; Hypotension; Monitoring, Physiologic; Multicenter Studies as Topic; Neprilysin; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reproducibility of Results; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
Topics: Aminobutyrates; Biphenyl Compounds; Chagas Cardiomyopathy; Drug Combinations; Heart Failure; Humans; Ivabradine; Tetrazoles; Valsartan | 2018 |
Growth differentiation factor-15 reveals the dark side of heart failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Growth Differentiation Factor 15; Heart Failure; Humans; Tetrazoles; Valsartan | 2018 |
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Decision-Making; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Patient Selection; Patients; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protease Inhibitors; Registries; Specialization; Tetrazoles; Time Factors; Treatment Outcome; United States; Valsartan | 2018 |
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Biomarkers; Female; Heart Failure; Humans; Insulin-Like Growth Factor Binding Proteins; Male; Middle Aged; Neprilysin; Stroke Volume; Valsartan | 2018 |
Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
Topics: Aminobutyrates; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Heart Rate; Humans; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
Safety and efficacy of sacubitril─valsartan in acute heart failure.
Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Topics: Aldosterone; Aminobutyrates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cross-Over Studies; Cyclic GMP; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptides; Renin-Angiotensin System; Sodium, Dietary; Tetrazoles; Valsartan | 2019 |
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; CD146 Antigen; Chronic Disease; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Fructosamine; Glucagon-Like Peptide 1; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Substance P; Tetrazoles; Treatment Outcome; Troponin I; Valsartan | 2019 |
Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Retrospective Studies; Tertiary Care Centers; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2019 |
Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Protease Inhibitors; Recovery of Function; Registries; Spain; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2019 |
Discussing Out-of-Pocket Costs With Patients: Shared Decision Making for Sacubitril-Valsartan in Heart Failure.
Topics: Adult; Aged; Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Cross-Sectional Studies; Decision Making, Shared; Drug Combinations; Drug Costs; Female; Health Expenditures; Heart Failure; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Tetrazoles; United States; Valsartan | 2019 |
Beta-Endorphin Elevation: Another Mechanism of Action of Sacubitril/Valsartan in Heart Failure?
Topics: Aminobutyrates; Animals; beta-Endorphin; Biphenyl Compounds; Drug Combinations; Exercise Tolerance; Heart Failure; Rats; Tetrazoles; Valsartan | 2019 |
Sacubitril/Valsartan in Adult Congenital Heart Disease Patients With Chronic Heart Failure - A Single Centre Case Series and Call for an International Registry.
Topics: Adult; Aminobutyrates; Biphenyl Compounds; Chronic Disease; Drug Combinations; Female; Heart Defects, Congenital; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Registries; Tetrazoles; Valsartan | 2020 |
Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Hospitalization; Humans; Male; Medication Adherence; Middle Aged; Neprilysin; Registries; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; United States; Valsartan | 2019 |
Sacubitril + valsartan (Entresto°) in chronic heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Patient Selection; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
PIONEERing the In-Hospital Initiation of Sacubitril-Valsartan.
Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2019 |
Unravelling the effect of sacubitril/valsartan on loop diuretic dosing.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Tetrazoles; Valsartan | 2019 |
Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Hyponatremia; Neprilysin; Tetrazoles; Valsartan | 2020 |
Is Sacubitril/Valsartan Antifibrotic?
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Belgium; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Neprilysin; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Patient Discharge; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas à cause du BNP?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Tetrazoles; Valsartan | 2019 |
Effect of low-dose sacubitril/valsartan on body composition, bioelectrical impedance analysis, heart rate variability and T-peak to T-end index in elderly patients with severe chronic heart failure: a pilot experience.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Body Composition; Chronic Disease; Drug Combinations; Electric Impedance; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Pilot Projects; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan: preliminary experience in post-acute stabilized patients with reduced ejection fraction heart failure.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Management of a patient with heart failure by sacubitril/valsartan: improvement of functional capacity.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2019 |
How does neprilysin inhibition in heart failure work?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan treatment improved the clinical outcome and reduced the hospitalization rate in three patients with chronic heart failure: a case series.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Sacubitril/valsartan effect on left ventricular remodeling: the case of a super-responder.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Case of a patient with heart failure, dilated cardiomyopathy and atrial fibrillation treated with sacubitril/valsartan.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Fibrillation; Biphenyl Compounds; Cardiomyopathy, Dilated; Drug Combinations; Heart Failure; Hospitalization; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Pharmacological Phenomena; Stroke Volume; Tetrazoles; Valsartan | 2019 |
What Explains the Benefits of ARNI Therapy in Heart Failure?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Tetrazoles; Valsartan | 2019 |
"Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Clinical Decision-Making; Drug Combinations; Eligibility Determination; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Selection; Peptide Fragments; Protease Inhibitors; Recovery of Function; Registries; Stroke Volume; Sweden; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2019 |
Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart; Heart Failure; Male; Myocardial Reperfusion Injury; Myocardium; Neovascularization, Physiologic; Neprilysin; Organotechnetium Compounds; Peptides, Cyclic; Rats; Rats, Inbred Lew; Single Photon Emission Computed Tomography Computed Tomography; Tetrazoles; Valsartan; Vascular Endothelial Growth Factor A; Ventricular Remodeling | 2019 |
Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiologists; Cohort Studies; Databases, Factual; Diuretics; Drug Combinations; Female; General Practitioners; Germany; Heart Failure; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Neprilysin; Practice Patterns, Physicians'; Retrospective Studies; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Mental Disorders; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cyclic GMP-Dependent Protein Kinases; Drug Combinations; Fibroblasts; Fibrosis; Heart; Heart Failure; Heart Ventricles; Male; Mice, Inbred C57BL; Neprilysin; Tetrazoles; Valsartan | 2019 |
Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Health Care Costs; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Stroke Volume; Tetrazoles; United States; Valsartan | 2019 |
Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure.
Topics: Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Animals; Biomarkers; Biphenyl Compounds; Blood Pressure; Creatine Kinase, MB Form; Drug Combinations; Female; Fumarates; Heart Failure; Heart Rate; Kidney; Matrix Metalloproteinase 9; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Ramipril; Rats, Wistar; Renin; Tetrazoles; Troponin I; Valsartan | 2019 |
Early Experience With Sacubitril/Valsartan in Adult Patients With Congenital Heart Disease.
Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Follow-Up Studies; Heart Defects, Congenital; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2019 |
A per-protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Protocols; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Tetrazoles; Treatment Outcome; United Arab Emirates; Valsartan | 2019 |
Effect of sacubitril/valsartan on cardiac filling pressures in patients with heart failure: Suggestions for statistical analysis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in chronic heart failure? The culmination of a 20-year journey.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Registries; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan | 2019 |
Confirmatory Trials for Drugs Approved on a Single Trial.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Dietary Supplements; Drug Approval; Drug Combinations; Eicosapentaenoic Acid; Evidence-Based Medicine; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Research Design; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Sacubitril/valsartan improves medium-term reverse left ventricular remodeling: why wait?
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Time-to-Treatment; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2019 |
The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Hypertension; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril.
Topics: Aldosterone; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/Valsartan, Cardiac Fibrosis, and Remodeling in Heart Failure.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Fibrosis; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2019 |
In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Patient Discharge; Tetrazoles; Valsartan | 2019 |
Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Risk Assessment; Risk Factors; Spain; Tachycardia, Ventricular; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2020 |
Sacubitril/valsartan for heart failure in adults with complex congenital heart disease.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Follow-Up Studies; Heart Defects, Congenital; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies; Tetrazoles; Valsartan | 2020 |
Alteration of medical therapy in patients with heart failure relative to change in symptom severity.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diuretics; Drug Combinations; Heart Failure; Humans; Practice Guidelines as Topic; Registries; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2019 |
Searching for Optimal Prognostic Marker of Heart Failure Progression in the Era of ARNI.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Prognosis; Tetrazoles; Valsartan | 2019 |
In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Evidence-Based Medicine; Heart Failure; Hospitalization; Humans; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Health Expenditures; Heart Failure; Humans; Insurance Coverage; Medicare Part D; Tetrazoles; United States; Valsartan | 2019 |
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Topics: Age Factors; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Diuretics; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Randomized Controlled Trials as Topic; Self Efficacy; Severity of Illness Index; Sex Factors; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Animals; Biphenyl Compounds; Cross Reactions; Drug Combinations; Epitopes; Heart Failure; Humans; Immunoassay; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Rats, Wistar; Tetrazoles; Valsartan | 2019 |
The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Follow-Up Studies; Heart Failure; Humans; Life; Tetrazoles; Valsartan | 2019 |
The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2019 |
Role of BNP vs NT-proBNP Testing in the Age of New Drug Therapies: Sacubitril-Valsartan.
Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2019 |
[Proportion of patients with heart failure in a specialized clinic eligible for novel therapies].
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Agents; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Patient Selection; Tetrazoles; Valsartan | 2019 |
First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Models, Biological; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2013 |
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
Topics: Adrenergic beta-Antagonists; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diuretics; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Patient Selection; Platelet Aggregation Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2014 |
Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Denmark; Female; Heart Failure; Humans; Insurance, Health, Reimbursement; Losartan; Male; Tetrazoles; Valine; Valsartan | 2014 |
Neprilysin inhibition--a novel therapy for heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Neprilysin; Tetrazoles; Valsartan | 2014 |
PARADIGM-HF--the experts' discussion.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan | 2014 |
Clinical trial results may lead to changes in cardiovascular care.
Topics: Aminobutyrates; Angioplasty; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Ivabradine; Myocardial Infarction; Practice Guidelines as Topic; Tetrazoles; Valsartan | 2014 |
Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2015 |
Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan | 2014 |
Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Heart Failure; Hospitalization; Humans; Neprilysin; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan | 2015 |
[New therapy concepts for heart failure with preserved ejection fraction].
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Evidence-Based Medicine; Heart Failure; Heart-Assist Devices; Humans; MicroRNAs; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2015 |
[Internal medicine in the hospital setting].
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases; Atrial Fibrillation; Biphenyl Compounds; Carotid Stenosis; Colchicine; Diuretics; Drug Combinations; Heart Failure; Hospitals; Humans; Internal Medicine; Liver Cirrhosis; Narcotics; Neprilysin; Pericarditis; Peritonitis; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Spironolactone; Stroke; Tetrazoles; Valsartan | 2015 |
Breakthroughs in internal and respiratory medicine.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Crohn Disease; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Oligonucleotides; Pulmonary Medicine; Respiratory Tract Diseases; Tetrazoles; Translational Research, Biomedical; Valsartan | 2015 |
Combination product approved for chronic heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Approval; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Tetrazoles; Valsartan | 2015 |
[Still trivialized too often].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Enalapril; Germany; Heart Failure; Humans; Tetrazoles; Valsartan | 2015 |
New Drug Entresto for Heart Failure Drums Up a Lot of Enthusiasm.
Topics: Angiotensin Receptor Antagonists; Drug Approval; Drug Combinations; Drug Costs; Heart Failure; Humans; Managed Care Programs; Neprilysin; Tetrazoles; Valine; Valsartan | 2015 |
The Role of Neprilysin Inhibitors in Cardiovascular Disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2015 |
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cause of Death; Drug Combinations; Heart Failure; Humans; Kaplan-Meier Estimate; Life Expectancy; Middle Aged; Tetrazoles; Valsartan | 2015 |
Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations.
Topics: Alzheimer Disease; Aminobutyrates; Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Brain; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haplorhini; Heart Failure; Humans; Mice; Neprilysin; Retinal Degeneration; Tetrazoles; Valsartan | 2016 |
Sacubitril/Valsartan (Entresto): The Next Blockbuster Medication?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2015 |
Heart failure in 2015: Better results from prevention than from additional treatment.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Diabetes Mellitus, Experimental; Drug Combinations; Fibrosis; Heart; Heart Failure; Heart Ventricles; Male; Mice; Mice, Inbred C57BL; Myocardial Reperfusion Injury; Myocardium; Neprilysin; RNA, Messenger; Stroke Volume; Tetrazoles; Transforming Growth Factor beta; Valsartan | 2016 |
Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Natriuretic Peptides; Neprilysin; Peptide Fragments; Predictive Value of Tests; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2016 |
Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.
Topics: Aminobutyrates; Antibodies, Monoclonal; Biphenyl Compounds; Drug Combinations; Epitopes; Escherichia coli; Glycosylation; Heart Failure; Humans; Immunoassay; Limit of Detection; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Protein Precursors; Proteolysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tetrazoles; Valsartan | 2016 |
Valsartan attenuates cardiac and renal hypertrophy in rats with experimental cardiorenal syndrome possibly through down-regulating galectin-3 signaling.
Topics: Animals; Cardio-Renal Syndrome; Cardiomegaly; Disease Models, Animal; Down-Regulation; Echocardiography; Galectin 3; Glomerular Filtration Rate; Heart; Heart Failure; Kidney; Male; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Signal Transduction; Valsartan | 2016 |
Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiologists; Drug Approval; Drug Combinations; Drug Discovery; Drug Industry; Heart Failure; Humans; Interprofessional Relations; Neprilysin; Tetrazoles; Valsartan | 2016 |
[Sacubitril/valsartan receives European approval].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Early Termination of Clinical Trials; Europe; Heart Failure; Humans; Survival Rate; Tetrazoles; Valsartan | 2015 |
The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Markov Chains; Middle Aged; Neprilysin; Quality-Adjusted Life Years; Stroke Volume; Tetrazoles; Valsartan | 2016 |
["It is important to reach the target dose"].
Topics: Aminobutyrates; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Germany; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
NICE approves innovative treatment for moderate to severe heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; England; Heart Failure; Humans; Tetrazoles; Valsartan | 2016 |
[A new medication - when should one switch?].
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Substitution; Heart Failure; Humans; Tetrazoles; Valsartan | 2016 |
▼ Sacubitril valsartan for heart failure.
Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2016 |
Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Patient Readmission; Tetrazoles; Valsartan | 2016 |
[Sacubitril-valsartan is a new cornerstone in heart failure therapy].
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sweden; Tetrazoles; Valsartan | 2016 |
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Dilated; Drug Combinations; Female; Genetic Markers; Genetic Predisposition to Disease; Heart Failure; Humans; Male; Middle Aged; Myocardial Ischemia; Natriuretic Peptide, Brain; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Stroke Volume; Syndecan-4; Tetrazoles; Transforming Growth Factor beta1; Valsartan | 2016 |
Chronic congestive heart failure - a new therapeutic choice.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Canada; Chronic Disease; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2016 |
New Recommendations for Heart Failure Treatment.
Topics: Antihypertensive Agents; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Valsartan | 2016 |
Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Hospitalization; Humans; Lisinopril; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Sacubitril-Valsartan in Heart Failure: Why Are More Physicians Not Prescribing It?
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan | 2016 |
Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan | 2017 |
Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valsartan | 2017 |
Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Chronic Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Early Medical Intervention; Echocardiography; Europe; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptides; Practice Guidelines as Topic; Spain; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Heart failure: Neprilysin inhibition attenuates risk of hyperkalaemia in HFrEF.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Neprilysin; Tetrazoles; Valsartan | 2017 |
Sacubitril/Valsartan (Entresto) for Heart Failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Hyperkalemia; Hypotension; Neprilysin; Renal Insufficiency; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Diuretics; Fibroblasts; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Hydrochlorothiazide; Male; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Recovery of Function; Signal Transduction; Smad2 Protein; Stroke Volume; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Stroke Volume; Tetrazoles; Valsartan | 2017 |
An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Financing, Personal; Health Care Costs; Heart Failure; Hospital Costs; Hospitalization; Humans; Kaplan-Meier Estimate; Netherlands; Quality-Adjusted Life Years; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; Cardiomegaly; Cyclic AMP Response Element Modulator; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 3; Gene Expression Regulation; Heart; Heart Failure; Myocardial Infarction; Myocardium; Rats; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2009 |
[Effects of valsartan on sarcoplasmic reticulum calcium adenosine triphosphatase, protein kinase A and protein phosphatase 1 alpha in a rabbit model of heart failure].
Topics: Animals; Cyclic AMP-Dependent Protein Kinases; Female; Heart Failure; Male; Protein Phosphatase 1; Rabbits; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Valine; Valsartan | 2008 |
[Valsartan improves symptoms and quality of life in patients with chronic heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Multicenter Studies as Topic; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan | 2008 |
Combination of ARB and ACE inhibitors in heart failure patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2009 |
[Effects of valsartan on myocardial calcium/calmodulin-dependent protein kinase-II expression and activity in a rabbit model of heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Female; Heart Failure; Male; Myocardium; Rabbits; Tetrazoles; Valine; Valsartan | 2009 |
The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Topics: Age Factors; Aged; Antihypertensive Agents; Chronic Disease; Computer Simulation; Cost-Benefit Analysis; Drug Costs; Female; Heart Failure; Hospital Costs; Humans; Italy; Male; Markov Chains; Middle Aged; Models, Statistical; Quality of Life; Quality-Adjusted Life Years; Sex Factors; Tetrazoles; Valine; Valsartan | 2009 |
Continuous positive airway pressure treatment in addition to optimal medical therapy for ventricular ectopy in a patient with heart failure and sleep-related breathing disorder.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Continuous Positive Airway Pressure; Coronary Artery Disease; Heart Failure; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Propanolamines; Radiography; Sleep Apnea, Obstructive; Tachycardia, Ventricular; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Premature Complexes | 2013 |
HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Evidence-Based Medicine; Heart Failure; Humans; Losartan; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
Topics: Aged; Analog-Digital Conversion; Angiotensin II Type 1 Receptor Blockers; Death; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Motion; Myocardial Contraction; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stress, Mechanical; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left; Video Recording | 2010 |
Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.
Topics: Acetamides; Animals; Biomarkers; Cardiac Volume; Cellular Senescence; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Inflammation; Mitochondria, Heart; Myocardial Infarction; Myocytes, Cardiac; Pyridazines; Random Allocation; Rats; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilator Agents; Ventricular Pressure | 2010 |
Determinants of masked hypertension in hypertensive patients treated in a primary care setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Comorbidity; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Masked Hypertension; Middle Aged; Obesity; Prevalence; Primary Health Care; Quebec; Risk; Tetrazoles; Valine; Valsartan; White Coat Hypertension | 2012 |
Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition.
Topics: Adipocytes; Adrenergic beta-Agonists; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Cells, Cultured; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Isoproterenol; Lipolysis; Male; Middle Aged; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2011 |
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confounding Factors, Epidemiologic; Electronic Health Records; Female; Heart Failure; Hospitalization; Humans; Irbesartan; Losartan; Male; Models, Structural; Proportional Hazards Models; Retrospective Studies; Risk; Tetrazoles; Treatment Outcome; United States; Valine; Valsartan | 2012 |
Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Diet, Sodium-Restricted; Echocardiography; Heart; Heart Failure; Heart Rate; Hydrazones; Hypertension; Kidney; Male; Myocytes, Cardiac; Pyridazines; Rats; Rats, Inbred Dahl; RNA, Messenger; Simendan; Sodium Chloride, Dietary; Sodium, Dietary; Tetrazoles; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling | 2011 |
Subtle issues in model specification and estimation of marginal structural models.
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; Humans; Irbesartan; Losartan; Male; Tetrazoles; Valine; Valsartan | 2012 |
Heart failure--does it matter whether LVEF is reduced?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Neprilysin; Tetrazoles; Valsartan | 2012 |
Trial watch: dual-acting combination meets heart failure end point.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials, Phase II as Topic; Drug Combinations; Endpoint Determination; Heart Failure; Humans; Tetrazoles; Valsartan | 2012 |
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, Animal; Down-Regulation; Heart Failure; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Valine; Valsartan | 2013 |
Ask the doctor. I have had heart failure since my heart attack a year ago. My physician initially prescribed lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. Unfortunately, I was one of the unlucky people who got a cough with this drug that w
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cough; Heart Failure; Humans; Lisinopril; Myocardial Infarction; Tetrazoles; Valine; Valsartan | 2002 |
[Therapy of heart failure. 2 neurohormone blockers are enough].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
Angiotensin receptor blockers in heart failure: a work in progress.
Topics: Angiotensin II; Heart Failure; Humans; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Progression; Echocardiography; Enzyme Activation; Heart Failure; Hypertension; Male; Myocardium; Organ Size; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-epsilon; Protein Transport; Rats; Rats, Inbred Dahl; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2002 |
Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Receptors, Angiotensin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
BP drug approved for heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Approval; Heart Failure; Humans; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2002 |
[Sartan as a new therapy option. When heart failure patients cannot tolerate an ACE inhibitor].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Heart Failure; Humans; Randomized Controlled Trials as Topic; Survival Rate; Tetrazoles; Treatment Outcome; United States; United States Food and Drug Administration; Valine; Valsartan | 2002 |
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Evaluation Studies as Topic; Heart Failure; Humans; Incidence; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Are angiotensin II receptor antagonists indicated in chronic heart failure?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diuretics; Dizziness; Drug Combinations; Drug Interactions; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Olmesartan Medoxomil; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2003 |
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
Topics: Aged; Angiotensin Receptor Antagonists; Captopril; Double-Blind Method; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
Effect of valsartan on hospitalization in Val-HeFT.
Topics: Heart Failure; Humans; Length of Stay; Patient Readmission; Prognosis; Tetrazoles; Valine; Valsartan | 2003 |
[ACE inhibitors and/or sartans in heart failure: is there a difference?].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Losartan; Tetrazoles; Valine; Valsartan | 2003 |
Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Survival Rate; Tetrazoles; Valine; Valsartan | 2003 |
Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dobutamine; Dogs; Drug Evaluation, Preclinical; Heart Failure; Myocardial Contraction; Norepinephrine; Phosphorylation; Protein Processing, Post-Translational; Receptors, Adrenergic, beta; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Tachycardia, Ventricular; Tacrolimus Binding Proteins; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2004 |
[When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2003 |
[New options against undertreatment].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Hospitalization; Humans; Losartan; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Implications of recent clinical trials for heart failure performance measures.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Practice Guidelines as Topic; Quality of Health Care; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2004 |
Valsartan, captopril, or both in myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Ethics, Clinical; Heart Failure; Humans; Myocardial Infarction; Placebos; Research Design; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Aquaporin 2; Aquaporins; Drug Therapy, Combination; Fosinopril; Gene Expression; Heart Failure; Kidney Cortex; Kidney Medulla; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2004 |
VALIANT and EUROPA.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
Aldosterone levels after angiotensin receptor blocker treatment.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Disease Progression; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2004 |
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Middle Aged; Muscle Weakness; Spironolactone; Tetrazoles; Valine; Valsartan | 2004 |
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2004 |
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Aged; Atrial Fibrillation; Comorbidity; Electrocardiography; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan | 2005 |
Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Budgets; Cost-Benefit Analysis; Heart Failure; Hospitalization; Humans; Models, Economic; Tetrazoles; Time Factors; Valine; Valsartan | 2005 |
How FDA currently makes decisions on clinical studies.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Carvedilol; Child; Clinical Trials as Topic; Diabetic Nephropathies; Evidence-Based Medicine; Heart Failure; Humans; Propanolamines; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2005 |
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Disease Progression; Echocardiography; Heart Failure; Heart Ventricles; Humans; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stroke Volume; Survival Rate; Tetrazoles; Valine; Valsartan | 2006 |
[Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Long-Term Care; Myocardial Infarction; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
[Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Evidence-Based Medicine; Family Practice; Germany; Heart Failure; Humans; Hypertension; Myocardial Infarction; Product Surveillance, Postmarketing; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
Topics: Aged; Antihypertensive Agents; C-Reactive Protein; Cholesterol; Chronic Disease; Creatinine; Databases, Factual; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morbidity; Prognosis; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study.
Topics: Aged; Antihypertensive Agents; Comorbidity; Echocardiography; Female; Heart Failure; Humans; Internationality; Male; Middle Aged; Myocardial Infarction; Prevalence; Prognosis; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2006 |
Left bundle branch block is not good for your heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Heart Failure; Humans; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; British Columbia; Drug Prescriptions; Female; Heart Failure; Hospital Information Systems; Humans; Irbesartan; Losartan; Male; Ontario; Proportional Hazards Models; Quebec; Retrospective Studies; Survival Analysis; Survival Rate; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea Nitrogen; Blotting, Western; Creatinine; Disease Models, Animal; DNA; Heart Failure; Immunohistochemistry; Kidney Failure, Chronic; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Nephrectomy; Oxidative Stress; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Treatment Outcome; Up-Regulation; Valine; Valsartan; Ventricular Function, Left | 2007 |
[Convincing results from the JIKEI Study].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Controlled Clinical Trials as Topic; Coronary Disease; Heart Failure; Humans; Hypertension; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2006 |
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2008 |
[New effective dosage of valsartan. High dosage--effective against high blood pressure].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Prognosis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Blood Pressure; Dose-Response Relationship, Drug; Endothelium, Vascular; Heart Failure; In Vitro Techniques; Male; Myocardial Infarction; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2007 |
From black and white to shades of gray: race and renin-angiotensin system blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Captopril; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People | 2008 |
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Black or African American; Captopril; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Systole; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People | 2008 |
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiac Output; Cardiac Pacing, Artificial; Diastole; Disease Models, Animal; Endothelins; Epinephrine; Heart Failure; Heart Rate; Hemodynamics; Norepinephrine; Pulmonary Artery; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1997 |
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Calcium Channels; Calcium Channels, L-Type; Calcium-Binding Proteins; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cell Membrane; Cells, Cultured; Dihydropyridines; Heart Failure; Myocardial Contraction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; Sarcoplasmic Reticulum; Sodium-Potassium-Exchanging ATPase; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1997 |
Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiac Pacing, Artificial; Endothelins; Epinephrine; Heart Failure; Hemodynamics; Male; Norepinephrine; Physical Exertion; Regional Blood Flow; Renin; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 1998 |
AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiac Pacing, Artificial; Coronary Vessels; Disease Models, Animal; Exercise Test; Heart Failure; Hemodynamics; Male; Regional Blood Flow; Swine; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1998 |
Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Reference Values; Research Design; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Quality of Life; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Volume; Cyclic GMP; Diuresis; Heart Failure; Male; Myocardium; Ramipril; Rats; Rats, Wistar; Renin-Angiotensin System; Statistics, Nonparametric; Tetrazoles; Valine; Valsartan | 1999 |
Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Losartan; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
AT1-receptor blockers.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Tetrazoles; Valine; Valsartan | 2000 |
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Fosinopril; Heart Failure; Humans; Lisinopril; Male; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Treatment Failure; Valine; Valsartan | 2000 |
Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Cardiac Pacing, Artificial; Combined Modality Therapy; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Myocardial Contraction; Norepinephrine; Receptor, Endothelin A; Renin; Sulfonamides; Swine; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2000 |
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Catecholamines; Collagen; Diastole; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Endothelin-1; Gene Expression; Heart Failure; Heart Function Tests; Hydroxyproline; Myocardium; Myosin Heavy Chains; Organ Size; Rats; Rats, Inbred Dahl; Receptors, Angiotensin; RNA, Messenger; Sodium Chloride, Dietary; Survival Rate; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2001 |
[AT1-blocker in heart failure. Patients are readmitted more infrequently to the clinic].
Topics: Angiotensin Receptor Antagonists; Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2000 |
[Info-congress. COPERNICUS and Val-HEFT studies].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coronary Disease; Heart Failure; Humans; Propanolamines; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Valine; Valsartan | 2000 |
[Heart failure. With the AT1-blocker less frequent rehospitalization].
Topics: Angiotensin Receptor Antagonists; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
Alterations of load-induced p38 MAP kinase activation in failing rat hearts.
Topics: Animals; Antihypertensive Agents; Body Weight; Diastole; Enzyme Activation; Heart; Heart Failure; Hemodynamics; In Vitro Techniques; Mitogen-Activated Protein Kinases; Myocardial Contraction; Myocardium; Organ Size; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Inbred Dahl; Reference Values; Systole; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Weight-Bearing | 2001 |
Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Heart Failure; Male; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan | 2001 |
Angiotensin II type 1 receptor blockers and congestive heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Receptor, Angiotensin, Type 1; Sample Size; Selection Bias; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2001 |
Are angiotensin II receptor blockers indicated in chronic heart failure?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
[Heart failure. Who benefits from an AT1 blocker?].
Topics: Angiotensin Receptor Antagonists; Clinical Trials as Topic; Heart Failure; Humans; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2001 |
[ESC guidelines for therapy of heart failure. AT1 blockers are now also included].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Heart Failure; Humans; Practice Guidelines as Topic; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
[Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Spironolactone; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2002 |
Myocardial bradykinin following acute angiotensin-converting enzyme inhibition, AT1 receptor blockade, or combined inhibition in congestive heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Bradykinin; Heart Failure; Male; Myocardium; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Swine; Tetrazoles; Valine; Valsartan | 2001 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Hypotension; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Risk; Tetrazoles; Valine; Valsartan | 2002 |
Valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2002 |